{
  "questions": [
    {
      "id": "65d3715b1930410b13000046",
      "type": "yesno",
      "body": "Is Durvalumab effective for locally advanced cervical cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
        "http://www.ncbi.nlm.nih.gov/pubmed/32447296",
        "http://www.ncbi.nlm.nih.gov/pubmed/36640944",
        "http://www.ncbi.nlm.nih.gov/pubmed/37445743",
        "http://www.ncbi.nlm.nih.gov/pubmed/33289347",
        "http://www.ncbi.nlm.nih.gov/pubmed/35319779",
        "http://www.ncbi.nlm.nih.gov/pubmed/33364266",
        "http://www.ncbi.nlm.nih.gov/pubmed/37943483",
        "http://www.ncbi.nlm.nih.gov/pubmed/33282370",
        "http://www.ncbi.nlm.nih.gov/pubmed/31782989"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "INTERPRETATION: Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3283,
          "endSection": "abstract",
          "offsetInEndSection": 3534
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "INTERPRETATION\nDurvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3289,
          "endSection": "abstract",
          "offsetInEndSection": 3539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "INTERPRETATION\nDurvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population. Concurrent durvalumab plus chemoradiotherapy warrants further exploration in patients with high tumoral PD-L1 expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3289,
          "endSection": "abstract",
          "offsetInEndSection": 3661
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "There was one treatment-related death in the placebo group (pneumonia related to chemoradiotherapy). INTERPRETATION\nDurvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population. Concurrent durvalumab plus chemoradiotherapy warrants further exploration in patients with high tumoral PD-L1 expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3186,
          "endSection": "abstract",
          "offsetInEndSection": 3661
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "There was one treatment-related death in the placebo group (pneumonia related to chemoradiotherapy). INTERPRETATION\nDurvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3186,
          "endSection": "abstract",
          "offsetInEndSection": 3539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "INTERPRETATION\nDurvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population. Concurrent durvalumab plus chemoradiotherapy warrants further exploration in patients with high tumoral PD-L1 expression. Rigorous monitoring ensured high chemoradiotherapy compliance with advanced technology and allowed patients to receive optimal care.",
          "beginSection": "abstract",
          "offsetInBeginSection": 3289,
          "endSection": "abstract",
          "offsetInEndSection": 3794
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer. METHODS\nThe CALLA randomised, double-blind, phase 3 trial included 105 hospitals across 15 countries.",
          "beginSection": "abstract",
          "offsetInBeginSection": 334,
          "endSection": "abstract",
          "offsetInEndSection": 576
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 334,
          "endSection": "abstract",
          "offsetInEndSection": 472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 137
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039991",
          "text": "BACKGROUND\nConcurrent chemoradiotherapy has been the standard of care for locally advanced cervical cancer for over 20 years; however, 30-40% of treated patients have recurrence or progression within 5 years. Immune checkpoint inhibition has improved outcomes for patients with PD-L1 positive metastatic or recurrent cervical cancer. We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 472
        }
      ],
      "ideal_answer": "No, Durvalumab is not effective for locally advanced cervical cancer. The study found that Durvalumab did not significantly improve progression-free survival in a biomarker unselected, all-comers population.",
      "exact_answer": "no"
    },
    {
      "id": "66099c57fdcbea915f000025",
      "type": "list",
      "body": "What clinical conditions influence the prognostic after the liver metastasis resection from colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10493478",
        "http://www.ncbi.nlm.nih.gov/pubmed/15029391",
        "http://www.ncbi.nlm.nih.gov/pubmed/1575626",
        "http://www.ncbi.nlm.nih.gov/pubmed/16241086",
        "http://www.ncbi.nlm.nih.gov/pubmed/9060531",
        "http://www.ncbi.nlm.nih.gov/pubmed/26388907",
        "http://www.ncbi.nlm.nih.gov/pubmed/17072953",
        "http://www.ncbi.nlm.nih.gov/pubmed/7940169",
        "http://www.ncbi.nlm.nih.gov/pubmed/26282898",
        "http://www.ncbi.nlm.nih.gov/pubmed/18027020"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15029391",
          "text": "The independent prognostic factors were: disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease. CONCLUSIONS\nThe liver resection for metastases from colorectal cancer is a safe procedure with more than 30% 5-year survival. Disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease were independent prognostic factors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1168,
          "endSection": "abstract",
          "offsetInEndSection": 1552
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15029391",
          "text": "CONCLUSIONS\nThe liver resection for metastases from colorectal cancer is a safe procedure with more than 30% 5-year survival. Disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease were independent prognostic factors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1301,
          "endSection": "abstract",
          "offsetInEndSection": 1552
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15029391",
          "text": "The independent prognostic factors were: disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease. CONCLUSIONS\nThe liver resection for metastases from colorectal cancer is a safe procedure with more than 30% 5-year survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1168,
          "endSection": "abstract",
          "offsetInEndSection": 1426
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15029391",
          "text": "The 5-year survival rate was 35%. The independent prognostic factors were: disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease. CONCLUSIONS\nThe liver resection for metastases from colorectal cancer is a safe procedure with more than 30% 5-year survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1134,
          "endSection": "abstract",
          "offsetInEndSection": 1426
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9060531",
          "text": "By multivariate analysis, positive margin, size greater than 10 cm, disease-free interval less than 12 months, multiple tumors, and extrahepatic disease were independent predictors of poorer outcome. Short disease-free interval or multiple tumors were nevertheless associated with a 5-year survival rate greater than 24%. CONCLUSION\nLiver resection for colorectal metastases is safe and effective therapy and currently represents the only potentially curative therapy for metastatic colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1166,
          "endSection": "abstract",
          "offsetInEndSection": 1669
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1575626",
          "text": "Careful patient selection for hepatic resection of colorectal cancer metastases is essential to improve current poor results. Carcinoembryonic antigen level and number of metastases were significant preoperative prognostic indicators of 5-year disease-free survival in patients selected clinically for hepatic surgery. Surgical margin, weight of hepatic tissue resected, carcinoembryonic antigen level, and flow cytometry were significant postoperative prognostic indicators.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 475
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16241086",
          "text": "The multivariate analysis showed three independent negative prognostic factors: G3-G4 primary cancer, CEA level > 5 ng/ml, and high MSKCC-CRS class. No single prognostic factor turned out to be associated with such disappointing outcomes after hepatic surgery for colorectal liver metastases as to permit the identification of specific subgroups of patients to be excluded on principle from undergoing liver resection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2151,
          "endSection": "abstract",
          "offsetInEndSection": 2569
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16241086",
          "text": "The aim of the study was to analyse the prognostic factors for long-term outcome of liver resections for metastases from colorectal cancer. The retrospective analysis included 297 liver resections for colorectal carcinoma liver metastases. The following prognostic factors were considered: age, gender, stage and grade of differentiation of the primary tumour, node metastases, site of the primary colorectal cancer, number and diameter of the hepatic lesions, time interval from primary cancer to liver metastases, preoperative CEA level, adjuvant chemotherapy after hepatic resection, type of hepatic resection, use of intraoperative ultrasound and portal triad clamping, blood loss and transfusions, postoperative complications and hospital stay, tumour-free surgical margins, clinical risk score (as defined by the Memorial Sloan-Kettering Cancer Centre group, MSKCC-CRS).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 876
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16241086",
          "text": "The multivariate analysis showed three independent negative prognostic factors: G3-G4 primary cancer, CEA level > 5 ng/ml, and high MSKCC-CRS class. No single prognostic factor turned out to be associated with such disappointing outcomes after hepatic surgery for colorectal liver metastases as to permit the identification of specific subgroups of patients to be excluded on principle from undergoing liver resection. However, in the presence of a number of specific prognostic factors (G3-G4 grade of differentiation of the primary tumour, preoperative CEA level > 5 ng/ml, high MSKCC-CRS) enrolment of the patient in trials exploring new diagnostic tools or new adjuvant treatments may be suggested to improve the preoperative staging of the disease and reduce the incidence of tumour recurrence after liver resection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2151,
          "endSection": "abstract",
          "offsetInEndSection": 2972
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15029391",
          "text": "The primary tumor was resected in all the patients. A screening protocol for liver metastases including clinical examinations every three months, ultrassonography and CEA level until 5 years of follow-up and after every 6 months, was applied. The prognostic factors analyzed regarding the impact on survival were: Dukes C stage of primary tumor, size of metastasis >5 cm, a disease-free interval from primary tumor to metastasis < 1 year, CEA level > 100 ng/mL, resection margins < 1 cm and extrahepatic disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 445,
          "endSection": "abstract",
          "offsetInEndSection": 957
        }
      ],
      "ideal_answer": "The clinical conditions that influence the prognostic after the liver metastasis resection from colorectal cancer patients are disease-free interval less than 1 year and extrahepatic disease.",
      "exact_answer": [
        [
          "disease-free interval < 1 year"
        ],
        [
          "extrahepatic disease"
        ]
      ]
    },
    {
      "id": "661be07748a2c27714000002",
      "type": "summary",
      "body": "What is Lennox-Gastaut syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37353676",
        "http://www.ncbi.nlm.nih.gov/pubmed/37054522",
        "http://www.ncbi.nlm.nih.gov/pubmed/36700706",
        "http://www.ncbi.nlm.nih.gov/pubmed/34183143",
        "http://www.ncbi.nlm.nih.gov/pubmed/29124439",
        "http://www.ncbi.nlm.nih.gov/pubmed/25400619",
        "http://www.ncbi.nlm.nih.gov/pubmed/21353345",
        "http://www.ncbi.nlm.nih.gov/pubmed/14734932",
        "http://www.ncbi.nlm.nih.gov/pubmed/24902608",
        "http://www.ncbi.nlm.nih.gov/pubmed/31879735"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124439",
          "text": "Lennox-Gastaut syndrome (LGS) is considered an epileptic encephalopathy and is defined by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability. The prevalence of LGS is estimated between 1 and 2% of all patients with epilepsy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 359
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34183143",
          "text": "Lennox Gastaut Syndrome (LGS) is a severe developmental epileptic encephalopathy with onset in childhood characterized by multiple seizure types and characteristic electroencephalogram findings. The majority of patients develop drug resistant epilepsy, defined as failure of 2 appropriate anti-seizure medications used at adequate doses.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 337
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124439",
          "text": "Lennox-Gastaut syndrome (LGS) is considered an epileptic encephalopathy and is defined by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 276
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124439",
          "text": "Lennox-Gastaut syndrome (LGS) is considered an epileptic encephalopathy and is defined by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability. The prevalence of LGS is estimated between 1 and 2% of all patients with epilepsy. The etiology of LGS is often divided into two groups: identifiable (genetic-structural-metabolic) in 65 to 75% of the patients and LGS of unknown cause in others.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 522
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34183143",
          "text": "Lennox Gastaut Syndrome (LGS) is a severe developmental epileptic encephalopathy with onset in childhood characterized by multiple seizure types and characteristic electroencephalogram findings. The majority of patients develop drug resistant epilepsy, defined as failure of 2 appropriate anti-seizure medications used at adequate doses. Epilepsy surgery can reduce seizure burden, in some cases leading to seizure freedom, and improve neuro-developmental outcomes and quality of life.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 485
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400619",
          "text": "Lennox-Gastaut Syndrome (LGS) is a category of severe, disabling epilepsy, characterized by frequent, treatment-resistant seizures, and cognitive impairment. Electroencephalography (EEG) shows characteristic generalized epileptic activity that is similar in those with lesional, genetic, or unknown causes, suggesting a common underlying mechanism. The condition typically begins in young children, leaving many severely disabled with recurring seizures throughout their adult life.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 482
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400619",
          "text": "Lennox-Gastaut Syndrome (LGS) is a category of severe, disabling epilepsy, characterized by frequent, treatment-resistant seizures, and cognitive impairment. Electroencephalography (EEG) shows characteristic generalized epileptic activity that is similar in those with lesional, genetic, or unknown causes, suggesting a common underlying mechanism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 348
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21353345",
          "text": "INTRODUCTION\nThe Lennox-Gastaut syndrome (LGS) is one of the most severe epileptic encephalopathies of childhood, characterized by electro-clinical triad of generalized spike-wave activity, slow (POL) in the electroencephalogram (EEG), multiple types of seizures and development delay.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 285
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21353345",
          "text": "INTRODUCTION\nThe Lennox-Gastaut syndrome (LGS) is one of the most severe epileptic encephalopathies of childhood, characterized by electro-clinical triad of generalized spike-wave activity, slow (POL) in the electroencephalogram (EEG), multiple types of seizures and development delay. This paper intends to describe the syndrome in a patient with a history of hypoxic-ischaemic encephalopathy and Lennox-Gastaut syndrome, and a good response to treatment with levetiracetam (LEV). METHOD\nDescriptive study on the development of a 3 year old child with intrauterine asphyxia, multiorgan failure, metabolic acidosis, hypovolemic shock, and seizures with cerebral oedema, who developed a West syndrome, resistant to drug treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 731
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21353345",
          "text": "INTRODUCTION\nThe Lennox-Gastaut syndrome (LGS) is one of the most severe epileptic encephalopathies of childhood, characterized by electro-clinical triad of generalized spike-wave activity, slow (POL) in the electroencephalogram (EEG), multiple types of seizures and development delay. This paper intends to describe the syndrome in a patient with a history of hypoxic-ischaemic encephalopathy and Lennox-Gastaut syndrome, and a good response to treatment with levetiracetam (LEV).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 481
        }
      ],
      "ideal_answer": "Lennox-Gastaut syndrome (LGS) is a severe, drug-resistant developmental and epileptic encephalopathy that affects about 1-2% of epilepsy patients. It is characterized by multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability. The etiology of LGS is often divided into two groups: identifiable (genetic-structural-metabolic) in 65 to 75% of the patients and LGS of unknown cause in others.",
      "exact_answer": "n/a"
    },
    {
      "id": "6616547dfdcbea915f00004f",
      "type": "factoid",
      "body": "What is the prevalence of neurofibromatosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
        "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
        "http://www.ncbi.nlm.nih.gov/pubmed/29215653",
        "http://www.ncbi.nlm.nih.gov/pubmed/26564071",
        "http://www.ncbi.nlm.nih.gov/pubmed/8641867",
        "http://www.ncbi.nlm.nih.gov/pubmed/20412983",
        "http://www.ncbi.nlm.nih.gov/pubmed/10344311",
        "http://www.ncbi.nlm.nih.gov/pubmed/17202204",
        "http://www.ncbi.nlm.nih.gov/pubmed/22832780",
        "http://www.ncbi.nlm.nih.gov/pubmed/15117362"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29215653",
          "text": "PURPOSE\nThe incidence of neurofibromatosis 1 (NF1) is ~1/2,000 live births, but the current estimates of prevalence vary greatly.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 129
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29215653",
          "text": "PURPOSE\nThe incidence of neurofibromatosis 1 (NF1) is ~1/2,000 live births, but the current estimates of prevalence vary greatly. This retrospective total-population study was aimed at determining the prevalence of NF1 in Finland.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 230
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29215653",
          "text": "PURPOSE\nThe incidence of neurofibromatosis 1 (NF1) is ~1/2,000 live births, but the current estimates of prevalence vary greatly. This retrospective total-population study was aimed at determining the prevalence of NF1 in Finland. METHODS\nAll secondary and tertiary referral centers of Finland were searched for NF1 patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 327
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
          "text": "OBJECTIVE\nTo obtain updated estimates of the incidence and prevalence of neurofibromatosis type 1 (NF1) and type 2 (NF2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 121
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
          "text": "OBJECTIVE\nTo obtain updated estimates of the incidence and prevalence of neurofibromatosis type 1 (NF1) and type 2 (NF2). STUDY DESIGN\nWe conducted a systematic search of NF1 and NF2 incidence or prevalence studies, in OVID Medline, OVID Embase, Web of Science, and Cinahl. Studies were appraised with the Joanna Briggs Institute Prevalence Critical Appraisal tool.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37710322",
          "text": "OBJECTIVE\nTo obtain updated estimates of the incidence and prevalence of neurofibromatosis type 1 (NF1) and type 2 (NF2). STUDY DESIGN\nWe conducted a systematic search of NF1 and NF2 incidence or prevalence studies, in OVID Medline, OVID Embase, Web of Science, and Cinahl.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 275
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
          "text": "UNLABELLED\nA strong relationship between congenital pseudarthrosis of the tibia (CPT) and neurofibromatosis type 1 (NF1) has been suggested, but prevalence varies widely throughout the literature and the criteria used for diagnosis are very heterogeneous. Literature focus is mainly on treatment and no specific review on the prevalence of NF1 has been published.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
          "text": "UNLABELLED\nA strong relationship between congenital pseudarthrosis of the tibia (CPT) and neurofibromatosis type 1 (NF1) has been suggested, but prevalence varies widely throughout the literature and the criteria used for diagnosis are very heterogeneous. Literature focus is mainly on treatment and no specific review on the prevalence of NF1 has been published. Based on our own observations, we hypothesized the prevalence of NF1 in patients with CPT to be higher than what is previously accepted.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 500
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
          "text": "What is New: • Prevalence of neurofibromatosis type 1 in patient with congenital pseudarthrosis of the tibia might be higher than what is reported until now.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1361,
          "endSection": "abstract",
          "offsetInEndSection": 1518
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27519821",
          "text": "UNLABELLED\nA strong relationship between congenital pseudarthrosis of the tibia (CPT) and neurofibromatosis type 1 (NF1) has been suggested, but prevalence varies widely throughout the literature and the criteria used for diagnosis are very heterogeneous.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 255
        }
      ],
      "ideal_answer": "The prevalence of neurofibromatosis type 1 (NF1) is 1 in 2,662 and the birth incidence is 1 in 2,662. The prevalence of neurofibromatosis type 2 (NF2) is 1.08 per 50,000 births.",
      "exact_answer": [
        "1 in 2,662"
      ]
    },
    {
      "id": "661d96c9eac11fad33000028",
      "type": "factoid",
      "body": "What is the key transcription factor for melanocyte development and differentiation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
        "http://www.ncbi.nlm.nih.gov/pubmed/16899407",
        "http://www.ncbi.nlm.nih.gov/pubmed/31709752",
        "http://www.ncbi.nlm.nih.gov/pubmed/28249010",
        "http://www.ncbi.nlm.nih.gov/pubmed/22570637",
        "http://www.ncbi.nlm.nih.gov/pubmed/20952536",
        "http://www.ncbi.nlm.nih.gov/pubmed/10080955",
        "http://www.ncbi.nlm.nih.gov/pubmed/16140982",
        "http://www.ncbi.nlm.nih.gov/pubmed/21326905",
        "http://www.ncbi.nlm.nih.gov/pubmed/21199918"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 141,
          "endSection": "abstract",
          "offsetInEndSection": 529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2). Loss-of-function mutations of MITF cause Waardenburg syndrome type IIA, whose phenotypes include depigmentation due to melanocyte loss, whereas amplification or specific mutation of MITF can be an oncogenic event that is seen in a subset of familial or sporadic melanomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 141,
          "endSection": "abstract",
          "offsetInEndSection": 802
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Certain transcription factors have vital roles in lineage development, including specification of cell types and control of differentiation. Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation. MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "Certain transcription factors have vital roles in lineage development, including specification of cell types and control of differentiation. Microphthalmia-associated transcription factor (MITF) is a key transcription factor for melanocyte development and differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 273,
          "endSection": "abstract",
          "offsetInEndSection": 529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16899407",
          "text": "Microphthalmia-associated transcription factor (MITF) acts as a master regulator of melanocyte development, function and survival by modulating various differentiation and cell-cycle progression genes. It has been demonstrated that MITF is an amplified oncogene in a fraction of human melanomas and that it also has an oncogenic role in human clear cell sarcoma. However, MITF also modulates the state of melanocyte differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 432
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16899407",
          "text": "Microphthalmia-associated transcription factor (MITF) acts as a master regulator of melanocyte development, function and survival by modulating various differentiation and cell-cycle progression genes. It has been demonstrated that MITF is an amplified oncogene in a fraction of human melanomas and that it also has an oncogenic role in human clear cell sarcoma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 362
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2). Loss-of-function mutations of MITF cause Waardenburg syndrome type IIA, whose phenotypes include depigmentation due to melanocyte loss, whereas amplification or specific mutation of MITF can be an oncogenic event that is seen in a subset of familial or sporadic melanomas. In this article, we review basic features of MITF biological function and highlight key unresolved questions regarding this remarkable transcription factor.",
          "beginSection": "abstract",
          "offsetInBeginSection": 273,
          "endSection": "abstract",
          "offsetInEndSection": 959
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16899407",
          "text": "Microphthalmia-associated transcription factor (MITF) acts as a master regulator of melanocyte development, function and survival by modulating various differentiation and cell-cycle progression genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 201
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263292",
          "text": "MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2). Loss-of-function mutations of MITF cause Waardenburg syndrome type IIA, whose phenotypes include depigmentation due to melanocyte loss, whereas amplification or specific mutation of MITF can be an oncogenic event that is seen in a subset of familial or sporadic melanomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 273,
          "endSection": "abstract",
          "offsetInEndSection": 802
        }
      ],
      "ideal_answer": "The key transcription factor for melanocyte development and differentiation is MITF, which regulates the expression of numerous pigmentation genes to promote melanocyte differentiation and fundamental genes for maintaining cell homeostasis.",
      "exact_answer": [
        "MITF"
      ]
    },
    {
      "id": "661d48a2eac11fad33000018",
      "type": "factoid",
      "body": "What is the cause of Phenylketonuria (PKU)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
        "http://www.ncbi.nlm.nih.gov/pubmed/31648944",
        "http://www.ncbi.nlm.nih.gov/pubmed/29909188",
        "http://www.ncbi.nlm.nih.gov/pubmed/11139255",
        "http://www.ncbi.nlm.nih.gov/pubmed/18566668",
        "http://www.ncbi.nlm.nih.gov/pubmed/24510568",
        "http://www.ncbi.nlm.nih.gov/pubmed/11180595",
        "http://www.ncbi.nlm.nih.gov/pubmed/7967476",
        "http://www.ncbi.nlm.nih.gov/pubmed/37553307",
        "http://www.ncbi.nlm.nih.gov/pubmed/30389586"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
          "text": "Phenylketonuria (PKU) is an inborn error caused by deficiencies in phenylalanine (Phe) metabolism. Mutations in the phenylalanine hydroxylase (PAH) gene are the main cause of the disease whose signature hallmarks of toxically elevated levels of Phe accumulation in plasma and organs such as the brain, result in irreversible intellectual disability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 349
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
          "text": "Phenylketonuria (PKU) is an inborn error caused by deficiencies in phenylalanine (Phe) metabolism. Mutations in the phenylalanine hydroxylase (PAH) gene are the main cause of the disease whose signature hallmarks of toxically elevated levels of Phe accumulation in plasma and organs such as the brain, result in irreversible intellectual disability. Here, we present a unique approach to treating PKU deficiency by using an mRNA replacement therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31648944",
          "text": "In phenylketonuria (PKU), mutations of the phenylalanine hydroxylase (PAH) gene decrease the ability of PAH to convert phenylalanine (Phe) to tyrosine (Tyr), resulting in Phe accumulation in the blood and brain and disruption of neurotransmitter (NT) biosynthesis and metabolism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
          "text": "Mutations in the phenylalanine hydroxylase (PAH) gene are the main cause of the disease whose signature hallmarks of toxically elevated levels of Phe accumulation in plasma and organs such as the brain, result in irreversible intellectual disability. Here, we present a unique approach to treating PKU deficiency by using an mRNA replacement therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 99,
          "endSection": "abstract",
          "offsetInEndSection": 449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
          "text": "Mutations in the phenylalanine hydroxylase (PAH) gene are the main cause of the disease whose signature hallmarks of toxically elevated levels of Phe accumulation in plasma and organs such as the brain, result in irreversible intellectual disability. Here, we present a unique approach to treating PKU deficiency by using an mRNA replacement therapy. A full-length mRNA encoding human PAH (hPAH) is encapsulated in our proprietary lipid nanoparticle LUNAR and delivered to a Pah enu2 mouse model that carries a missense mutation in the mouse PAH gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 99,
          "endSection": "abstract",
          "offsetInEndSection": 650
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29909188",
          "text": "Phenylketonuria (PKU) is a prevalent inherited metabolic disorder caused by a phenylalanine hydroxylase (PAH) or tetrahydrobiopterin (BH4) deficiency, which leads to the accumulation of phenylalanine (PHE). High blood levels of PHE have a toxic effect on the brain and are associated with several neurological signs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 316
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29909188",
          "text": "Phenylketonuria (PKU) is a prevalent inherited metabolic disorder caused by a phenylalanine hydroxylase (PAH) or tetrahydrobiopterin (BH4) deficiency, which leads to the accumulation of phenylalanine (PHE). High blood levels of PHE have a toxic effect on the brain and are associated with several neurological signs. Most cases of PKU are identified during infancy, and diagnosis of PKU in adult is rare.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18566668",
          "text": "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH). Most forms of PKU and hyperphenylalaninaemia (HPA) are caused by mutations in the PAH gene on chromosome 12q23.2. Untreated PKU is associated with an abnormal phenotype which includes growth failure, poor skin pigmentation, microcephaly, seizures, global developmental delay and severe intellectual impairment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 467
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31648944",
          "text": "In phenylketonuria (PKU), mutations of the phenylalanine hydroxylase (PAH) gene decrease the ability of PAH to convert phenylalanine (Phe) to tyrosine (Tyr), resulting in Phe accumulation in the blood and brain and disruption of neurotransmitter (NT) biosynthesis and metabolism. The following translational study explored the relationship between pegvaliase-mediated Phe correction in plasma and the NT biosynthesis and metabolism pathway in mice and humans with PKU.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 468
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35356682",
          "text": "Mutations in the phenylalanine hydroxylase (PAH) gene are the main cause of the disease whose signature hallmarks of toxically elevated levels of Phe accumulation in plasma and organs such as the brain, result in irreversible intellectual disability.",
          "beginSection": "abstract",
          "offsetInBeginSection": 99,
          "endSection": "abstract",
          "offsetInEndSection": 349
        }
      ],
      "ideal_answer": "Phenylketonuria (PKU) is caused by mutations in the PAH gene, which leads to deficiencies in phenylalanine (Phe) metabolism and results in toxically elevated levels of Phe accumulation in plasma and organs such as the brain, causing irreversible intellectual disability.",
      "exact_answer": [
        "Mutations in the PAH gene"
      ]
    },
    {
      "id": "65cebc0c1930410b13000003",
      "type": "factoid",
      "body": "Which disease is treated with nirsevimab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36577878",
        "http://www.ncbi.nlm.nih.gov/pubmed/36634694",
        "http://www.ncbi.nlm.nih.gov/pubmed/36599520",
        "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
        "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
        "http://www.ncbi.nlm.nih.gov/pubmed/36328884",
        "http://www.ncbi.nlm.nih.gov/pubmed/37901217",
        "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
        "http://www.ncbi.nlm.nih.gov/pubmed/37616235",
        "http://www.ncbi.nlm.nih.gov/pubmed/36922390"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "INTRODUCTION\nNirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain. OBJECTIVES\nTo provide recommendations for the administration of nirsevimab for prevention of RSV disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 285
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
          "text": "Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 156
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "INTRODUCTION\nNirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain. OBJECTIVES\nTo provide recommendations for the administration of nirsevimab for prevention of RSV disease. METHODS\nThe approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 438
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
          "text": "INTRODUCTION\nNirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36328884",
          "text": "INTRODUCTION\nRespiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease. A new and potentially longer-lasting monoclonal antibody, Nirsevimab, showed promising results in phase IIb/III trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 353
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
          "text": "Respiratory syncytial virus (RSV) infects nearly all infants in their first year of life and is the leading cause of hospitalization for infants younger than 1 year of age in the United States. Historically, the only option for RSV prevention was palivizumab. However, not all infants are eligible for palivizumab, it requires multiple doses per RSV season, and it is costly.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 375
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
          "text": "INTRODUCTION\nRespiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract infection (LRTI) in infants and young children. Palivizumab is an RSV-specific prophylactic for use in high-risk infants but treatment requires monthly injections and only modestly reduces hospitalization. Thus, new immunoprophylactic candidates are under development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 369
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
          "text": "INTRODUCTION\nRespiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract infection (LRTI) in infants and young children. Palivizumab is an RSV-specific prophylactic for use in high-risk infants but treatment requires monthly injections and only modestly reduces hospitalization.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 306
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
          "text": "Respiratory syncytial virus (RSV) infects nearly all infants in their first year of life and is the leading cause of hospitalization for infants younger than 1 year of age in the United States. Historically, the only option for RSV prevention was palivizumab.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 259
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38070539",
          "text": "In July 2023, the U.S. Food and Drug Administration approved nirsevimab for the prevention of RSV-associated lower respiratory tract infections for all infants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 376,
          "endSection": "abstract",
          "offsetInEndSection": 536
        }
      ],
      "ideal_answer": "Respiratory syncytial virus (RSV) is treated with nirsevimab.",
      "exact_answer": [
        "Respiratory syncytial virus"
      ]
    },
    {
      "id": "660998ecfdcbea915f000014",
      "type": "summary",
      "body": "Why does rectal cancer have worse prognosis than other colon tumors?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30200215",
        "http://www.ncbi.nlm.nih.gov/pubmed/27497831",
        "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
        "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
        "http://www.ncbi.nlm.nih.gov/pubmed/10836006",
        "http://www.ncbi.nlm.nih.gov/pubmed/30577807",
        "http://www.ncbi.nlm.nih.gov/pubmed/15462343",
        "http://www.ncbi.nlm.nih.gov/pubmed/18334831",
        "http://www.ncbi.nlm.nih.gov/pubmed/22188913",
        "http://www.ncbi.nlm.nih.gov/pubmed/19581844"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "The prognosis of rectal cancer was not worse than that of colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1401,
          "endSection": "abstract",
          "offsetInEndSection": 1472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "CONCLUSION\nThis was a population-based study. The prognosis of rectal cancer was not worse than that of colon cancer. Local advanced colorectal cancer had a poorer prognosis than local regional lymph node metastasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1355,
          "endSection": "abstract",
          "offsetInEndSection": 1571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "The prognosis of rectal cancer was not worse than that of colon cancer. Local advanced colorectal cancer had a poorer prognosis than local regional lymph node metastasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1401,
          "endSection": "abstract",
          "offsetInEndSection": 1571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "The prognosis of rectal cancer was not worse than that of colon cancer. Local advanced colorectal cancer had a poorer prognosis than local regional lymph node metastasis. Stage IIB might require more aggressive chemotherapy, and no less than that for stage III.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1401,
          "endSection": "abstract",
          "offsetInEndSection": 1662
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
          "text": "Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers, and these patient subgroups respond differently to biological therapies. Historically, management of patients with metastatic colon and rectal cancers has been similar, and colon and rectal cancer patients have been grouped together in large clinical trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
          "text": "Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers, and these patient subgroups respond differently to biological therapies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 344
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
          "text": "Tumor sidedness has emerged as an important prognostic and predictive factor in the treatment of colorectal cancer. Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers, and these patient subgroups respond differently to biological therapies. Historically, management of patients with metastatic colon and rectal cancers has been similar, and colon and rectal cancer patients have been grouped together in large clinical trials.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265711",
          "text": "CONCLUSION\nThis was a population-based study. The prognosis of rectal cancer was not worse than that of colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1355,
          "endSection": "abstract",
          "offsetInEndSection": 1472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29156800",
          "text": "Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers, and these patient subgroups respond differently to biological therapies. Historically, management of patients with metastatic colon and rectal cancers has been similar, and colon and rectal cancer patients have been grouped together in large clinical trials. Clearly, the differences in molecular biology among right-sided colon, left-sided colon, and rectal cancers should be further studied in order to account for disparities in clinical outcomes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 722
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30577807",
          "text": "Right-sided colon cancer (RCC) has worse prognosis compared to left-sided colon cancer (LCC) and rectal cancer. The reason for this difference in outcomes is not well understood. We performed comparative somatic and proteomic analyses of RCC, LCC and rectal cancers to understand the unique molecular features of each tumor sub-types.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 334
        }
      ],
      "ideal_answer": "Rectal cancer does not have worse prognosis than other colon tumors. However, recent studies show that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers. The differences in molecular biology among right-sided colon, left-sided colon, and rectal cancers should be further studied to account for disparities in clinical outcomes.",
      "exact_answer": "n/a"
    },
    {
      "id": "661a6733fdcbea915f00005c",
      "type": "yesno",
      "body": "Is Loeys-Dietz syndrome (LDS) associated with Aortic Aneurysm?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37823753",
        "http://www.ncbi.nlm.nih.gov/pubmed/37916856",
        "http://www.ncbi.nlm.nih.gov/pubmed/37755470",
        "http://www.ncbi.nlm.nih.gov/pubmed/33487195",
        "http://www.ncbi.nlm.nih.gov/pubmed/37876949",
        "http://www.ncbi.nlm.nih.gov/pubmed/31724649",
        "http://www.ncbi.nlm.nih.gov/pubmed/29687491",
        "http://www.ncbi.nlm.nih.gov/pubmed/30534260",
        "http://www.ncbi.nlm.nih.gov/pubmed/21801912",
        "http://www.ncbi.nlm.nih.gov/pubmed/20662229"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31724649",
          "text": "Loeys-Dietz syndrome (LDS) is a recently reported autosomal dominant aortic aneurysm syndrome with widespread systemic involvement.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 131
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31724649",
          "text": "Loeys-Dietz syndrome (LDS) is a recently reported autosomal dominant aortic aneurysm syndrome with widespread systemic involvement. Although connective tissue diseases carry a theoretical risk of aneurysmal degeneration in vein grafts, there are no reports of vein graft aneurysm (VGA) in patients with connective tissue disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 329
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21801912",
          "text": "BACKGROUND\nLoeys-Dietz syndrome (LDS) is a recently recognized aggressive aortic disorder characterized by root aneurysm, arterial tortuosity, hypertelorism, and bifid uvula or cleft palate.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 190
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37876949",
          "text": "Loeys-Dietz syndrome (LDS) is less commonly seen as a cause of ascending aortic aneurysms in children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 171,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37876949",
          "text": "Loeys-Dietz syndrome (LDS) is less commonly seen as a cause of ascending aortic aneurysms in children. In this case report, we describe pediatric Bentall procedure, which we successfully performed to a child with LDS (Type I) with giant ascending aortic enlargement and significant aortic regurgitation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 171,
          "endSection": "abstract",
          "offsetInEndSection": 474
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20662229",
          "text": "After the 1st operation, she was diagnosed with Loeys-Dietz syndrome (LDS), which is recently described as an autosomal dominant aortic aneurysm syndrome caused by heterozygous mutations in the transforming growth factor-beta receptor type 1 and 2 genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 299,
          "endSection": "abstract",
          "offsetInEndSection": 553
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31724649",
          "text": "Loeys-Dietz syndrome (LDS) is a recently reported autosomal dominant aortic aneurysm syndrome with widespread systemic involvement. Although connective tissue diseases carry a theoretical risk of aneurysmal degeneration in vein grafts, there are no reports of vein graft aneurysm (VGA) in patients with connective tissue disease. We herein report the first case of a giant VGA that was manifested 5 years after the reconstruction of a popliteal artery aneurysm associated with LDS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 481
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20662229",
          "text": "After the 1st operation, she was diagnosed with Loeys-Dietz syndrome (LDS), which is recently described as an autosomal dominant aortic aneurysm syndrome caused by heterozygous mutations in the transforming growth factor-beta receptor type 1 and 2 genes. Only 2 months after the 1st operation, she developed heart failure due to recurrence of aortic regurgitation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 299,
          "endSection": "abstract",
          "offsetInEndSection": 663
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33487195",
          "text": "Loeys-Dietz syndrome is a connective tissue disorder known to cause aggressive aortopathy in paediatric patients, but it is extremely rare for cardiovascular events to present during infancy. We report the first successful aortic repair in a neonate with LDS presenting in extremis with an early onset, massive aortic aneurysm.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 327
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21801912",
          "text": "BACKGROUND\nLoeys-Dietz syndrome (LDS) is a recently recognized aggressive aortic disorder characterized by root aneurysm, arterial tortuosity, hypertelorism, and bifid uvula or cleft palate. The results of prophylactic root replacement using valve-sparing procedures (valve-sparing root replacement [VSRR]) in patients with LDS is not known.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 341
        }
      ],
      "ideal_answer": "Yes, Loeys-Dietz syndrome (LDS) is associated with Aortic Aneurysm.",
      "exact_answer": "yes"
    },
    {
      "id": "66150366fdcbea915f000046",
      "type": "summary",
      "body": "What is borderline personality disorder?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
        "http://www.ncbi.nlm.nih.gov/pubmed/29505390",
        "http://www.ncbi.nlm.nih.gov/pubmed/15342323",
        "http://www.ncbi.nlm.nih.gov/pubmed/19287553",
        "http://www.ncbi.nlm.nih.gov/pubmed/32547429",
        "http://www.ncbi.nlm.nih.gov/pubmed/28301180",
        "http://www.ncbi.nlm.nih.gov/pubmed/35166488",
        "http://www.ncbi.nlm.nih.gov/pubmed/36853245",
        "http://www.ncbi.nlm.nih.gov/pubmed/9811134",
        "http://www.ncbi.nlm.nih.gov/pubmed/15992977"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "Borderline personality disorder.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 32
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "Caretakers are often intimidated or alienated by patients with borderline personality disorder (BPD), compounding the clinical challenges posed by the severe morbidity, high social costs and substantial prevalence of this disorder in many health-care settings. BPD is found in ∼1.7% of the general population but in 15-28% of patients in psychiatric clinics or hospitals and in a large proportion of individuals seeking help for psychological problems in general health facilities. BPD is characterized by extreme sensitivity to perceived interpersonal slights, an unstable sense of self, intense and volatile emotionality and impulsive behaviours that are often self-destructive.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 680
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "Caretakers are often intimidated or alienated by patients with borderline personality disorder (BPD), compounding the clinical challenges posed by the severe morbidity, high social costs and substantial prevalence of this disorder in many health-care settings. BPD is found in ∼1.7% of the general population but in 15-28% of patients in psychiatric clinics or hospitals and in a large proportion of individuals seeking help for psychological problems in general health facilities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 481
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "Caretakers are often intimidated or alienated by patients with borderline personality disorder (BPD), compounding the clinical challenges posed by the severe morbidity, high social costs and substantial prevalence of this disorder in many health-care settings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 260
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29505390",
          "text": "Ongoing research is shifting towards a dimensional understanding of borderline personality disorder (BPD). Aim of this study was to identify personality profiles in BPD that are predictive of self-destructive behaviors. Personality traits were assessed (n = 130) according to the five-factor model of personality (i.e., Neuroticism, Extraversion, Openness to Experience, Agreeableness, Conscientiousness) and an additional factor called Risk Preference.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 453
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "BPD is found in ∼1.7% of the general population but in 15-28% of patients in psychiatric clinics or hospitals and in a large proportion of individuals seeking help for psychological problems in general health facilities. BPD is characterized by extreme sensitivity to perceived interpersonal slights, an unstable sense of self, intense and volatile emotionality and impulsive behaviours that are often self-destructive.",
          "beginSection": "abstract",
          "offsetInBeginSection": 261,
          "endSection": "abstract",
          "offsetInEndSection": 680
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795363",
          "text": "BPD is found in ∼1.7% of the general population but in 15-28% of patients in psychiatric clinics or hospitals and in a large proportion of individuals seeking help for psychological problems in general health facilities. BPD is characterized by extreme sensitivity to perceived interpersonal slights, an unstable sense of self, intense and volatile emotionality and impulsive behaviours that are often self-destructive. Most patients gradually enter symptomatic remission, and their rate of remission can be accelerated by evidence-based psychosocial treatments.",
          "beginSection": "abstract",
          "offsetInBeginSection": 261,
          "endSection": "abstract",
          "offsetInEndSection": 823
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19287553",
          "text": "Borderline personality disorder was assessed with the following 3 measures: the borderline personality scale of the Personality Diagnostic Questionnaire-4 (PDQ-4), the Self-Harm Inventory (SHI), and the McLean Screening Inventory for Borderline Personality Disorder (MSI-BPD). Data were collected from May 2006 to November 2007. RESULTS\nFor the 76 respondents (63.3%) who reported having engaged in at least 1 medically self-sabotaging behavior, the mean number of different medically self-sabotaging behaviors was 4.11 (SD = 3.93).",
          "beginSection": "abstract",
          "offsetInBeginSection": 540,
          "endSection": "abstract",
          "offsetInEndSection": 1074
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29505390",
          "text": "Ongoing research is shifting towards a dimensional understanding of borderline personality disorder (BPD). Aim of this study was to identify personality profiles in BPD that are predictive of self-destructive behaviors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32547429",
          "text": "Self-harm is considered a pervasive problem in several psychopathologies, and especially in Borderline Personality Disorder (BPD). Self-harming behaviors may be enacted for many purposes for example to regulate emotions and to reduce dissociation. BPD patients often report dissociative episodes, which may be related to an altered body awareness, and in particular to an altered awareness of the sense of agency.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 413
        }
      ],
      "ideal_answer": "Borderline personality disorder (BPD) is a mental health condition characterized by extreme sensitivity to perceived interpersonal slights, an unstable sense of self, intense and volatile emotionality, impulsive behaviors that are often self-destructive, and persistent social disabilities related to depression or self-harming behaviors. It is found in approximately 1.7% of the general population, but its prevalence is significantly higher in psychiatric clinics, hospitals, and general health facilities.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d9cc3eac11fad33000029",
      "type": "summary",
      "body": "What is the role of the FOXA1 transcription factor in estrogen-receptor-positive (ER+) breast cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
        "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
        "http://www.ncbi.nlm.nih.gov/pubmed/21503684",
        "http://www.ncbi.nlm.nih.gov/pubmed/27791031",
        "http://www.ncbi.nlm.nih.gov/pubmed/31826955",
        "http://www.ncbi.nlm.nih.gov/pubmed/25707489",
        "http://www.ncbi.nlm.nih.gov/pubmed/17163418",
        "http://www.ncbi.nlm.nih.gov/pubmed/23771556",
        "http://www.ncbi.nlm.nih.gov/pubmed/22476979",
        "http://www.ncbi.nlm.nih.gov/pubmed/37568077"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. Mechanistically, H-FOXA1 reprograms ER-chromatin binding to elicit a core gene signature (CGS) enriched in ER+ endocrine-resistant (EndoR) cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 471
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. Mechanistically, H-FOXA1 reprograms ER-chromatin binding to elicit a core gene signature (CGS) enriched in ER+ endocrine-resistant (EndoR) cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 99,
          "endSection": "abstract",
          "offsetInEndSection": 471
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 325
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 99,
          "endSection": "abstract",
          "offsetInEndSection": 325
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. Mechanistically, H-FOXA1 reprograms ER-chromatin binding to elicit a core gene signature (CGS) enriched in ER+ endocrine-resistant (EndoR) cells. We identify Secretome14, a CGS subset encoding ER-dependent cancer secretory proteins, as a strong predictor for poor outcomes of ER+ BC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 609
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 325
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37467106",
          "text": "Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 326
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31826955",
          "text": "Forkhead box A1 (FOXA1) is a pioneer factor that facilitates chromatin binding and function of lineage-specific and oncogenic transcription factors. Hyperactive FOXA1 signaling due to gene amplification or overexpression has been reported in estrogen receptor-positive (ER+) endocrine-resistant metastatic breast cancer. However, the molecular mechanisms by which FOXA1 up-regulation promotes these processes and the key downstream targets of the FOXA1 oncogenic network remain elusive.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 486
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
          "text": "FoxA1 acts as a pioneer factor for both androgen receptor (AR) and estrogen receptor-α (ER), dictating the binding location, and therefore function of these transcription factors. It is an essential protein for the transcriptional activity of both ER and AR, yet it has distinct roles with the two different nuclear receptors. In both malignancies, FoxA1 plays a pivotal role from early stage cancer through to drug resistant and metastatic disease. Due to this key role in mediating ER and AR function, FoxA1 is not only an attractive therapeutic target but could potentially function as a novel biomarker.",
          "beginSection": "abstract",
          "offsetInBeginSection": 120,
          "endSection": "abstract",
          "offsetInEndSection": 727
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649425",
          "text": "FoxA1 acts as a pioneer factor for both androgen receptor (AR) and estrogen receptor-α (ER), dictating the binding location, and therefore function of these transcription factors. It is an essential protein for the transcriptional activity of both ER and AR, yet it has distinct roles with the two different nuclear receptors. In both malignancies, FoxA1 plays a pivotal role from early stage cancer through to drug resistant and metastatic disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 120,
          "endSection": "abstract",
          "offsetInEndSection": 569
        }
      ],
      "ideal_answer": "The FOXA1 transcription factor plays a pivotal role in estrogen-receptor-positive (ER+) breast cancer, from early stage cancer through to drug resistant and metastatic disease. It is an attractive therapeutic target and could potentially function as a novel biomarker.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d62dceac11fad33000026",
      "type": "summary",
      "body": "How is Huntington's Disease inherited?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35829908",
        "http://www.ncbi.nlm.nih.gov/pubmed/29325616",
        "http://www.ncbi.nlm.nih.gov/pubmed/14960907",
        "http://www.ncbi.nlm.nih.gov/pubmed/25432725",
        "http://www.ncbi.nlm.nih.gov/pubmed/34636452",
        "http://www.ncbi.nlm.nih.gov/pubmed/8715551",
        "http://www.ncbi.nlm.nih.gov/pubmed/20802793",
        "http://www.ncbi.nlm.nih.gov/pubmed/16925544",
        "http://www.ncbi.nlm.nih.gov/pubmed/1387416",
        "http://www.ncbi.nlm.nih.gov/pubmed/26439718"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8715551",
          "text": "Huntington disease is an autosomal dominant inherited disease, characterised by emotional problems, abnormalities of movement and dementia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 163,
          "endSection": "abstract",
          "offsetInEndSection": 302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8715551",
          "text": "Huntington disease is an autosomal dominant inherited disease, characterised by emotional problems, abnormalities of movement and dementia. The disease is slowly progressive leading to a severely debilitated state and finally death in ten to twenty years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 163,
          "endSection": "abstract",
          "offsetInEndSection": 418
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34636452",
          "text": "Huntington disease is an autosomal dominant inherited brain disorder that typically becomes manifest in adulthood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 114
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34636452",
          "text": "Huntington disease is an autosomal dominant inherited brain disorder that typically becomes manifest in adulthood. Juvenile-onset Huntington disease refers to approximately 5% of patients with symptom onset before the age of 21 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 234
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34636452",
          "text": "Huntington disease is an autosomal dominant inherited brain disorder that typically becomes manifest in adulthood. Juvenile-onset Huntington disease refers to approximately 5% of patients with symptom onset before the age of 21 years. The causal factor is a pathologically expanded CAG repeat in the Huntingtin gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 316
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8715551",
          "text": "Huntington disease is an autosomal dominant inherited disease, characterised by emotional problems, abnormalities of movement and dementia. The disease is slowly progressive leading to a severely debilitated state and finally death in ten to twenty years. In 1983, DNA testing became available for persons at risk for Huntington disease and for confirmation of diagnosis for those showing symptoms.",
          "beginSection": "abstract",
          "offsetInBeginSection": 163,
          "endSection": "abstract",
          "offsetInEndSection": 561
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29325616",
          "text": "Huntington disease is a monogenic neurodegenerative disorder that displays an autosomal-dominant pattern of inheritance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 120
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25432725",
          "text": "Huntington disease (HD) is an autosomal dominant inherited neurodegenerative disease characterized by progressive motor, behavioral, and cognitive decline, culminating in death. It is caused by an expanded CAG repeat in the huntingtin gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 240
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25432725",
          "text": "Huntington disease (HD) is an autosomal dominant inherited neurodegenerative disease characterized by progressive motor, behavioral, and cognitive decline, culminating in death.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25432725",
          "text": "Huntington disease (HD) is an autosomal dominant inherited neurodegenerative disease characterized by progressive motor, behavioral, and cognitive decline, culminating in death. It is caused by an expanded CAG repeat in the huntingtin gene. Even years before symptoms become overt, mutation carriers show subtle but progressive striatal and cerebral white matter atrophy by volumetric MRI.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 389
        }
      ],
      "ideal_answer": "Huntington's Disease is inherited in an autosomal dominant pattern, meaning that a child of an affected parent has a 50% chance of inheriting the disease.",
      "exact_answer": "n/a"
    },
    {
      "id": "65cfcd541930410b13000019",
      "type": "factoid",
      "body": "Burrow Ink Test can be used to diagnose which disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
        "http://www.ncbi.nlm.nih.gov/pubmed/23904181",
        "http://www.ncbi.nlm.nih.gov/pubmed/8308357",
        "http://www.ncbi.nlm.nih.gov/pubmed/21268539",
        "http://www.ncbi.nlm.nih.gov/pubmed/33063894",
        "http://www.ncbi.nlm.nih.gov/pubmed/36895725",
        "http://www.ncbi.nlm.nih.gov/pubmed/26492406",
        "http://www.ncbi.nlm.nih.gov/pubmed/28883737",
        "http://www.ncbi.nlm.nih.gov/pubmed/1173898",
        "http://www.ncbi.nlm.nih.gov/pubmed/36028790"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "CONCLUSIONS\nIn the face of such diagnostic inaccuracy, clinical judgment is still practical in diagnosing scabies. Two tests are used - the burrow ink test and handheld dermatoscopy. The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1104,
          "endSection": "abstract",
          "offsetInEndSection": 1398
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients. Handheld dermatoscopy is an accurate test, but requires special equipment and trained practitioners. Given the morbidity and costs of scabies infection, and that studies to date lack adequate internal and external validity, research to identify or develop accurate diagnostic tests for scabies infection is needed and justifiable.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1287,
          "endSection": "abstract",
          "offsetInEndSection": 1729
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": " Two tests are used - the burrow ink test and handheld dermatoscopy. The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients. Handheld dermatoscopy is an accurate test, but requires special equipment and trained practitioners. Given the morbidity and costs of scabies infection, and that studies to date lack adequate internal and external validity, research to identify or develop accurate diagnostic tests for scabies infection is needed and justifiable.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1211,
          "endSection": "abstract",
          "offsetInEndSection": 1722
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "CONCLUSIONS\nIn the face of such diagnostic inaccuracy, clinical judgment is still practical in diagnosing scabies. Two tests are used - the burrow ink test and handheld dermatoscopy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1104,
          "endSection": "abstract",
          "offsetInEndSection": 1286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "The accuracy of other diagnostic tests could not be calculated from the data in the literature. CONCLUSIONS\nIn the face of such diagnostic inaccuracy, clinical judgment is still practical in diagnosing scabies. Two tests are used - the burrow ink test and handheld dermatoscopy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1006,
          "endSection": "abstract",
          "offsetInEndSection": 1286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "Two tests are used - the burrow ink test and handheld dermatoscopy. The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1219,
          "endSection": "abstract",
          "offsetInEndSection": 1398
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1287,
          "endSection": "abstract",
          "offsetInEndSection": 1398
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients. Handheld dermatoscopy is an accurate test, but requires special equipment and trained practitioners.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1287,
          "endSection": "abstract",
          "offsetInEndSection": 1499
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "Two tests are used - the burrow ink test and handheld dermatoscopy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1219,
          "endSection": "abstract",
          "offsetInEndSection": 1286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23205026",
          "text": "Two tests are used - the burrow ink test and handheld dermatoscopy. The burrow ink test is a simple, rapid, noninvasive test that can be used to screen a large number of patients. Handheld dermatoscopy is an accurate test, but requires special equipment and trained practitioners.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1219,
          "endSection": "abstract",
          "offsetInEndSection": 1499
        }
      ],
      "ideal_answer": "Scabies.",
      "exact_answer": [
        "scabies"
      ]
    },
    {
      "id": "6609994bfdcbea915f000017",
      "type": "list",
      "body": "What drugs are effective for the treatment of EGFR inhibitors skin rash?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20142600",
        "http://www.ncbi.nlm.nih.gov/pubmed/32609305",
        "http://www.ncbi.nlm.nih.gov/pubmed/33910927",
        "http://www.ncbi.nlm.nih.gov/pubmed/23314653",
        "http://www.ncbi.nlm.nih.gov/pubmed/24488631",
        "http://www.ncbi.nlm.nih.gov/pubmed/30232957",
        "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
        "http://www.ncbi.nlm.nih.gov/pubmed/24422792",
        "http://www.ncbi.nlm.nih.gov/pubmed/19452131",
        "http://www.ncbi.nlm.nih.gov/pubmed/25039761"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "The EGFR inhibitors (EGFRIS) approved in Canada include the tyrosine kinase inhibitors erlotinib and gefitinib (in selected cases), and the monoclonal antibodies (mAbs) panitumumab and cetuximab. Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash. This reversible condition requires intervention in approximately one third of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 346,
          "endSection": "abstract",
          "offsetInEndSection": 838
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "The EGFR inhibitors (EGFRIS) approved in Canada include the tyrosine kinase inhibitors erlotinib and gefitinib (in selected cases), and the monoclonal antibodies (mAbs) panitumumab and cetuximab. Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash.",
          "beginSection": "abstract",
          "offsetInBeginSection": 346,
          "endSection": "abstract",
          "offsetInEndSection": 750
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314653",
          "text": "Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 135
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33910927",
          "text": "We then conducted a phase I clinical trial testing the hypothesis that topical therapy with the BRAF inhibitor LUT014 could improve skin toxicities induced by EGFR inhibitors. Ten patients with metastatic colorectal cancer who had developed acneiform rash while being treated with cetuximab or panitumumab were enrolled in three cohorts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 256,
          "endSection": "abstract",
          "offsetInEndSection": 593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33910927",
          "text": "We then conducted a phase I clinical trial testing the hypothesis that topical therapy with the BRAF inhibitor LUT014 could improve skin toxicities induced by EGFR inhibitors. Ten patients with metastatic colorectal cancer who had developed acneiform rash while being treated with cetuximab or panitumumab were enrolled in three cohorts. LUT014 was well tolerated, and there were no dose-limiting toxicities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 256,
          "endSection": "abstract",
          "offsetInEndSection": 664
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33910927",
          "text": "BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human skin keratinocytes. We then conducted a phase I clinical trial testing the hypothesis that topical therapy with the BRAF inhibitor LUT014 could improve skin toxicities induced by EGFR inhibitors. Ten patients with metastatic colorectal cancer who had developed acneiform rash while being treated with cetuximab or panitumumab were enrolled in three cohorts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 124,
          "endSection": "abstract",
          "offsetInEndSection": 593
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33910927",
          "text": "The acneiform rash improved in the 6 patients who started with grade 2 rash in the low and intermediate cohorts. We conclude that topical LUT014 is safe and efficacious in improving rash from EGFR inhibitors, consistent with the mechanism of action inducting paradoxical MAPK activation. SIGNIFICANCE: BRAF inhibitor topical therapy could avoid dose reductions of EGFR inhibitors, locally treating the main dose-limiting skin toxicity of this class of agents.This article is highlighted in the In This Issue feature, p. 2113.",
          "beginSection": "abstract",
          "offsetInBeginSection": 665,
          "endSection": "abstract",
          "offsetInEndSection": 1190
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33910927",
          "text": "We conclude that topical LUT014 is safe and efficacious in improving rash from EGFR inhibitors, consistent with the mechanism of action inducting paradoxical MAPK activation. SIGNIFICANCE: BRAF inhibitor topical therapy could avoid dose reductions of EGFR inhibitors, locally treating the main dose-limiting skin toxicity of this class of agents.This article is highlighted in the In This Issue feature, p. 2113.",
          "beginSection": "abstract",
          "offsetInBeginSection": 778,
          "endSection": "abstract",
          "offsetInEndSection": 1190
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash. This reversible condition requires intervention in approximately one third of patients. A proactive, multidisciplinary approach to management can help to improve skin rash and optimize clinical outcomes by preventing EGFRI dose reduction or discontinuation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 542,
          "endSection": "abstract",
          "offsetInEndSection": 1008
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229368",
          "text": "Agents targeting the EGFR-mediated signalling pathway are increasingly part of the therapeutic armamentarium for the treatment of advanced lung, head-and-neck, and colorectal carcinoma. The EGFR inhibitors (EGFRIS) approved in Canada include the tyrosine kinase inhibitors erlotinib and gefitinib (in selected cases), and the monoclonal antibodies (mAbs) panitumumab and cetuximab. Although EGFRIS have been proven effective in the treatment of a variety of malignancies, the entire class of agents is associated with a high prevalence of dermatologic side effects, most commonly skin rash.",
          "beginSection": "abstract",
          "offsetInBeginSection": 160,
          "endSection": "abstract",
          "offsetInEndSection": 750
        }
      ],
      "ideal_answer": "Doxycycline, topical corticosteroids, skin moisturizers, and sunscreen are effective for the treatment of EGFR inhibitors skin rash.",
      "exact_answer": [
        [
          "doxycycline"
        ],
        [
          "topical corticosteroid"
        ],
        [
          "skin moisturizers"
        ],
        [
          "sunscreen"
        ]
      ]
    },
    {
      "id": "660810a0fdcbea915f000005",
      "type": "yesno",
      "body": "Is MIRPE, also known as the Nuss procedure, considered to be an very invasive form of surgical treatment?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
        "http://www.ncbi.nlm.nih.gov/pubmed/34743569",
        "http://www.ncbi.nlm.nih.gov/pubmed/36935229",
        "http://www.ncbi.nlm.nih.gov/pubmed/35455522",
        "http://www.ncbi.nlm.nih.gov/pubmed/30214110",
        "http://www.ncbi.nlm.nih.gov/pubmed/27458490",
        "http://www.ncbi.nlm.nih.gov/pubmed/16982197",
        "http://www.ncbi.nlm.nih.gov/pubmed/26693119",
        "http://www.ncbi.nlm.nih.gov/pubmed/18098112",
        "http://www.ncbi.nlm.nih.gov/pubmed/14725098"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
          "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 171
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
          "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 170
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
          "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum. Minimally invasive repair of pectus excavatum is regarded as a low-risk operation with a reported life-threatening complication rate estimated at around 0.1%.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 330
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881966",
          "text": "The minimally invasive repair of pectus excavatum (MIRPE), or Nuss procedure, is regarded as the gold standard technique for the treatment of symptomatic pectus excavatum. Minimally invasive repair of pectus excavatum is regarded as a low-risk operation with a reported life-threatening complication rate estimated at around 0.1%. Presented are three cases of right internal mammary artery injury (RIMA) after MIRPE resulting in massive hemorrhage in both the acute and chronic postoperative setting and subsequent management strategies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 537
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27458490",
          "text": "INTRODUCTION\nThe Nuss procedure is suitable for prepubertal and early pubertal patients but can also be used in adult patients. AIM\nTo determine whether the minimally invasive technique (MIRPE) can also be performed successfully in adults. MATERIAL AND METHODS\nBetween July 2006 and January 2016, 836 patients (744 male, 92 female) underwent correction of pectus excavatum with the MIRPE technique at our institution.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 421
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30214110",
          "text": "The most frequently used techniques include Ravitch (costochondral resection) and Nuss (minimally invasive pectus repair of pectus excavatum [MIRPE]). The Nuss technique includes using temporary metallic bars without costochondral resection to correct the chest wall deformity. Modified MIRPE can be learned easily and performed safely with few complications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 76,
          "endSection": "abstract",
          "offsetInEndSection": 435
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35455522",
          "text": "In 1998, D. Nuss described a minimally invasive procedure for surgical repair of Pectus excavatum (PE). Today, the Nuss procedure is performed with increasing frequency worldwide and considered as the \"gold standard\".",
          "beginSection": "abstract",
          "offsetInBeginSection": 128,
          "endSection": "abstract",
          "offsetInEndSection": 345
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35455522",
          "text": "In 1998, D. Nuss described a minimally invasive procedure for surgical repair of Pectus excavatum (PE). Today, the Nuss procedure is performed with increasing frequency worldwide and considered as the \"gold standard\". After its introduction, the method experienced numerous modifications such as routine thoracoscopy and/or sternal elevation, increasing safety of the procedure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 128,
          "endSection": "abstract",
          "offsetInEndSection": 506
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35455522",
          "text": "However, the widespread use of the minimally invasive repair of pectus excavatum (MIRPE) procedure has been associated with a significant number of serious complications. Furthermore, several studies report near-fatal complications, not only during bar placement, but also during bar removal. This review focuses upon the most relevant modifications, including recent published surgical techniques of MIRPE, in order to describe current developments in the field.",
          "beginSection": "abstract",
          "offsetInBeginSection": 854,
          "endSection": "abstract",
          "offsetInEndSection": 1317
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35455522",
          "text": "However, the widespread use of the minimally invasive repair of pectus excavatum (MIRPE) procedure has been associated with a significant number of serious complications. Furthermore, several studies report near-fatal complications, not only during bar placement, but also during bar removal.",
          "beginSection": "abstract",
          "offsetInBeginSection": 854,
          "endSection": "abstract",
          "offsetInEndSection": 1146
        }
      ],
      "ideal_answer": "No, MIRPE, also known as the Nuss procedure, is not considered to be a very invasive form of surgical treatment. It is actually regarded as the gold standard technique for the treatment of symptomatic pectus excavatum and is considered minimally invasive.",
      "exact_answer": "no"
    },
    {
      "id": "66154a32fdcbea915f00004b",
      "type": "list",
      "body": "What are major complications of mastoiditis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32073562",
        "http://www.ncbi.nlm.nih.gov/pubmed/31563751",
        "http://www.ncbi.nlm.nih.gov/pubmed/37056111",
        "http://www.ncbi.nlm.nih.gov/pubmed/16859571",
        "http://www.ncbi.nlm.nih.gov/pubmed/20707254",
        "http://www.ncbi.nlm.nih.gov/pubmed/24653915",
        "http://www.ncbi.nlm.nih.gov/pubmed/24060321",
        "http://www.ncbi.nlm.nih.gov/pubmed/29755803",
        "http://www.ncbi.nlm.nih.gov/pubmed/33030245",
        "http://www.ncbi.nlm.nih.gov/pubmed/15895789"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29755803",
          "text": "Lateral sinus thrombosis is another intracranial complication of acute mastoiditis that can occur, but there are only few reports of concomitant ispilateral Bezold's abscess and lateral sinus thrombosis with favorable outcome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 80,
          "endSection": "abstract",
          "offsetInEndSection": 306
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859571",
          "text": "A quartet of lateral sinus thrombosis, extradural abscess, subdural abscess and occipital abscess: complications of acute mastoiditis in a pre-adolescent child.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 160
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29755803",
          "text": "Bezold's abscess is a very rare extracranial complication of acute mastoiditis. Lateral sinus thrombosis is another intracranial complication of acute mastoiditis that can occur, but there are only few reports of concomitant ispilateral Bezold's abscess and lateral sinus thrombosis with favorable outcome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 306
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859571",
          "text": "Neurological complications of acute mastoiditis are rare but can be life threatening. Their presentation may be masked by the use of antibiotics. We present a unique case of acute otitis media progressing to occipital, extradural and subdural abscess formation and lateral sinus thrombosis in a child.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 301
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29755803",
          "text": "Bezold's abscess is a very rare extracranial complication of acute mastoiditis. Lateral sinus thrombosis is another intracranial complication of acute mastoiditis that can occur, but there are only few reports of concomitant ispilateral Bezold's abscess and lateral sinus thrombosis with favorable outcome. We diagnosed and treated successfully a 14-year-old girl suffering from Streptococcus pneumoniae acute mastoiditis complicated with Bezold's abscess and lateral sinus thrombosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 485
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29755803",
          "text": "Lateral sinus thrombosis is another intracranial complication of acute mastoiditis that can occur, but there are only few reports of concomitant ispilateral Bezold's abscess and lateral sinus thrombosis with favorable outcome. We diagnosed and treated successfully a 14-year-old girl suffering from Streptococcus pneumoniae acute mastoiditis complicated with Bezold's abscess and lateral sinus thrombosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 80,
          "endSection": "abstract",
          "offsetInEndSection": 485
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20707254",
          "text": "Still many controversies exist on the diagnosis and treatment of some of them. In this report we describe a pediatric case of upper cervical abscess (bezold abscess), sigmoid sinus thrombosis and occipital osteomyelitis following mastoiditis, presenting with persistent fever and otorrhea. The patient responded well to intravenous antibiotics and wall-intact mastoidectomy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 90,
          "endSection": "abstract",
          "offsetInEndSection": 464
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29755803",
          "text": "Acute Mastoiditis Complicated with Concomitant Bezold's Abscess and Lateral Sinus Thrombosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 93
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20707254",
          "text": "Still many controversies exist on the diagnosis and treatment of some of them. In this report we describe a pediatric case of upper cervical abscess (bezold abscess), sigmoid sinus thrombosis and occipital osteomyelitis following mastoiditis, presenting with persistent fever and otorrhea.",
          "beginSection": "abstract",
          "offsetInBeginSection": 90,
          "endSection": "abstract",
          "offsetInEndSection": 379
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20707254",
          "text": "In this report we describe a pediatric case of upper cervical abscess (bezold abscess), sigmoid sinus thrombosis and occipital osteomyelitis following mastoiditis, presenting with persistent fever and otorrhea. The patient responded well to intravenous antibiotics and wall-intact mastoidectomy. We discuss methods of early diagnosis and appropriate treatment options.",
          "beginSection": "abstract",
          "offsetInBeginSection": 169,
          "endSection": "abstract",
          "offsetInEndSection": 537
        }
      ],
      "ideal_answer": "Major complications of mastoiditis include subperiosteal abscess, sinus thrombosis, cerebral abscess, Bezold's abscess, labyrinthitis, facial nerve palsy, and subdural abscess.",
      "exact_answer": [
        [
          "subperiosteal abscess"
        ],
        [
          "sinus thrombosis"
        ],
        [
          "cerebral abscess"
        ],
        [
          "Bezold's abscess"
        ],
        [
          "labyrinthitis"
        ],
        [
          "facial nerve palsy"
        ],
        [
          "subdural abscess"
        ]
      ]
    },
    {
      "id": "661c41d448a2c27714000009",
      "type": "list",
      "body": "Which DNA language models currently exist to model the human genome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33538820",
        "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
        "http://www.ncbi.nlm.nih.gov/pubmed/37426456",
        "http://www.ncbi.nlm.nih.gov/pubmed/37883436",
        "http://www.ncbi.nlm.nih.gov/pubmed/36523764",
        "http://www.ncbi.nlm.nih.gov/pubmed/37090673",
        "http://www.ncbi.nlm.nih.gov/pubmed/23324351",
        "http://www.ncbi.nlm.nih.gov/pubmed/35536244",
        "http://www.ncbi.nlm.nih.gov/pubmed/3748365",
        "http://www.ncbi.nlm.nih.gov/pubmed/35389869"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "To address this challenge, we here introduce GPN-MSA, a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species and takes only a few hours to train. Across several benchmarks on clinical databases (ClinVar, COSMIC, and OMIM) and population genomic data (gnomAD), our model for the human genome achieves outstanding performance on deleteriousness prediction for both coding and non-coding variants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 282,
          "endSection": "abstract",
          "offsetInEndSection": 735
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "Whereas protein language models have demonstrated remarkable efficacy in predicting the effects of missense variants, DNA counterparts have not yet achieved a similar competitive edge for genome-wide variant effect predictions, especially in complex genomes such as that of humans. To address this challenge, we here introduce GPN-MSA, a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species and takes only a few hours to train. Across several benchmarks on clinical databases (ClinVar, COSMIC, and OMIM) and population genomic data (gnomAD), our model for the human genome achieves outstanding performance on deleteriousness prediction for both coding and non-coding variants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 735
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "GPN-MSA: an alignment-based DNA language model for genome-wide variant effect prediction.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "To address this challenge, we here introduce GPN-MSA, a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species and takes only a few hours to train.",
          "beginSection": "abstract",
          "offsetInBeginSection": 282,
          "endSection": "abstract",
          "offsetInEndSection": 486
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37873118",
          "text": "Whereas protein language models have demonstrated remarkable efficacy in predicting the effects of missense variants, DNA counterparts have not yet achieved a similar competitive edge for genome-wide variant effect predictions, especially in complex genomes such as that of humans. To address this challenge, we here introduce GPN-MSA, a novel framework for DNA language models that leverages whole-genome sequence alignments across multiple species and takes only a few hours to train.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 486
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37426456",
          "text": "In addition, these methods rely on tokenizers or fixed k-mers to aggregate meaningful DNA units, losing single nucleotide resolution where subtle genetic variations can completely alter protein function via single nucleotide polymorphisms (SNPs). Recently, Hyena, a large language model based on implicit convolutions was shown to match attention in quality while allowing longer context lengths and lower time complexity. Leveraging Hyena's new long-range capabilities, we present HyenaDNA, a genomic foundation model pretrained on the human reference genome with context lengths of up to 1 million tokens at the single nucleotide-level - an up to 500x increase over previous dense attention-based models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 574,
          "endSection": "abstract",
          "offsetInEndSection": 1280
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37426456",
          "text": "Recently, Hyena, a large language model based on implicit convolutions was shown to match attention in quality while allowing longer context lengths and lower time complexity. Leveraging Hyena's new long-range capabilities, we present HyenaDNA, a genomic foundation model pretrained on the human reference genome with context lengths of up to 1 million tokens at the single nucleotide-level - an up to 500x increase over previous dense attention-based models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 821,
          "endSection": "abstract",
          "offsetInEndSection": 1280
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37883436",
          "text": "Expanding on this idea, we here introduce the Genomic Pre-trained Network (GPN), a model designed to learn genome-wide variant effects through unsupervised pretraining on genomic DNA sequences. Our model also successfully learns gene structure and DNA motifs without any supervision. To demonstrate its utility, we train GPN on unaligned reference genomes of Arabidopsis thaliana and seven related species within the Brassicales order and evaluate its ability to predict the functional impact of genetic variants in A. thaliana by utilizing allele frequencies from the 1001 Genomes Project and a comprehensive database of GWAS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 722,
          "endSection": "abstract",
          "offsetInEndSection": 1349
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37883436",
          "text": "Expanding on this idea, we here introduce the Genomic Pre-trained Network (GPN), a model designed to learn genome-wide variant effects through unsupervised pretraining on genomic DNA sequences. Our model also successfully learns gene structure and DNA motifs without any supervision.",
          "beginSection": "abstract",
          "offsetInBeginSection": 722,
          "endSection": "abstract",
          "offsetInEndSection": 1005
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37426456",
          "text": "Recently, Hyena, a large language model based on implicit convolutions was shown to match attention in quality while allowing longer context lengths and lower time complexity. Leveraging Hyena's new long-range capabilities, we present HyenaDNA, a genomic foundation model pretrained on the human reference genome with context lengths of up to 1 million tokens at the single nucleotide-level - an up to 500x increase over previous dense attention-based models. HyenaDNA scales sub-quadratically in sequence length (training up to 160x faster than Transformer), uses single nucleotide tokens, and has full global context at each layer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 821,
          "endSection": "abstract",
          "offsetInEndSection": 1454
        }
      ],
      "ideal_answer": "GPN, DNABERT, and HyenaDNA are DNA language models that currently exist to model the human genome.",
      "exact_answer": [
        [
          "GPN"
        ],
        [
          "DNABERT"
        ],
        [
          "HyenaDNA"
        ]
      ]
    },
    {
      "id": "661d1d2deac11fad33000015",
      "type": "list",
      "body": "What biomarkers are used for the identification of neonatal sepsis in low-income countries?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
        "http://www.ncbi.nlm.nih.gov/pubmed/26351925",
        "http://www.ncbi.nlm.nih.gov/pubmed/37560860",
        "http://www.ncbi.nlm.nih.gov/pubmed/22708043",
        "http://www.ncbi.nlm.nih.gov/pubmed/29577181",
        "http://www.ncbi.nlm.nih.gov/pubmed/33180390",
        "http://www.ncbi.nlm.nih.gov/pubmed/25379046",
        "http://www.ncbi.nlm.nih.gov/pubmed/29895470",
        "http://www.ncbi.nlm.nih.gov/pubmed/28879270",
        "http://www.ncbi.nlm.nih.gov/pubmed/33817066"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "CRP of ≥60 mg/L (AUC 0.87, 95% CI 0.76 to 0.91) among 1339 neonates and PCT of ≥0.5 ng/mL (AUC 0.87, 95% CI 0.70 to 0.92) among 617 neonates demonstrated the greatest discriminatory value for the diagnosis of neonatal sepsis using blood culture as the reference standard in LMICs. CONCLUSIONS\nPCT and CRP had good discriminatory value for neonatal sepsis in LMICs. ESR and WBC demonstrated poor discrimination for neonatal sepsis in LMICs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1185,
          "endSection": "abstract",
          "offsetInEndSection": 1626
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "There were 80 (59.7%) studies conducted in LMICs. CRP of ≥60 mg/L (AUC 0.87, 95% CI 0.76 to 0.91) among 1339 neonates and PCT of ≥0.5 ng/mL (AUC 0.87, 95% CI 0.70 to 0.92) among 617 neonates demonstrated the greatest discriminatory value for the diagnosis of neonatal sepsis using blood culture as the reference standard in LMICs. CONCLUSIONS\nPCT and CRP had good discriminatory value for neonatal sepsis in LMICs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1135,
          "endSection": "abstract",
          "offsetInEndSection": 1551
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "CRP of ≥60 mg/L (AUC 0.87, 95% CI 0.76 to 0.91) among 1339 neonates and PCT of ≥0.5 ng/mL (AUC 0.87, 95% CI 0.70 to 0.92) among 617 neonates demonstrated the greatest discriminatory value for the diagnosis of neonatal sepsis using blood culture as the reference standard in LMICs. CONCLUSIONS\nPCT and CRP had good discriminatory value for neonatal sepsis in LMICs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1185,
          "endSection": "abstract",
          "offsetInEndSection": 1551
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "RESULTS\nOf 6570 studies related to biomarkers in children, 134 met inclusion criteria and included 23 179 neonates. There were 80 (59.7%) studies conducted in LMICs. CRP of ≥60 mg/L (AUC 0.87, 95% CI 0.76 to 0.91) among 1339 neonates and PCT of ≥0.5 ng/mL (AUC 0.87, 95% CI 0.70 to 0.92) among 617 neonates demonstrated the greatest discriminatory value for the diagnosis of neonatal sepsis using blood culture as the reference standard in LMICs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1019,
          "endSection": "abstract",
          "offsetInEndSection": 1465
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "CRP of ≥60 mg/L (AUC 0.87, 95% CI 0.76 to 0.91) among 1339 neonates and PCT of ≥0.5 ng/mL (AUC 0.87, 95% CI 0.70 to 0.92) among 617 neonates demonstrated the greatest discriminatory value for the diagnosis of neonatal sepsis using blood culture as the reference standard in LMICs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1185,
          "endSection": "abstract",
          "offsetInEndSection": 1465
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "There were 80 (59.7%) studies conducted in LMICs. CRP of ≥60 mg/L (AUC 0.87, 95% CI 0.76 to 0.91) among 1339 neonates and PCT of ≥0.5 ng/mL (AUC 0.87, 95% CI 0.70 to 0.92) among 617 neonates demonstrated the greatest discriminatory value for the diagnosis of neonatal sepsis using blood culture as the reference standard in LMICs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1135,
          "endSection": "abstract",
          "offsetInEndSection": 1465
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26351925",
          "text": "CONCLUSIONS\nnCD64 and PCT are better diagnostic biomarkers for early diagnosis of neonatal sepsis as compared to CRP. With the help of optimal cut-off value based on ROC curve and logistic regression analysis, the combination of these biomarkers could improve the sensitivity for the diagnosis of suspected late-onset neonatal sepsis based on common serum biomarkers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1304,
          "endSection": "abstract",
          "offsetInEndSection": 1671
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649385",
          "text": "CONCLUSIONS\nPCT and CRP had good discriminatory value for neonatal sepsis in LMICs. ESR and WBC demonstrated poor discrimination for neonatal sepsis in LMICs. Future studies may incorporate biomarkers into clinical evaluation in LMICs to diagnose neonatal sepsis more accurately.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1468,
          "endSection": "abstract",
          "offsetInEndSection": 1747
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26351925",
          "text": "CONCLUSIONS\nnCD64 and PCT are better diagnostic biomarkers for early diagnosis of neonatal sepsis as compared to CRP.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1304,
          "endSection": "abstract",
          "offsetInEndSection": 1421
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26351925",
          "text": "The best combination was nCD64 and PCT, which obtained sensitivity of 90.9%, largest AUC of 0.922, and a negative predictive value of 89.2%. However by using an optimal cut-off value, the sensitivities of all four biomarkers for the diagnosis of neonatal sepsis were increased to 95.5%.",
          "beginSection": "abstract",
          "offsetInBeginSection": 896,
          "endSection": "abstract",
          "offsetInEndSection": 1182
        }
      ],
      "ideal_answer": "CRP and PCT are used for the identification of neonatal sepsis in low-income countries. CRP of ≥60 mg/L and PCT of ≥0.5 ng/mL have the greatest discriminatory value for the diagnosis of neonatal sepsis.",
      "exact_answer": [
        [
          "CRP"
        ],
        [
          "PCT"
        ]
      ]
    },
    {
      "id": "65cfdd9c1930410b13000027",
      "type": "summary",
      "body": "What is the mechanism of action of Mirikizumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
        "http://www.ncbi.nlm.nih.gov/pubmed/37069321",
        "http://www.ncbi.nlm.nih.gov/pubmed/37389706",
        "http://www.ncbi.nlm.nih.gov/pubmed/37379135",
        "http://www.ncbi.nlm.nih.gov/pubmed/37714687",
        "http://www.ncbi.nlm.nih.gov/pubmed/33105016",
        "http://www.ncbi.nlm.nih.gov/pubmed/30215632",
        "http://www.ncbi.nlm.nih.gov/pubmed/36881820",
        "http://www.ncbi.nlm.nih.gov/pubmed/30734266",
        "http://www.ncbi.nlm.nih.gov/pubmed/37610533"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37714687",
          "text": "This study describes the generation and characterization of mirikizumab (miri), a humanized IgG4 monoclonal antibody directed against the p19 subunit of IL-23. Miri binds human and cynomolgus monkey IL-23 with high affinity and binds rabbit IL-23 weakly but does not bind to rodent IL-23 or the other IL-23 family members IL-12, IL-27, or IL-35.",
          "beginSection": "abstract",
          "offsetInBeginSection": 336,
          "endSection": "abstract",
          "offsetInEndSection": 681
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 289,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 289,
          "endSection": "abstract",
          "offsetInEndSection": 451
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. It is effective for the induction and maintenance of remission in moderately to severely active UC, including patients with prior failure of biological or tofacitinib therapy. Like other IL-23 antagonists, mirikizumab has a favorable safety profile.",
          "beginSection": "abstract",
          "offsetInBeginSection": 289,
          "endSection": "abstract",
          "offsetInEndSection": 700
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. It is effective for the induction and maintenance of remission in moderately to severely active UC, including patients with prior failure of biological or tofacitinib therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 289,
          "endSection": "abstract",
          "offsetInEndSection": 626
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "The IL-23 pathway has emerged as an important therapeutic target for UC. Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance. It is effective for the induction and maintenance of remission in moderately to severely active UC, including patients with prior failure of biological or tofacitinib therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 216,
          "endSection": "abstract",
          "offsetInEndSection": 626
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37714687",
          "text": "This study describes the generation and characterization of mirikizumab (miri), a humanized IgG4 monoclonal antibody directed against the p19 subunit of IL-23. Miri binds human and cynomolgus monkey IL-23 with high affinity and binds rabbit IL-23 weakly but does not bind to rodent IL-23 or the other IL-23 family members IL-12, IL-27, or IL-35. Miri effectively inhibits the interaction of IL-23 with its receptor, and potently blocks IL-23-induced IL-17 production in cell-based assays while preserving the function of IL-12.",
          "beginSection": "abstract",
          "offsetInBeginSection": 336,
          "endSection": "abstract",
          "offsetInEndSection": 863
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37465925",
          "text": "The IL-23 pathway has emerged as an important therapeutic target for UC. Mirikizumab is a humanized IgG4 monoclonal antibody against the p19 subunit of IL-23, dosed intravenously during induction and subcutaneously during maintenance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 216,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36881820",
          "text": "INTRODUCTION\nMirikizumab, a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, demonstrated efficacy and was well-tolerated in a phase 2 randomized clinical trial in patients with moderate-to-severe ulcerative colitis (UC) (NCT02589665). We explored gene expression changes in colonic tissue from study patients and their association with clinical outcomes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 376
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37714687",
          "text": "This study describes the generation and characterization of mirikizumab (miri), a humanized IgG4 monoclonal antibody directed against the p19 subunit of IL-23.",
          "beginSection": "abstract",
          "offsetInBeginSection": 336,
          "endSection": "abstract",
          "offsetInEndSection": 495
        }
      ],
      "ideal_answer": "Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor and thereby preventing the downstream inflammatory cascade.",
      "exact_answer": "n/a"
    },
    {
      "id": "66099c30fdcbea915f000024",
      "type": "list",
      "body": "What clinical indications does the self-expanding colon stent have in colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
        "http://www.ncbi.nlm.nih.gov/pubmed/26064818",
        "http://www.ncbi.nlm.nih.gov/pubmed/10924576",
        "http://www.ncbi.nlm.nih.gov/pubmed/17356934",
        "http://www.ncbi.nlm.nih.gov/pubmed/20607252",
        "http://www.ncbi.nlm.nih.gov/pubmed/21909857",
        "http://www.ncbi.nlm.nih.gov/pubmed/14719149",
        "http://www.ncbi.nlm.nih.gov/pubmed/20205505",
        "http://www.ncbi.nlm.nih.gov/pubmed/17704890",
        "http://www.ncbi.nlm.nih.gov/pubmed/20123331"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
          "text": "Self-expanding metallic stent placement for malignant colorectal obstruction has gained popularity as a safe and effective procedure for relieving obstruction. This technique can be used in the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 601
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
          "text": "Self-expanding metallic stent placement for malignant colorectal obstruction has gained popularity as a safe and effective procedure for relieving obstruction. This technique can be used in the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. Self-expanding metallic stent has its own advantages and disadvantages over the surgery in these indications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 116,
          "endSection": "abstract",
          "offsetInEndSection": 711
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
          "text": "This technique can be used in the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. Self-expanding metallic stent has its own advantages and disadvantages over the surgery in these indications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 276,
          "endSection": "abstract",
          "offsetInEndSection": 711
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
          "text": "This technique can be used in the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases. Self-expanding metallic stent has its own advantages and disadvantages over the surgery in these indications. During the insertion of the self-expanding metallic stent, and in the follow-up, short term and long term morbidities should be kept in mind.",
          "beginSection": "abstract",
          "offsetInBeginSection": 276,
          "endSection": "abstract",
          "offsetInEndSection": 853
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
          "text": "This technique can be used in the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 276,
          "endSection": "abstract",
          "offsetInEndSection": 601
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
          "text": "This technique can be used in the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases",
          "beginSection": "abstract",
          "offsetInBeginSection": 276,
          "endSection": "abstract",
          "offsetInEndSection": 600
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798442",
          "text": "Acute malignant colorectal obstruction is a complication of colorectal cancer that can occur in 7%-29% of patients. Self-expanding metallic stent placement for malignant colorectal obstruction has gained popularity as a safe and effective procedure for relieving obstruction. This technique can be used in the palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 601
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17356934",
          "text": "BACKGROUND\nColorectal stents are being used for palliation and as a \"bridge to surgery\" in obstructing colorectal carcinoma. The purpose of this study was to review our experience with self-expanding metal stents (SEMS) as the initial interventional approach in the management of acute malignant large bowel obstruction. METHODS\nBetween February 2002 and May 2006, 67 patients underwent the insertion of a SEMS for an obstructing malignant lesion of the left-sided colon or rectum.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 483
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20607252",
          "text": "PURPOSE\nColorectal stents are being used for palliation and as a \"bridge to surgery\" in obstructing colorectal carcinoma. The purpose of this study was to review our experience with self-expanding metal stents (SEMS) as the initial interventional approach in the management of acute malignant large-bowel obstruction. METHODS\nBetween February 2002 and August 2009, 93 patients underwent the insertion of a SEMS for an obstructing malignant lesion of the left-sided colon or rectum.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 483
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17356934",
          "text": "BACKGROUND\nColorectal stents are being used for palliation and as a \"bridge to surgery\" in obstructing colorectal carcinoma. The purpose of this study was to review our experience with self-expanding metal stents (SEMS) as the initial interventional approach in the management of acute malignant large bowel obstruction.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 320
        }
      ],
      "ideal_answer": "The self-expanding colon stent is clinically indicated for palliation of malignant colorectal obstruction, as a bridge to elective surgery for resectable colorectal cancers, palliation of extracolonic malignant obstruction, and for nonmalignant etiologies such as anastomotic strictures, Crohn's disease, radiation therapy, and diverticular diseases.",
      "exact_answer": [
        [
          "palliation of malignant colorectal obstruction"
        ],
        [
          "bridge to elective surgery"
        ],
        [
          "palliation of extracolonic malignant obstruction"
        ],
        [
          "anastomotic strictures"
        ],
        [
          "Crohn's disease"
        ],
        [
          "radiation therapy"
        ],
        [
          "diverticular diseases"
        ]
      ]
    },
    {
      "id": "661a624bfdcbea915f00005b",
      "type": "list",
      "body": "List the cells which have CD21 on the surface.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27010233",
        "http://www.ncbi.nlm.nih.gov/pubmed/11367532",
        "http://www.ncbi.nlm.nih.gov/pubmed/28449602",
        "http://www.ncbi.nlm.nih.gov/pubmed/28061947",
        "http://www.ncbi.nlm.nih.gov/pubmed/8655878",
        "http://www.ncbi.nlm.nih.gov/pubmed/8996252",
        "http://www.ncbi.nlm.nih.gov/pubmed/12908519",
        "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
        "http://www.ncbi.nlm.nih.gov/pubmed/7858501",
        "http://www.ncbi.nlm.nih.gov/pubmed/18624951"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface. Expression of the CD21 exon 11 has been reported being restricted to follicular dendritic cells only. To the contrary, we found that both purified B and T cell subpopulations expressed CD21 mRNA with and without exon 11.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1189,
          "endSection": "abstract",
          "offsetInEndSection": 1526
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface. Expression of the CD21 exon 11 has been reported being restricted to follicular dendritic cells only.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1189,
          "endSection": "abstract",
          "offsetInEndSection": 1407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "B lymphocytes and CD4+ or CD8+ T cells expressed similar amounts of CD21 mRNA. Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface. Expression of the CD21 exon 11 has been reported being restricted to follicular dendritic cells only.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1110,
          "endSection": "abstract",
          "offsetInEndSection": 1407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "CD21 is primarily expressed on B lymphocytes and follicular dendritic cells, but has also been reported on T cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 420,
          "endSection": "abstract",
          "offsetInEndSection": 535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "Expression of the CD21 exon 11 has been reported being restricted to follicular dendritic cells only. To the contrary, we found that both purified B and T cell subpopulations expressed CD21 mRNA with and without exon 11.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1306,
          "endSection": "abstract",
          "offsetInEndSection": 1526
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "CD21 is primarily expressed on B lymphocytes and follicular dendritic cells, but has also been reported on T cells. We established a semi-quantitative PCR and compared the CD21 mRNA levels of B and T lymphocytes with the expression of the CD21 glycoprotein on the surface of the respective cells by flow cytometry. The B cell lines Raji and Ramos and the T cell lines Jurkat and Molt4 expressed equal amounts of CD21 mRNA, but differed in surface staining.",
          "beginSection": "abstract",
          "offsetInBeginSection": 420,
          "endSection": "abstract",
          "offsetInEndSection": 876
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "Expression of the CD21 exon 11 has been reported being restricted to follicular dendritic cells only.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1306,
          "endSection": "abstract",
          "offsetInEndSection": 1407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "CD21 is primarily expressed on B lymphocytes and follicular dendritic cells, but has also been reported on T cells. We established a semi-quantitative PCR and compared the CD21 mRNA levels of B and T lymphocytes with the expression of the CD21 glycoprotein on the surface of the respective cells by flow cytometry.",
          "beginSection": "abstract",
          "offsetInBeginSection": 420,
          "endSection": "abstract",
          "offsetInEndSection": 734
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8996252",
          "text": "Follicular dendritic cells specifically express the long CR2/CD21 isoform.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 74
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723706",
          "text": "Nevertheless only B cells, but not CD4+ or CD8+ T cells, expressed detectable amounts of CD21 on their cell surface.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1189,
          "endSection": "abstract",
          "offsetInEndSection": 1305
        }
      ],
      "ideal_answer": "B cells and follicular dendritic cells have CD21 on their surface.",
      "exact_answer": [
        [
          "B cells"
        ],
        [
          "follicular dendritic cells"
        ]
      ]
    },
    {
      "id": "6616a250fdcbea915f000059",
      "type": "yesno",
      "body": "Do PPIs increase the risk of gastric cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34226290",
        "http://www.ncbi.nlm.nih.gov/pubmed/37505975",
        "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
        "http://www.ncbi.nlm.nih.gov/pubmed/36626449",
        "http://www.ncbi.nlm.nih.gov/pubmed/37326271",
        "http://www.ncbi.nlm.nih.gov/pubmed/31445426",
        "http://www.ncbi.nlm.nih.gov/pubmed/36585832",
        "http://www.ncbi.nlm.nih.gov/pubmed/30651922",
        "http://www.ncbi.nlm.nih.gov/pubmed/34074826",
        "http://www.ncbi.nlm.nih.gov/pubmed/37882179"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Recently, two epidemiological studies showed that long-term treatment with proton pump inhibitors (PPIs) increased the risk of gastric cancer. It is well known that hypergastrinemia predisposes to gastric neoplasia in animals as well as man. Recently a study showed that hypergastrinemic patients had an increased risk of gastric cancer when followed for about 25 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Recently, two epidemiological studies showed that long-term treatment with proton pump inhibitors (PPIs) increased the risk of gastric cancer. It is well known that hypergastrinemia predisposes to gastric neoplasia in animals as well as man.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 241
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Recently, two epidemiological studies showed that long-term treatment with proton pump inhibitors (PPIs) increased the risk of gastric cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 142
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34226290",
          "text": "OBJECTIVE\nTo determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). DESIGN\nUsing the UK Clinical Practice Research Datalink, we conducted a population-based cohort study using a new-user active comparator design.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 332
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34226290",
          "text": "OBJECTIVE\nTo determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 185
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36626449",
          "text": "BACKGROUND\nThis study aimed to systematically analyze the association between long-term use of proton pump inhibitors (PPIs) and the risk of gastric cancer (GC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 161
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34226290",
          "text": "users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer ",
          "beginSection": "abstract",
          "offsetInBeginSection": 36,
          "endSection": "abstract",
          "offsetInEndSection": 118
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29852782",
          "text": "Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 79
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34226290",
          "text": "OBJECTIVE\nTo determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). DESIGN\nUsing the UK Clinical Practice Research Datalink, we conducted a population-based cohort study using a new-user active comparator design. From 1 January 1990 to 30 April 2018, we identified 973 281 new users of PPIs and 193 306 new users of H2RAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 442
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36626449",
          "text": "BACKGROUND\nThis study aimed to systematically analyze the association between long-term use of proton pump inhibitors (PPIs) and the risk of gastric cancer (GC). METHODS\nWe performed a systematic search of articles on the relationship between long-term use of PPIs and the risk of GC from PubMed and EMBASE.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 309
        }
      ],
      "ideal_answer": "Yes, users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer, especially with chronic use.",
      "exact_answer": "yes"
    },
    {
      "id": "661c414d48a2c27714000007",
      "type": "yesno",
      "body": "Can enhancers act as promoters?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
        "http://www.ncbi.nlm.nih.gov/pubmed/31605096",
        "http://www.ncbi.nlm.nih.gov/pubmed/22264824",
        "http://www.ncbi.nlm.nih.gov/pubmed/3016550",
        "http://www.ncbi.nlm.nih.gov/pubmed/36167150",
        "http://www.ncbi.nlm.nih.gov/pubmed/33872375",
        "http://www.ncbi.nlm.nih.gov/pubmed/26317464",
        "http://www.ncbi.nlm.nih.gov/pubmed/30287902",
        "http://www.ncbi.nlm.nih.gov/pubmed/30696717",
        "http://www.ncbi.nlm.nih.gov/pubmed/25715743"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "Conversely, bidirectional promoters often act as strong enhancers, while unidirectional promoters generally cannot. The balance between enhancer and promoter activity is generally reflected in the levels and directionality of eRNA transcription and is likely an inherent sequence property of the elements themselves.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1162,
          "endSection": "abstract",
          "offsetInEndSection": 1478
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "Some enhancers (mainly bidirectional) can act as weak promoters, producing overlapping spatio-temporal expression. Conversely, bidirectional promoters often act as strong enhancers, while unidirectional promoters generally cannot. The balance between enhancer and promoter activity is generally reflected in the levels and directionality of eRNA transcription and is likely an inherent sequence property of the elements themselves.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1047,
          "endSection": "abstract",
          "offsetInEndSection": 1478
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "The balance between enhancer and promoter activity is generally reflected in the levels and directionality of eRNA transcription and is likely an inherent sequence property of the elements themselves.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1278,
          "endSection": "abstract",
          "offsetInEndSection": 1478
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "Extensive transgenic analysis revealed a relationship between the direction of endogenous transcription and the ability to function as an enhancer or promoter in vivo, although enhancer RNA (eRNA) production and activity are not always strictly coupled. Some enhancers (mainly bidirectional) can act as weak promoters, producing overlapping spatio-temporal expression. Conversely, bidirectional promoters often act as strong enhancers, while unidirectional promoters generally cannot.",
          "beginSection": "abstract",
          "offsetInBeginSection": 793,
          "endSection": "abstract",
          "offsetInEndSection": 1277
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "Extensive transgenic analysis revealed a relationship between the direction of endogenous transcription and the ability to function as an enhancer or promoter in vivo, although enhancer RNA (eRNA) production and activity are not always strictly coupled. Some enhancers (mainly bidirectional) can act as weak promoters, producing overlapping spatio-temporal expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 793,
          "endSection": "abstract",
          "offsetInEndSection": 1161
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "To assess how this impacts function, we developed a dual transgenic assay to simultaneously measure enhancer and promoter activities from a single element in the same embryo. Extensive transgenic analysis revealed a relationship between the direction of endogenous transcription and the ability to function as an enhancer or promoter in vivo, although enhancer RNA (eRNA) production and activity are not always strictly coupled. Some enhancers (mainly bidirectional) can act as weak promoters, producing overlapping spatio-temporal expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 618,
          "endSection": "abstract",
          "offsetInEndSection": 1161
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "We show that while the timing of enhancer transcription is generally correlated with enhancer activity, the levels and directionality of transcription are highly varied among active enhancers. To assess how this impacts function, we developed a dual transgenic assay to simultaneously measure enhancer and promoter activities from a single element in the same embryo. Extensive transgenic analysis revealed a relationship between the direction of endogenous transcription and the ability to function as an enhancer or promoter in vivo, although enhancer RNA (eRNA) production and activity are not always strictly coupled.",
          "beginSection": "abstract",
          "offsetInBeginSection": 425,
          "endSection": "abstract",
          "offsetInEndSection": 1046
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "Some enhancers (mainly bidirectional) can act as weak promoters, producing overlapping spatio-temporal expression. Conversely, bidirectional promoters often act as strong enhancers, while unidirectional promoters generally cannot.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1047,
          "endSection": "abstract",
          "offsetInEndSection": 1277
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "Extensive transgenic analysis revealed a relationship between the direction of endogenous transcription and the ability to function as an enhancer or promoter in vivo, although enhancer RNA (eRNA) production and activity are not always strictly coupled.",
          "beginSection": "abstract",
          "offsetInBeginSection": 793,
          "endSection": "abstract",
          "offsetInEndSection": 1046
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29378788",
          "text": "The degree of enhancer or promoter activity is reflected by the levels and directionality of eRNA transcription.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 112
        }
      ],
      "ideal_answer": "Yes, enhancers can act as promoters, but this is more common in bidirectional enhancers and not in unidirectional promoters.",
      "exact_answer": "yes"
    },
    {
      "id": "661d575eeac11fad33000020",
      "type": "summary",
      "body": "How is pain treated in patients with Ehlers-Danlos Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
        "http://www.ncbi.nlm.nih.gov/pubmed/36124037",
        "http://www.ncbi.nlm.nih.gov/pubmed/31060411",
        "http://www.ncbi.nlm.nih.gov/pubmed/22616833",
        "http://www.ncbi.nlm.nih.gov/pubmed/34124258",
        "http://www.ncbi.nlm.nih.gov/pubmed/28967365",
        "http://www.ncbi.nlm.nih.gov/pubmed/26897449",
        "http://www.ncbi.nlm.nih.gov/pubmed/32176287",
        "http://www.ncbi.nlm.nih.gov/pubmed/31075184",
        "http://www.ncbi.nlm.nih.gov/pubmed/15605135"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
          "text": "Since hEDS associated chronic pain is multifactorial in origin, treatment requires a multidisciplinary approach which includes physical therapy, psychotherapy, pharmacotherapy and interventional pain procedures such as trigger point injections, peripheral nerve block, radiofrequency ablation and peripheral nerve stimulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 594,
          "endSection": "abstract",
          "offsetInEndSection": 920
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
          "text": "This study reviews two cases of chronic pain in hEDS patients and the multimodal treatment regimen used along with peripheral nerve stimulation for shoulder and knee pains, never before reported in hEDS patients. Since hEDS associated chronic pain is multifactorial in origin, treatment requires a multidisciplinary approach which includes physical therapy, psychotherapy, pharmacotherapy and interventional pain procedures such as trigger point injections, peripheral nerve block, radiofrequency ablation and peripheral nerve stimulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 381,
          "endSection": "abstract",
          "offsetInEndSection": 920
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
          "text": "The effective management of chronic pain in hEDS patients is a challenge. This study reviews two cases of chronic pain in hEDS patients and the multimodal treatment regimen used along with peripheral nerve stimulation for shoulder and knee pains, never before reported in hEDS patients. Since hEDS associated chronic pain is multifactorial in origin, treatment requires a multidisciplinary approach which includes physical therapy, psychotherapy, pharmacotherapy and interventional pain procedures such as trigger point injections, peripheral nerve block, radiofrequency ablation and peripheral nerve stimulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 307,
          "endSection": "abstract",
          "offsetInEndSection": 920
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
          "text": "Ehlers-Danlos syndromes (EDS) are a group of disorders characterized by abnormal connective tissue affecting several organ systems. Patients with the hypermobile type of EDS (hEDS) commonly experience chronic pain which can present as musculoskeletal pain, fibromyalgia, neuropathic pain or abdominal pain. The effective management of chronic pain in hEDS patients is a challenge.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 380
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34124258",
          "text": "BACKGROUND\nThe hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue mainly characterized by joint hypermobility. Patients with hEDS suffer joint pain, in particular low back pain, commonly resistant to drug therapy. The aim of this research was to evaluate a neurocognitive rehabilitation approach based not only on the motion and function recovery but also on the pain management.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 445
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
          "text": "Ehlers-Danlos syndromes (EDS) are a group of disorders characterized by abnormal connective tissue affecting several organ systems. Patients with the hypermobile type of EDS (hEDS) commonly experience chronic pain which can present as musculoskeletal pain, fibromyalgia, neuropathic pain or abdominal pain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 306
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36124037",
          "text": "Multidisciplinary Approach to Treating Chronic Pain in Patients with Ehlers-Danlos Syndrome: Critically Appraised Topic.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 120
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36305215",
          "text": "Multidisciplinary chronic pain management strategies in patients with Ehlers-Danlos syndromes.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 94
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22616833",
          "text": "Questions from patients about pain conditions and analgesic pharmacotherapy and responses from authors are presented to help educate patients and make them more effective self-advocates. The topics addressed in this issue are Ehlers-Danlos syndrome and associated chronic pain; the information is meant to help readers understand the mechanisms for pain in this connective tissue disorder as well as general treatment principles for chronic pain management.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36124037",
          "text": "The multidisciplinary approach includes physiotherapy, occupational therapy, cognitive behavioral therapy, and pharmacologic interventions to decrease pain. This review identifies literature examining the components of this conservative multidisciplinary approach and their effectiveness across the PubMed, EMBASE, CINAHL, Web of Science, and Trip databases, using the terms \"Ehlers-Danlos Syndrome AND Pain Management\" that was then subsequently evaluated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 832,
          "endSection": "abstract",
          "offsetInEndSection": 1289
        }
      ],
      "ideal_answer": "Pain in patients with Ehlers-Danlos Syndrome is treated with a multidisciplinary approach that includes physical therapy, psychotherapy, pharmacotherapy, and interventional pain procedures such as trigger point injections, peripheral nerve blocks, radiofrequency ablation, and peripheral nerve stimulation.",
      "exact_answer": "n/a"
    },
    {
      "id": "65cfa6201930410b1300000e",
      "type": "yesno",
      "body": "Is Patisiran used for Transthyretin Cardiac Amyloidosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37888916",
        "http://www.ncbi.nlm.nih.gov/pubmed/36336119",
        "http://www.ncbi.nlm.nih.gov/pubmed/37288260",
        "http://www.ncbi.nlm.nih.gov/pubmed/37599395",
        "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
        "http://www.ncbi.nlm.nih.gov/pubmed/30644768",
        "http://www.ncbi.nlm.nih.gov/pubmed/37456349",
        "http://www.ncbi.nlm.nih.gov/pubmed/32519928",
        "http://www.ncbi.nlm.nih.gov/pubmed/31309347",
        "http://www.ncbi.nlm.nih.gov/pubmed/30480471"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37888916",
          "text": "Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 71
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.",
          "beginSection": "abstract",
          "offsetInBeginSection": 351,
          "endSection": "abstract",
          "offsetInEndSection": 541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis. The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications. Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 541
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33841597",
          "text": "We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 181
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37456349",
          "text": "Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 86
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30644768",
          "text": "Expert Commentary: Patisiran offers a new treatment option for patients with hereditary transthyretin-mediated amyloidosis. Patisiran can significantly reduce the TTR level and improve patient's neuropathy and quality of life.",
          "beginSection": "abstract",
          "offsetInBeginSection": 446,
          "endSection": "abstract",
          "offsetInEndSection": 672
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30644768",
          "text": "Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 77
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30644768",
          "text": "Expert Commentary: Patisiran offers a new treatment option for patients with hereditary transthyretin-mediated amyloidosis. Patisiran can significantly reduce the TTR level and improve patient's neuropathy and quality of life. The common adverse reactions were upper respiratory tract infections and infusion-related reactions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 446,
          "endSection": "abstract",
          "offsetInEndSection": 773
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30644768",
          "text": "Expert Commentary: Patisiran offers a new treatment option for patients with hereditary transthyretin-mediated amyloidosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 446,
          "endSection": "abstract",
          "offsetInEndSection": 569
        }
      ],
      "ideal_answer": "Yes, patisiran is used for Transthyretin Cardiac Amyloidosis.",
      "exact_answer": "yes"
    },
    {
      "id": "65f77a32c4010b4d7800003a",
      "type": "list",
      "body": "What are the molecular mechanisms for secondary resistance to Bevacizumab in advanced colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32175278",
        "http://www.ncbi.nlm.nih.gov/pubmed/29184575",
        "http://www.ncbi.nlm.nih.gov/pubmed/19836845",
        "http://www.ncbi.nlm.nih.gov/pubmed/20005148",
        "http://www.ncbi.nlm.nih.gov/pubmed/23755727",
        "http://www.ncbi.nlm.nih.gov/pubmed/29670046",
        "http://www.ncbi.nlm.nih.gov/pubmed/36001383",
        "http://www.ncbi.nlm.nih.gov/pubmed/29357916",
        "http://www.ncbi.nlm.nih.gov/pubmed/35152220",
        "http://www.ncbi.nlm.nih.gov/pubmed/23997938"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32175278",
          "text": "Mechanisms of resistance are categorized into VEGF-dependent alterations, non-VEGF pathways and stromal cell interactions. Thus, complementary approaches such as the combination of these inhibitors with agents targeting alternative mechanisms of blood vessel formation are urgently needed. This review provides an updated overview on the pathophysiology of angiogenesis during tumor growth.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1298,
          "endSection": "abstract",
          "offsetInEndSection": 1688
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23755727",
          "text": "In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer. However, the source of VEGF in colon cancer tissue, the mechanisms of VEGF generation in colon cancer cells and the molecular pathways involved in VEGF mediated angiogenesis in colon cancer are not fully known. The possibility that VEGF directly stimulates cancer cell growth in an autocrine manner has not been explored in depth.",
          "beginSection": "abstract",
          "offsetInBeginSection": 919,
          "endSection": "abstract",
          "offsetInEndSection": 1378
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23755727",
          "text": "This role of VEGF is strongly supported by studies showing that inhibition of VEGF using the blocking antibody, bevacizumab, results in decreased angiogenesis and abrogation of cancer growth. In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer. However, the source of VEGF in colon cancer tissue, the mechanisms of VEGF generation in colon cancer cells and the molecular pathways involved in VEGF mediated angiogenesis in colon cancer are not fully known.",
          "beginSection": "abstract",
          "offsetInBeginSection": 727,
          "endSection": "abstract",
          "offsetInEndSection": 1258
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23755727",
          "text": "Several studies have highlighted the role of VEGF in colon cancer, specifically in the stimulation of angiogenesis. This role of VEGF is strongly supported by studies showing that inhibition of VEGF using the blocking antibody, bevacizumab, results in decreased angiogenesis and abrogation of cancer growth. In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 611,
          "endSection": "abstract",
          "offsetInEndSection": 1047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670046",
          "text": "Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 672
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23755727",
          "text": "This role of VEGF is strongly supported by studies showing that inhibition of VEGF using the blocking antibody, bevacizumab, results in decreased angiogenesis and abrogation of cancer growth. In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 727,
          "endSection": "abstract",
          "offsetInEndSection": 1047
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670046",
          "text": "Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 372
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23755727",
          "text": "In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer. However, the source of VEGF in colon cancer tissue, the mechanisms of VEGF generation in colon cancer cells and the molecular pathways involved in VEGF mediated angiogenesis in colon cancer are not fully known.",
          "beginSection": "abstract",
          "offsetInBeginSection": 919,
          "endSection": "abstract",
          "offsetInEndSection": 1258
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32175278",
          "text": "The minimal benefits could be secondary to primary or acquired resistance, through the activation of alternative mechanisms that sustain tumor vascularization and growth. Mechanisms of resistance are categorized into VEGF-dependent alterations, non-VEGF pathways and stromal cell interactions. Thus, complementary approaches such as the combination of these inhibitors with agents targeting alternative mechanisms of blood vessel formation are urgently needed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1127,
          "endSection": "abstract",
          "offsetInEndSection": 1587
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670046",
          "text": "The primary or acquired resistance towards many oncological drugs, including anti-VEGF inhibitors, is a common problem in cancer treatment. This review summarizes the proposed alternative mechanisms of angiogenesis other than the VEGF pathway. These mechanisms are involved in the development of resistance to anti-VEGF therapies in cancer patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 827,
          "endSection": "abstract",
          "offsetInEndSection": 1176
        }
      ],
      "ideal_answer": "Secondary resistance to Bevacizumab in advanced colorectal cancer patients can occur through VEGF-dependent alterations, non-VEGF pathways, stromal cell interactions, and compensatory angiogenic pathways. These mechanisms can contribute to restoration of tumor growth, enhancement of invasion, and metastasis, thereby overcoming antiangiogenic strategies.",
      "exact_answer": [
        [
          "VEGF-dependent alterations"
        ],
        [
          "non-VEGF pathways"
        ],
        [
          "stromal cell interactions"
        ],
        [
          "compensatory angiogenic pathways"
        ]
      ]
    },
    {
      "id": "661a6a67fdcbea915f00005d",
      "type": "yesno",
      "body": "Does early stage oral squamous cell carcinoma have  good survival rates?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36688107",
        "http://www.ncbi.nlm.nih.gov/pubmed/37779502",
        "http://www.ncbi.nlm.nih.gov/pubmed/37356209",
        "http://www.ncbi.nlm.nih.gov/pubmed/36891418",
        "http://www.ncbi.nlm.nih.gov/pubmed/37294162",
        "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
        "http://www.ncbi.nlm.nih.gov/pubmed/17307596",
        "http://www.ncbi.nlm.nih.gov/pubmed/35700039",
        "http://www.ncbi.nlm.nih.gov/pubmed/38048906",
        "http://www.ncbi.nlm.nih.gov/pubmed/23350600"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "Treatment delay in early-stage oral squamous cell carcinoma and its relation to survival.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "For patients with advanced-stage disease, no significant differences have been observed. As patients with early-stage oral squamous cell carcinoma profit from early treatment initiation, we suggest an acceptable maximum treatment delay of no more than 20 days in the surgical management of these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1481,
          "endSection": "abstract",
          "offsetInEndSection": 1786
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "The aim of this study was to investigate the impact of a prolonged treatment delay on survival in patients with primary oral squamous cell carcinoma. The investigators hypothesized that treatment delay affects survival, supposing a poor outcome in patients with prolonged treatment initiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 293
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17307596",
          "text": "PURPOSE\nLymph node metastasis from oral squamous cell carcinoma (SCC) correlates with a poor prognosis. Therefore, accurate assessment of lymph node status is crucial in treatment planning. Furthermore, prediction of delayed neck metastasis (DNM), especially in early stage tumors with a clinically negative (N0) neck, will determine the need for neck dissection or irradiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 378
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17307596",
          "text": "PURPOSE\nLymph node metastasis from oral squamous cell carcinoma (SCC) correlates with a poor prognosis. Therefore, accurate assessment of lymph node status is crucial in treatment planning.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 189
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17307596",
          "text": "Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35700039",
          "text": "Stage-Specific Survival in Young Patients With Oral Tongue Squamous Cell Carcinoma.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 83
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "For patients with early-stage disease, a treatment delay of 20 days is critical regarding overall survival (p = 0.011). For patients with advanced-stage disease, no significant differences have been observed. As patients with early-stage oral squamous cell carcinoma profit from early treatment initiation, we suggest an acceptable maximum treatment delay of no more than 20 days in the surgical management of these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1361,
          "endSection": "abstract",
          "offsetInEndSection": 1786
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17307596",
          "text": "PURPOSE\nLymph node metastasis from oral squamous cell carcinoma (SCC) correlates with a poor prognosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 103
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33648813",
          "text": "The aim of this study was to investigate the impact of a prolonged treatment delay on survival in patients with primary oral squamous cell carcinoma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 149
        }
      ],
      "ideal_answer": "No, early stage oral squamous cell carcinoma does not always have good survival rates. This is because patients with early-stage oral cancer can still develop locally recurring and/or regional lymph node metastasis, which results in disease-associated mortality.",
      "exact_answer": "no"
    },
    {
      "id": "65f85fdbc4010b4d78000054",
      "type": "factoid",
      "body": "What is the technique of choice to perform a caesarean section?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32760792",
        "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
        "http://www.ncbi.nlm.nih.gov/pubmed/3191053",
        "http://www.ncbi.nlm.nih.gov/pubmed/35886",
        "http://www.ncbi.nlm.nih.gov/pubmed/25646621",
        "http://www.ncbi.nlm.nih.gov/pubmed/24111613",
        "http://www.ncbi.nlm.nih.gov/pubmed/1251272",
        "http://www.ncbi.nlm.nih.gov/pubmed/10796080",
        "http://www.ncbi.nlm.nih.gov/pubmed/5572385",
        "http://www.ncbi.nlm.nih.gov/pubmed/30316719"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
          "text": "There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby. A low vertical incision has more advantages and less dangers than a classical fundal incision. It is prudent to defer the decision regarding the type of incision until the uterus is inspected intraoperatively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 293,
          "endSection": "abstract",
          "offsetInEndSection": 660
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
          "text": "There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby. A low vertical incision has more advantages and less dangers than a classical fundal incision.",
          "beginSection": "abstract",
          "offsetInBeginSection": 293,
          "endSection": "abstract",
          "offsetInEndSection": 545
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
          "text": "There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby.",
          "beginSection": "abstract",
          "offsetInBeginSection": 293,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
          "text": "All the others were the standard transverse lower segment operation except for 1 which was a postmortem classical Caesarean section. There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby. A low vertical incision has more advantages and less dangers than a classical fundal incision.",
          "beginSection": "abstract",
          "offsetInBeginSection": 160,
          "endSection": "abstract",
          "offsetInEndSection": 545
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
          "text": "All the others were the standard transverse lower segment operation except for 1 which was a postmortem classical Caesarean section. There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby.",
          "beginSection": "abstract",
          "offsetInBeginSection": 160,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497629",
          "text": "Eleven of the 3,420 Caesarean sections performed in Westmead Hospital, Sydney during a 6-year period from 1979 to 1985 were by a low vertical uterine incision. All the others were the standard transverse lower segment operation except for 1 which was a postmortem classical Caesarean section. There are indications when the preferred lower segment Caesarean section with a transverse incision should be avoided in the interest of the mother and baby.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25646621",
          "text": "The choice of the type of abdominal incision performed in caesarean delivery is made chiefly on the basis of the individual surgeon's experience and preference. A general consensus on the most appropriate surgical technique has not yet been reached. The aim of this systematic review of the literature is to compare the two most commonly used transverse abdominal incisions for caesarean delivery, the Pfannenstiel incision and the modified Joel-Cohen incision, in terms of acute and chronic post-surgical pain and their subsequent influence in terms of quality of life.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 570
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3191053",
          "text": "Classical versus low-segment transverse incision for preterm caesarean section: maternal complications and outcome of subsequent pregnancies.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 141
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25646621",
          "text": "A general consensus on the most appropriate surgical technique has not yet been reached. The aim of this systematic review of the literature is to compare the two most commonly used transverse abdominal incisions for caesarean delivery, the Pfannenstiel incision and the modified Joel-Cohen incision, in terms of acute and chronic post-surgical pain and their subsequent influence in terms of quality of life.",
          "beginSection": "abstract",
          "offsetInBeginSection": 161,
          "endSection": "abstract",
          "offsetInEndSection": 570
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35886",
          "text": "A comparison of 619 sections performed by low midline incision with 328 section by Pfannenstiel incision showed no difference with regard to postoperative complications such as disturbance in wound healing or haematoma formation. In conclusion, with respect to the IDT and postoperative complications we have found no contraindication to the use of the low transverse Pfannenstiel incision for Caesarean section.",
          "beginSection": "abstract",
          "offsetInBeginSection": 894,
          "endSection": "abstract",
          "offsetInEndSection": 1306
        }
      ],
      "ideal_answer": "The technique of choice to perform a caesarean section is usually a laparotomy followed by hysterotomy with a low transverse incision.",
      "exact_answer": [
        "low transverse incision"
      ]
    },
    {
      "id": "661d9e79fe9d0b3967000001",
      "type": "list",
      "body": "Which cell states can exist in melanomas?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
        "http://www.ncbi.nlm.nih.gov/pubmed/34874265",
        "http://www.ncbi.nlm.nih.gov/pubmed/30560804",
        "http://www.ncbi.nlm.nih.gov/pubmed/2670726",
        "http://www.ncbi.nlm.nih.gov/pubmed/35338512",
        "http://www.ncbi.nlm.nih.gov/pubmed/24504051",
        "http://www.ncbi.nlm.nih.gov/pubmed/33999497",
        "http://www.ncbi.nlm.nih.gov/pubmed/34087163",
        "http://www.ncbi.nlm.nih.gov/pubmed/37961316",
        "http://www.ncbi.nlm.nih.gov/pubmed/37082838"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "text": "Melanoma cells can switch between a melanocytic and a mesenchymal-like state. Scattered evidence indicates that additional intermediate state(s) may exist. Here, to search for such states and decipher their underlying gene regulatory network (GRN), we studied 10 melanoma cultures using single-cell RNA sequencing (RNA-seq) as well as 26 additional cultures using bulk RNA-seq.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 377
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "text": "Melanoma cells can switch between a melanocytic and a mesenchymal-like state. Scattered evidence indicates that additional intermediate state(s) may exist.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 155
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "text": "Melanoma cells can switch between a melanocytic and a mesenchymal-like state.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 77
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30560804",
          "text": "During EMT, cells do not necessarily exist in 'pure' epithelial or mesenchymal states. There are cells with mixed (or hybrid) features of the two, which are termed as the intermediate cell states (ICSs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 178,
          "endSection": "abstract",
          "offsetInEndSection": 381
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30560804",
          "text": "During EMT, cells do not necessarily exist in 'pure' epithelial or mesenchymal states.",
          "beginSection": "abstract",
          "offsetInBeginSection": 178,
          "endSection": "abstract",
          "offsetInEndSection": 264
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
          "text": "Scattered evidence indicates that additional intermediate state(s) may exist. Here, to search for such states and decipher their underlying gene regulatory network (GRN), we studied 10 melanoma cultures using single-cell RNA sequencing (RNA-seq) as well as 26 additional cultures using bulk RNA-seq. Although each culture exhibited a unique transcriptome, we identified shared GRNs that underlie the extreme melanocytic and mesenchymal states and the intermediate state.",
          "beginSection": "abstract",
          "offsetInBeginSection": 78,
          "endSection": "abstract",
          "offsetInEndSection": 548
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30560804",
          "text": "During EMT, cells do not necessarily exist in 'pure' epithelial or mesenchymal states. There are cells with mixed (or hybrid) features of the two, which are termed as the intermediate cell states (ICSs). While the exact functions of ICS remain elusive, together with EMT it appears to play important roles in embryogenesis, tissue development, and pathological processes such as cancer metastasis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 178,
          "endSection": "abstract",
          "offsetInEndSection": 575
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35338512",
          "text": "Nevus, melanoma, or something else? Mesenchymal neoplasms with melanocytic differentiation.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 91
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30560804",
          "text": "Intermediate cell states in epithelial-to-mesenchymal transition.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 65
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2670726",
          "text": "p21ras expressions in both melanomas and melanocytic nevi may represent a marker of the immature state of cells corresponding to early stages of the melanocyte evolution as well as the morphologic and enzymologic characteristics.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1055,
          "endSection": "abstract",
          "offsetInEndSection": 1284
        }
      ],
      "ideal_answer": "Melanoma cells can exist in a melanocytic state, a mesenchymal-like state, and potentially additional intermediate states.",
      "exact_answer": [
        [
          "melanocytic state"
        ],
        [
          "mesenchymal-like state"
        ],
        [
          "intermediate state"
        ]
      ]
    },
    {
      "id": "661d1c3ceac11fad33000012",
      "type": "yesno",
      "body": "Are there any molecular signatures identified for the differentiation between bacterial and viral infections?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
        "http://www.ncbi.nlm.nih.gov/pubmed/34142256",
        "http://www.ncbi.nlm.nih.gov/pubmed/34912024",
        "http://www.ncbi.nlm.nih.gov/pubmed/37081881",
        "http://www.ncbi.nlm.nih.gov/pubmed/36692131",
        "http://www.ncbi.nlm.nih.gov/pubmed/33491921",
        "http://www.ncbi.nlm.nih.gov/pubmed/35313598",
        "http://www.ncbi.nlm.nih.gov/pubmed/36543117",
        "http://www.ncbi.nlm.nih.gov/pubmed/36250865",
        "http://www.ncbi.nlm.nih.gov/pubmed/32359149"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34142256",
          "text": "A 29-mRNA host response test from blood accurately distinguishes bacterial and viral infections among emergency department patients.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 132
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "A Novel 29-Messenger RNA Host-Response Assay From Whole Blood Accurately Identifies Bacterial and Viral Infections in Patients Presenting to the Emergency Department With Suspected Infections: A Prospective Observational Study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "A Novel 29-Messenger RNA Host-Response Assay From Whole Blood Accurately Identifies Bacterial and Viral Infections in Patients Presenting to the Emergency Department With Suspected Infections",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 191
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections",
          "beginSection": "abstract",
          "offsetInBeginSection": 275,
          "endSection": "abstract",
          "offsetInEndSection": 507
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 274,
          "endSection": "abstract",
          "offsetInEndSection": 507
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections. DESIGN\nProspective observational study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 274,
          "endSection": "abstract",
          "offsetInEndSection": 549
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections. DESIGN\nProspective observational study. SETTING\nEmergency Department, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Germany.",
          "beginSection": "abstract",
          "offsetInBeginSection": 274,
          "endSection": "abstract",
          "offsetInEndSection": 652
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "As a result of limitations in current diagnostics, guidelines recommend early antimicrobials for suspected sepsis patients to improve outcomes at a cost to antimicrobial stewardship. We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 91,
          "endSection": "abstract",
          "offsetInEndSection": 507
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "OBJECTIVES\nThe rapid diagnosis of acute infections and sepsis remains a serious challenge. As a result of limitations in current diagnostics, guidelines recommend early antimicrobials for suspected sepsis patients to improve outcomes at a cost to antimicrobial stewardship. We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 507
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166284",
          "text": "As a result of limitations in current diagnostics, guidelines recommend early antimicrobials for suspected sepsis patients to improve outcomes at a cost to antimicrobial stewardship. We aimed to develop and prospectively validate a new, 29-messenger RNA blood-based host-response classifier Inflammatix Bacterial Viral Non-Infected version 2 (IMX-BVN-2) to determine the likelihood of bacterial and viral infections. DESIGN\nProspective observational study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 91,
          "endSection": "abstract",
          "offsetInEndSection": 549
        }
      ],
      "ideal_answer": "Yes, a 29-messenger RNA host-response assay from whole blood has been identified to accurately differentiate between bacterial and viral infections in patients presenting to the emergency department with suspected infections.",
      "exact_answer": "yes"
    },
    {
      "id": "65d1369c1930410b1300003b",
      "type": "list",
      "body": "What are active ingredients of Xacduro?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37523122",
        "http://www.ncbi.nlm.nih.gov/pubmed/37817550",
        "http://www.ncbi.nlm.nih.gov/pubmed/36551450",
        "http://www.ncbi.nlm.nih.gov/pubmed/32516359",
        "http://www.ncbi.nlm.nih.gov/pubmed/38095417",
        "http://www.ncbi.nlm.nih.gov/pubmed/36005804",
        "http://www.ncbi.nlm.nih.gov/pubmed/32306049",
        "http://www.ncbi.nlm.nih.gov/pubmed/37740370",
        "http://www.ncbi.nlm.nih.gov/pubmed/37839896",
        "http://www.ncbi.nlm.nih.gov/pubmed/37125470"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37523122",
          "text": "Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37523122",
          "text": "Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a β-lactamase inhibitor with potent activity against a broad range of serine β-lactamases) with sulbactam (an established class A β-lactamase inhibitor with antibacterial activity against A. baumannii) prevents sulbactam degradation by ABC-produced β-lactamases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 516
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37523122",
          "text": "Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a β-lactamase inhibitor with potent activity against a broad range of serine β-lactamases) with sulbactam (an established class A β-lactamase inhibitor with antibacterial activity against A. baumannii) prevents sulbactam degradation by ABC-produced β-lactamases. In May 2023, sulbactam/durlobactam was approved in the USA for use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of ABC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 777
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36551450",
          "text": "Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 107,
          "endSection": "abstract",
          "offsetInEndSection": 239
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37817550",
          "text": "DATA SOURCES\nPubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam Durlobactam, ETX2514, Xacduro, Sulbactam-ETX2514, ETX2514SUL. STUDY SELECTION AND DATA EXTRACTION\nArticles published in English between January 1985 and September 13, 2023, related to pharmacology, safety, efficacy, and clinical trials were reviewed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 192,
          "endSection": "abstract",
          "offsetInEndSection": 548
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37817550",
          "text": "DATA SOURCES\nPubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam Durlobactam, ETX2514, Xacduro, Sulbactam-ETX2514, ETX2514SUL. STUDY SELECTION AND DATA EXTRACTION\nArticles published in English between January 1985 and September 13, 2023, related to pharmacology, safety, efficacy, and clinical trials were reviewed. DATA SYNTHESIS\nA phase II trial compared SUL-DUR with placebo with imipenem and cilastatin in both groups.",
          "beginSection": "abstract",
          "offsetInBeginSection": 192,
          "endSection": "abstract",
          "offsetInEndSection": 657
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37817550",
          "text": "DATA SOURCES\nPubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam Durlobactam, ETX2514, Xacduro, Sulbactam-ETX2514, ETX2514SUL.",
          "beginSection": "abstract",
          "offsetInBeginSection": 192,
          "endSection": "abstract",
          "offsetInEndSection": 357
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36551450",
          "text": "Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a systematic review on in vitro studies reporting A. baumannii resistances against sulbactam/durlobactam.",
          "beginSection": "abstract",
          "offsetInBeginSection": 107,
          "endSection": "abstract",
          "offsetInEndSection": 358
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37523122",
          "text": "Sulbactam/Durlobactam: First Approval.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 38
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36551450",
          "text": "Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a systematic review on in vitro studies reporting A. baumannii resistances against sulbactam/durlobactam. We considered \"resistant\" species to be those with MIC ≥ 8 mg/L.",
          "beginSection": "abstract",
          "offsetInBeginSection": 107,
          "endSection": "abstract",
          "offsetInEndSection": 423
        }
      ],
      "ideal_answer": "The active ingredients of Xacduro are Sulbactam and Durlobactam.",
      "exact_answer": [
        [
          "Sulbactam"
        ],
        [
          "Durlobactam"
        ]
      ]
    },
    {
      "id": "66099967fdcbea915f000018",
      "type": "factoid",
      "body": "What is the faster length time for oxaliplatin infusion?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
        "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
        "http://www.ncbi.nlm.nih.gov/pubmed/14968944",
        "http://www.ncbi.nlm.nih.gov/pubmed/12111116",
        "http://www.ncbi.nlm.nih.gov/pubmed/12712487",
        "http://www.ncbi.nlm.nih.gov/pubmed/23053686",
        "http://www.ncbi.nlm.nih.gov/pubmed/35125319",
        "http://www.ncbi.nlm.nih.gov/pubmed/20038320",
        "http://www.ncbi.nlm.nih.gov/pubmed/31118678",
        "http://www.ncbi.nlm.nih.gov/pubmed/24172094"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
          "text": "CONCLUSION\nInfusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1406,
          "endSection": "abstract",
          "offsetInEndSection": 1595
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
          "text": " Infusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1411,
          "endSection": "abstract",
          "offsetInEndSection": 1590
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
          "text": "We then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc). The incidence of HSRs with the new infusion rate was actively monitored.",
          "beginSection": "abstract",
          "offsetInBeginSection": 694,
          "endSection": "abstract",
          "offsetInEndSection": 937
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
          "text": "Maintenance of a prolonged infusion time has been largely based on the concern for a potential hypersensitivity reaction (HSR) if administered too quickly. METHODS\nWe first performed a retrospective review of our institutional experience to assess whether HSR rates were similar in FOLFOX and CapeOx by using computerized pharmacy records between January 1, 2011, and December 31, 2013. We then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc).",
          "beginSection": "abstract",
          "offsetInBeginSection": 305,
          "endSection": "abstract",
          "offsetInEndSection": 864
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
          "text": "PURPOSE\nThe National Comprehensive Cancer Network guidelines state that the oxaliplatin dose of 85 mg/m2 used in various gastrointestinal cancer regimens may be infused over a rapid rate of 85 min instead of the standard time of 120 min. We evaluated the safety outcomes of rapid administration of oxaliplatin compared to standard infusion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 340
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525581",
          "text": "PURPOSE\nThe National Comprehensive Cancer Network guidelines state that the oxaliplatin dose of 85 mg/m2 used in various gastrointestinal cancer regimens may be infused over a rapid rate of 85 min instead of the standard time of 120 min. We evaluated the safety outcomes of rapid administration of oxaliplatin compared to standard infusion. METHODS\nWe performed a retrospective, cohort study by chart review.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 410
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
          "text": "PURPOSE\nOxaliplatin at a dose of 85 mg/m(2) traditionally has been administered over 120 min in the standard FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) regimen. CapeOx (capecitabine plus oxaliplatin), in which the dose of oxaliplatin is 130 mg/m(2), has also been infused over 120 min. Maintenance of a prolonged infusion time has been largely based on the concern for a potential hypersensitivity reaction (HSR) if administered too quickly.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 460
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
          "text": "CapeOx (capecitabine plus oxaliplatin), in which the dose of oxaliplatin is 130 mg/m(2), has also been infused over 120 min. Maintenance of a prolonged infusion time has been largely based on the concern for a potential hypersensitivity reaction (HSR) if administered too quickly.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 460
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
          "text": "We then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m(2)/min (85 mg/m(2) given over 85 min; 68 mg/m(2) over 68 min, etc). The incidence of HSRs with the new infusion rate was actively monitored. RESULTS\nOf 2,097 patients who previously received oxaliplatin over 120 min, 1,936 received a dose of 85 mg/m(2) (± 10%), and 161 received a dose of 130 mg/m(2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 694,
          "endSection": "abstract",
          "offsetInEndSection": 1100
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072569",
          "text": "The incidence of HSRs in patients treated at this fixed infusion rate was 8%. CONCLUSION\nInfusing oxaliplatin at a rate of 1 mg/m(2)/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1326,
          "endSection": "abstract",
          "offsetInEndSection": 1595
        }
      ],
      "ideal_answer": "The faster length time for oxaliplatin infusion is 1 mg/m(2)/min.",
      "exact_answer": [
        "1 mg/m(2)/min"
      ]
    },
    {
      "id": "661be55f48a2c27714000003",
      "type": "factoid",
      "body": "What disease is treated by Callosotomy",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36435385",
        "http://www.ncbi.nlm.nih.gov/pubmed/37303192",
        "http://www.ncbi.nlm.nih.gov/pubmed/36637309",
        "http://www.ncbi.nlm.nih.gov/pubmed/8681170",
        "http://www.ncbi.nlm.nih.gov/pubmed/35500873",
        "http://www.ncbi.nlm.nih.gov/pubmed/25456300",
        "http://www.ncbi.nlm.nih.gov/pubmed/37770691",
        "http://www.ncbi.nlm.nih.gov/pubmed/29999448",
        "http://www.ncbi.nlm.nih.gov/pubmed/23046918",
        "http://www.ncbi.nlm.nih.gov/pubmed/35399875"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36435385",
          "text": "BACKGROUND\nCorpus callosotomy (CC) is a surgical palliative procedure done for a selected group of patients with drug resistant epilepsy (DRE) to stop drop attacks and prevent falls. METHODS\nWe performed a retrospective chart review of consecutive patients who underwent CC for DRE with drop attacks at our center between 2015 and 2019.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 338
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36435385",
          "text": "BACKGROUND\nCorpus callosotomy (CC) is a surgical palliative procedure done for a selected group of patients with drug resistant epilepsy (DRE) to stop drop attacks and prevent falls. METHODS\nWe performed a retrospective chart review of consecutive patients who underwent CC for DRE with drop attacks at our center between 2015 and 2019. Clinical, imaging details and surgical findings were noted.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 398
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36435385",
          "text": "BACKGROUND\nCorpus callosotomy (CC) is a surgical palliative procedure done for a selected group of patients with drug resistant epilepsy (DRE) to stop drop attacks and prevent falls.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 182
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36435385",
          "text": "Corpus callosotomy (CC) is a surgical palliative procedure done for a selected group of patients with drug resistant epilepsy (DRE) to stop drop attacks and prevent ",
          "beginSection": "abstract",
          "offsetInBeginSection": 12,
          "endSection": "abstract",
          "offsetInEndSection": 177
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36435385",
          "text": "Corpus Callosotomy for Non-Localizing Drug Resistant Epilepsy with Drop Attacks.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 80
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8681170",
          "text": "[Callosotomy in the treatment of drug-resistant epilepsy].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 58
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8681170",
          "text": "At the present time corpus callosotomy is a valuable option in the management of some patients with drug-resistant epilepsy who are not candidates for resective procedures. The records of six patients who underwent callosotomy at 'Hospital Virgen de las Nieves' (Granada, Spain) in the past four years were retrospectively analyzed. The patients all had intractable primary or secondarily generalized seizures, were severely handicapped by its frequency and nature (especially with drop attacks and multiple injuries) and were not suitable for other surgical procedure.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 569
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8681170",
          "text": "At the present time corpus callosotomy is a valuable option in the management of some patients with drug-resistant epilepsy who are not candidates for resective procedures.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 172
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8681170",
          "text": "The best results are obtained in those patients with drop attacks (including atonic seizures) as the most frequent and disabling seizure type. According to the type of epilepsy, patients with localization-related epilepsy (especially when symptomatic of a focal brain damage) and those with the Lennox-Gastaut syndrome are the most likely to benefit from the procedure. It is suggested that, in the first place, a two-thirds anterior callosotomy should be performed particularly with atonic seizure are the most frequent seizure type.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1211,
          "endSection": "abstract",
          "offsetInEndSection": 1745
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35500873",
          "text": "Corpus callosotomy is an interhemispheric disconnection by callosal commissural fiber ablation. Its rationale is the disruption of ictal spread to prevent seizure generalization. The objective pursued is alleviation of intractable, debilitating, and injurious manifestations of generalized epilepsy.1 Eight decades of experience support this procedure's safety and effectiveness for appropriately selected patients with drug-resistant epilepsy not amenable to optimal resection; particularly, favorable outcomes for tonic or atonic seizures with drop attacks have been reported.2,3 Children may benefit more than adults from callosotomy for improved daily function, psychosocial adjustment, and family satisfaction.4 A meta-analysis found a better seizure reduction from total than partial callosotomy (88.2% vs. 58.6% of worthwhile reduction) comprising drop-attacks (77.8% vs. 45.4%) with an increased but transient (i.e., resolution within 6 weeks) risk of significant disconnection syndromes (12.5% vs. none).5 Here, we present the illustrative case of a 4-year-old boy with Lennox-Gastaut syndrome who underwent open single-stage complete callosotomy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 1156
        }
      ],
      "ideal_answer": "Epilepsy is treated by Callosotomy.",
      "exact_answer": [
        "epilepsy"
      ]
    },
    {
      "id": "6614fe3dfdcbea915f000045",
      "type": "yesno",
      "body": "Is there an approved vaccine to prevent Zika virus infection during pregnancy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36690159",
        "http://www.ncbi.nlm.nih.gov/pubmed/37058415",
        "http://www.ncbi.nlm.nih.gov/pubmed/36762592",
        "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
        "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
        "http://www.ncbi.nlm.nih.gov/pubmed/34461793",
        "http://www.ncbi.nlm.nih.gov/pubmed/27902933",
        "http://www.ncbi.nlm.nih.gov/pubmed/35087081",
        "http://www.ncbi.nlm.nih.gov/pubmed/27079865",
        "http://www.ncbi.nlm.nih.gov/pubmed/29523447"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "There is currently no vaccine or intervention to prevent the adverse effects of Zika virus infection during pregnancy; therefore, prevention has been the focus of public health activities, especially for pregnant women (3).",
          "beginSection": "abstract",
          "offsetInBeginSection": 358,
          "endSection": "abstract",
          "offsetInEndSection": 581
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "There is currently no vaccine or intervention to prevent the adverse effects of Zika virus infection during pregnancy; therefore, prevention has been the focus of public health activities, especially for pregnant women (3). CDC and the Puerto Rico Department of Health analyzed data from the Pregnancy Risk Assessment Monitoring System Zika Postpartum Emergency Response (PRAMS-ZPER) survey conducted from August through December 2016 among Puerto Rico residents with a live birth.",
          "beginSection": "abstract",
          "offsetInBeginSection": 358,
          "endSection": "abstract",
          "offsetInEndSection": 839
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "From January 1, 2016 through March 29, 2017, Puerto Rico reported approximately 3,300 pregnant women with laboratory evidence of possible Zika virus infection (2). There is currently no vaccine or intervention to prevent the adverse effects of Zika virus infection during pregnancy; therefore, prevention has been the focus of public health activities, especially for pregnant women (3).",
          "beginSection": "abstract",
          "offsetInBeginSection": 194,
          "endSection": "abstract",
          "offsetInEndSection": 581
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "Infection during pregnancy can cause microcephaly, brain abnormalities, and other severe birth defects (1). From January 1, 2016 through March 29, 2017, Puerto Rico reported approximately 3,300 pregnant women with laboratory evidence of possible Zika virus infection (2). There is currently no vaccine or intervention to prevent the adverse effects of Zika virus infection during pregnancy; therefore, prevention has been the focus of public health activities, especially for pregnant women (3).",
          "beginSection": "abstract",
          "offsetInBeginSection": 86,
          "endSection": "abstract",
          "offsetInEndSection": 581
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "Measures Taken to Prevent Zika Virus Infection During Pregnancy - Puerto Rico, 2016.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 84
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
          "text": "Here Shan et al. show that a single dose of a live-attenuated Zika vaccine prevents infection, testis damage and transmission to the fetus during pregnancy in different animal models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1232,
          "endSection": "abstract",
          "offsetInEndSection": 1415
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
          "text": "A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
          "text": "Zika virus infection during pregnancy can cause congenital abnormities or fetal demise. The persistence of Zika virus in the male reproductive system poses a risk of sexual transmission. Here we demonstrate that live-attenuated Zika virus vaccine candidates containing deletions in the 3' untranslated region of the Zika virus genome (ZIKV-3'UTR-LAV) prevent viral transmission during pregnancy and testis damage in mice, as well as infection of nonhuman primates.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 464
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939807",
          "text": "These results suggest that further development of ZIKV-3'UTR-LAV is warranted for humans.Zika virus infection can result in congenital disorders and cause disease in adults, and there is currently no approved vaccine. Here Shan et al. show that a single dose of a live-attenuated Zika vaccine prevents infection, testis damage and transmission to the fetus during pregnancy in different animal models.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1014,
          "endSection": "abstract",
          "offsetInEndSection": 1415
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28594787",
          "text": "There is currently no vaccine or intervention to prevent the adverse effects of Zika virus infection during pregnancy; therefore, prevention has been the focus of public health activities, especially for pregnant women (3). CDC and the Puerto Rico Department of Health analyzed data from the Pregnancy Risk Assessment Monitoring System Zika Postpartum Emergency Response (PRAMS-ZPER) survey conducted from August through December 2016 among Puerto Rico residents with a live birth. Most women (98.1%) reported using at least one measure to avoid mosquitos in their home environment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 358,
          "endSection": "abstract",
          "offsetInEndSection": 940
        }
      ],
      "ideal_answer": "No, there is currently no approved vaccine to prevent Zika virus infection during pregnancy. Prevention measures are the focus of public health activities.",
      "exact_answer": "no"
    },
    {
      "id": "661c416048a2c27714000008",
      "type": "summary",
      "body": "What are eRNAs and what is their function?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36039999",
        "http://www.ncbi.nlm.nih.gov/pubmed/37537618",
        "http://www.ncbi.nlm.nih.gov/pubmed/36909657",
        "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
        "http://www.ncbi.nlm.nih.gov/pubmed/34016622",
        "http://www.ncbi.nlm.nih.gov/pubmed/28599852",
        "http://www.ncbi.nlm.nih.gov/pubmed/30026829",
        "http://www.ncbi.nlm.nih.gov/pubmed/36923642",
        "http://www.ncbi.nlm.nih.gov/pubmed/28533025",
        "http://www.ncbi.nlm.nih.gov/pubmed/32810208"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
          "text": "Enhancer RNAs (eRNAs) are non-coding RNAs (ncRNAs) transcribed in enhancer regions. They play an important role in transcriptional regulation, mainly during cellular differentiation. eRNAs are tightly tissue- and cell-type specific and are induced by specific stimuli, activating promoters of target genes in turn.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 314
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35454885",
          "text": "Enhancer RNAs (eRNAs) are non-coding RNAs (ncRNAs) transcribed in enhancer regions. They play an important role in transcriptional regulation, mainly during cellular differentiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 182
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37537618",
          "text": "eRNAs are non-coding RNA molecules produced by the transcription of DNA cis-acting elements, enhancer fragments. Recent studies revealed that the transcription of eRNAs may be a biological marker responding to enhancer activity that can participate in the regulation of coding gene transcription.",
          "beginSection": "abstract",
          "offsetInBeginSection": 396,
          "endSection": "abstract",
          "offsetInEndSection": 692
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37537618",
          "text": "The discovery of enhancer RNAs (eRNAs) in 2010 has further broadened the range of non-coding RNAs revealed. eRNAs are non-coding RNA molecules produced by the transcription of DNA cis-acting elements, enhancer fragments. Recent studies revealed that the transcription of eRNAs may be a biological marker responding to enhancer activity that can participate in the regulation of coding gene transcription.",
          "beginSection": "abstract",
          "offsetInBeginSection": 288,
          "endSection": "abstract",
          "offsetInEndSection": 692
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36039999",
          "text": "Over the last decade, the transcription of enhancer RNAs (eRNAs) - nascent RNAs transcribed from active enhancers - has emerged as a key factor regulating enhancer activity. eRNAs are relatively short-lived RNA species that are transcribed at very high rates but also quickly degraded. Nevertheless, eRNAs are deeply intertwined within enhancer regulatory networks and are implicated in a number of transcriptional control mechanisms.",
          "beginSection": "abstract",
          "offsetInBeginSection": 124,
          "endSection": "abstract",
          "offsetInEndSection": 558
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36039999",
          "text": "eRNAs are relatively short-lived RNA species that are transcribed at very high rates but also quickly degraded. Nevertheless, eRNAs are deeply intertwined within enhancer regulatory networks and are implicated in a number of transcriptional control mechanisms. Enhancers show changes in function and sequence over evolutionary time, raising questions about the relationship between enhancer sequences and eRNA function.",
          "beginSection": "abstract",
          "offsetInBeginSection": 298,
          "endSection": "abstract",
          "offsetInEndSection": 717
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36039999",
          "text": "Over the last decade, the transcription of enhancer RNAs (eRNAs) - nascent RNAs transcribed from active enhancers - has emerged as a key factor regulating enhancer activity. eRNAs are relatively short-lived RNA species that are transcribed at very high rates but also quickly degraded.",
          "beginSection": "abstract",
          "offsetInBeginSection": 124,
          "endSection": "abstract",
          "offsetInEndSection": 409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36039999",
          "text": "eRNAs are relatively short-lived RNA species that are transcribed at very high rates but also quickly degraded. Nevertheless, eRNAs are deeply intertwined within enhancer regulatory networks and are implicated in a number of transcriptional control mechanisms.",
          "beginSection": "abstract",
          "offsetInBeginSection": 298,
          "endSection": "abstract",
          "offsetInEndSection": 558
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28599852",
          "text": "Long non-coding RNAs (lncRNAs) have gained widespread interest in the past decade owing to their enormous amount and surprising functions implicated in a variety of biological processes. Some lncRNAs exert function as enhancers, i.e., activating gene transcription by serving as the cis-regulatory molecules. Furthermore, recent studies have demonstrated that many enhancer elements can be transcribed and produce RNA molecules, which are termed as enhancer RNAs (eRNAs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 471
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28599852",
          "text": "Some lncRNAs exert function as enhancers, i.e., activating gene transcription by serving as the cis-regulatory molecules. Furthermore, recent studies have demonstrated that many enhancer elements can be transcribed and produce RNA molecules, which are termed as enhancer RNAs (eRNAs). The eRNAs are not merely the by-product of the enhancer transcription.",
          "beginSection": "abstract",
          "offsetInBeginSection": 187,
          "endSection": "abstract",
          "offsetInEndSection": 542
        }
      ],
      "ideal_answer": "eRNAs are non-coding RNA molecules transcribed from enhancer fragments that are highly correlated with enhancer activities. They are relatively short-lived and transcribed at high rates, and their transcription may serve as a biological marker of enhancer activity. eRNAs are deeply intertwined within enhancer regulatory networks and are implicated in various transcriptional control mechanisms.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d20b7eac11fad33000016",
      "type": "yesno",
      "body": "Can cytomegalovirus (CMV) be transmitted via breast milk to premature infants?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20670291",
        "http://www.ncbi.nlm.nih.gov/pubmed/24172840",
        "http://www.ncbi.nlm.nih.gov/pubmed/34809592",
        "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
        "http://www.ncbi.nlm.nih.gov/pubmed/23713111",
        "http://www.ncbi.nlm.nih.gov/pubmed/21164427",
        "http://www.ncbi.nlm.nih.gov/pubmed/27751206",
        "http://www.ncbi.nlm.nih.gov/pubmed/32662174",
        "http://www.ncbi.nlm.nih.gov/pubmed/16615961",
        "http://www.ncbi.nlm.nih.gov/pubmed/12777549"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24172840",
          "text": "Cytomegalovirus (CMV) may transmit perinatally or from breast milk. The risk for development of symptomatic CMV disease in very-low-birth-weight premature infants after transmission from maternal breast milk is not clear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 221
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34809592",
          "text": "BACKGROUND\nThis study aimed to investigate the transmission of cytomegalovirus (CMV) via breast milk in low birth weight (LBW) and premature infants and its effects. METHODS\nPubMed, Medline, Cochrane Library, and Embase were searched for studies (without language and time restriction) published before March 27, 2020, that examined the effect of CMV transmitted by breast milk on LBW and premature infants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 409
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24172840",
          "text": "Cytomegalovirus (CMV) may transmit perinatally or from breast milk. The risk for development of symptomatic CMV disease in very-low-birth-weight premature infants after transmission from maternal breast milk is not clear. There are scarce data in the literature about congenital CMV infection in multiple pregnancies, being mostly with twin gestations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 352
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
          "text": "Human cytomegalovirus (HCMV) can be transmitted through breast milk to neonates. Although healthy full-term infants rarely develop symptoms of CMV infection; premature or low-birth-weight infants can experience symptomatic infection that is occasionally severe.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 261
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17661570",
          "text": "Human cytomegalovirus (HCMV) can be transmitted through breast milk to neonates. Although healthy full-term infants rarely develop symptoms of CMV infection; premature or low-birth-weight infants can experience symptomatic infection that is occasionally severe. There is limited information on the long-term effects of postnatal CMV infection in premature infants, suggesting that these infants do not develop cognitive function delays or hearing loss, although those with intrapartum infection do.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 498
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164427",
          "text": "OBJECTIVE\nWe prospectively evaluated the rate of postnatal cytomegalovirus (CMV) transmission through breast milk in extremely premature infants to address the impact of CMV infection on preterm infants during lactation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34809592",
          "text": "BACKGROUND\nThis study aimed to investigate the transmission of cytomegalovirus (CMV) via breast milk in low birth weight (LBW) and premature infants and its effects.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34809592",
          "text": "BACKGROUND\nThis study aimed to investigate the transmission of cytomegalovirus (CMV) via breast milk in low birth weight (LBW) and premature infants and its effects. METHODS\nPubMed, Medline, Cochrane Library, and Embase were searched for studies (without language and time restriction) published before March 27, 2020, that examined the effect of CMV transmitted by breast milk on LBW and premature infants. The rates of breast milk-acquired CMV infection, CMV-related symptoms, and CMV-related sepsis-like syndrome (CMV-SLS) in LBW and premature infants were pooled from each study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 585
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24172840",
          "text": "Cytomegalovirus (CMV) may transmit perinatally or from breast milk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 67
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164427",
          "text": "OBJECTIVE\nWe prospectively evaluated the rate of postnatal cytomegalovirus (CMV) transmission through breast milk in extremely premature infants to address the impact of CMV infection on preterm infants during lactation. STUDY DESIGN\nA total of 25 mothers and 27 infants (two sets of twins) with birth weights <1000 g and/or gestational ages <28 weeks were enrolled in the study. They were mostly fed frozen-thawed breast milk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 429
        }
      ],
      "ideal_answer": "Yes, cytomegalovirus (CMV) can be transmitted via breast milk to premature infants, but the rates of symptomatic disease are low and there is no evidence of certain long-term sequelae.",
      "exact_answer": "yes"
    },
    {
      "id": "65cfcb4c1930410b13000017",
      "type": "list",
      "body": "What enzymes are inhibited by Vorasidenib?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
        "http://www.ncbi.nlm.nih.gov/pubmed/34078652",
        "http://www.ncbi.nlm.nih.gov/pubmed/36453510",
        "http://www.ncbi.nlm.nih.gov/pubmed/37276325",
        "http://www.ncbi.nlm.nih.gov/pubmed/37812369",
        "http://www.ncbi.nlm.nih.gov/pubmed/36698225",
        "http://www.ncbi.nlm.nih.gov/pubmed/8369302",
        "http://www.ncbi.nlm.nih.gov/pubmed/31257503",
        "http://www.ncbi.nlm.nih.gov/pubmed/19228619",
        "http://www.ncbi.nlm.nih.gov/pubmed/35143931"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078652",
          "text": "Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 316,
          "endSection": "abstract",
          "offsetInEndSection": 433
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
          "text": "Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 278
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
          "text": "Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 149,
          "endSection": "abstract",
          "offsetInEndSection": 279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078652",
          "text": "The majority of LGGs harbor mutations in the genes encoding isocitrate dehydrogenase 1 or 2 (IDH1/IDH2). Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 211,
          "endSection": "abstract",
          "offsetInEndSection": 433
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078652",
          "text": "The majority of LGGs harbor mutations in the genes encoding isocitrate dehydrogenase 1 or 2 (IDH1/IDH2). Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. PATIENTS AND METHODS\nWe conducted a multicenter, open-label, phase I, dose-escalation study of vorasidenib in 93 patients with mutant IDH1/2 (mIDH1/2) solid tumors, including 52 patients with glioma that had recurred or progressed following standard therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 211,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078652",
          "text": "Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 317,
          "endSection": "abstract",
          "offsetInEndSection": 434
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
          "text": "BACKGROUND\nIsocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 278
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272516",
          "text": "BACKGROUND\nIsocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas. METHODS\nIn a double-blind, phase 3 trial, we randomly assigned patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery to receive either oral vorasidenib (40 mg once daily) or matched placebo in 28-day cycles.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078652",
          "text": "Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. PATIENTS AND METHODS\nWe conducted a multicenter, open-label, phase I, dose-escalation study of vorasidenib in 93 patients with mutant IDH1/2 (mIDH1/2) solid tumors, including 52 patients with glioma that had recurred or progressed following standard therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 316,
          "endSection": "abstract",
          "offsetInEndSection": 694
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078652",
          "text": "Progression to higher tumor grade is associated with contrast enhancement on MRI. The majority of LGGs harbor mutations in the genes encoding isocitrate dehydrogenase 1 or 2 (IDH1/IDH2). Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 129,
          "endSection": "abstract",
          "offsetInEndSection": 433
        }
      ],
      "ideal_answer": "Vorasidenib inhibits the mutant isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) enzymes.",
      "exact_answer": [
        [
          "IDH1"
        ],
        [
          "IDH2"
        ]
      ]
    },
    {
      "id": "66099a03fdcbea915f00001d",
      "type": "factoid",
      "body": "From what age is it recommended to start population screening for colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34003218",
        "http://www.ncbi.nlm.nih.gov/pubmed/34794803",
        "http://www.ncbi.nlm.nih.gov/pubmed/34794816",
        "http://www.ncbi.nlm.nih.gov/pubmed/34962727",
        "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
        "http://www.ncbi.nlm.nih.gov/pubmed/34486085",
        "http://www.ncbi.nlm.nih.gov/pubmed/22692444",
        "http://www.ncbi.nlm.nih.gov/pubmed/19892375",
        "http://www.ncbi.nlm.nih.gov/pubmed/12473428",
        "http://www.ncbi.nlm.nih.gov/pubmed/23299409"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "Colorectal cancer is a growing burden in adults less than 50 years old. In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "Colorectal cancer is a growing burden in adults less than 50 years old. In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 251
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 251
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "In 2018, the American Cancer Society published a guideline update recommending a reduction in the colorectal cancer screening start age for average-risk individuals from 50 to 45. Implementing these recommendations would have important implications for public health. However, the approximate number of people impacted by this change, the average-risk population ages 45-49, is not well-described in the literature.",
          "beginSection": "abstract",
          "offsetInBeginSection": 72,
          "endSection": "abstract",
          "offsetInEndSection": 487
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34486085",
          "text": "It is unclear whether increasing incidence trends will confer increased risk beyond age 50, the previously most commonly recommended age to initiate screening, when screening availability might modify incidence trends. AIM\nEvaluate US trends in colorectal cancer (CRC) for ages 40-59 years. METHODS\nWe analyzed counts and incidence rates for CRC, including by anatomic subsite, using the US Cancer Statistics dataset covering 100% of the population 2003-2017.",
          "beginSection": "abstract",
          "offsetInBeginSection": 172,
          "endSection": "abstract",
          "offsetInEndSection": 635
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34486085",
          "text": "It is unclear whether increasing incidence trends will confer increased risk beyond age 50, the previously most commonly recommended age to initiate screening, when screening availability might modify incidence trends. AIM\nEvaluate US trends in colorectal cancer (CRC) for ages 40-59 years.",
          "beginSection": "abstract",
          "offsetInBeginSection": 172,
          "endSection": "abstract",
          "offsetInEndSection": 464
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "Estimating the Screening-Eligible Population Size, Ages 45-74, at Average Risk to Develop Colorectal Cancer in the United States.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 129
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "Within this population, we estimated the number of screening-eligible individuals by subtracting those with previous colorectal cancer screening (45- to 49-year-old) or up to date with colorectal cancer screening (50- to 74-year-old).",
          "beginSection": "abstract",
          "offsetInBeginSection": 1001,
          "endSection": "abstract",
          "offsetInEndSection": 1235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029430",
          "text": "Estimating the population size impacted by lowering the recommended colorectal cancer screening start age enables more accurate decision-making for policymakers and epidemiologists focused on cancer prevention.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1627,
          "endSection": "abstract",
          "offsetInEndSection": 1837
        }
      ],
      "ideal_answer": "The American Cancer Society recommends starting population screening for colorectal cancer at the age of 45 for average-risk individuals.",
      "exact_answer": [
        "50"
      ]
    },
    {
      "id": "65f03bf8c4010b4d78000003",
      "type": "summary",
      "body": "What is acupotomy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32280270",
        "http://www.ncbi.nlm.nih.gov/pubmed/37123050",
        "http://www.ncbi.nlm.nih.gov/pubmed/36050272",
        "http://www.ncbi.nlm.nih.gov/pubmed/30174711",
        "http://www.ncbi.nlm.nih.gov/pubmed/28951845",
        "http://www.ncbi.nlm.nih.gov/pubmed/31383431",
        "http://www.ncbi.nlm.nih.gov/pubmed/30142818",
        "http://www.ncbi.nlm.nih.gov/pubmed/31393365",
        "http://www.ncbi.nlm.nih.gov/pubmed/36607879",
        "http://www.ncbi.nlm.nih.gov/pubmed/30290635"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32280270",
          "text": "Acupotomy, which involves the addition of a scalpel function to the conventional acupuncture treatment, has recently been applied as a conservative treatment method for lumbar disc herniation (LDH). T",
          "beginSection": "abstract",
          "offsetInBeginSection": 12,
          "endSection": "abstract",
          "offsetInEndSection": 212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37123050",
          "text": "Acupotomy, as one kind acupuncture that has flat knife-shaped tip, has been widely used for treating shoulder pain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 185,
          "endSection": "abstract",
          "offsetInEndSection": 300
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37123050",
          "text": "Acupotomy, as one kind acupuncture that has flat knife-shaped tip, has been widely used for treating shoulder pain. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 186,
          "endSection": "abstract",
          "offsetInEndSection": 302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37123050",
          "text": "Acupotomy, as one kind acupuncture that has flat knife-shaped tip, has been widely used for treating shoulder pain. However, despite the widespread use of acupotomy in primary medical institutions, large sample size clinical trials have not sufficiently been performed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 185,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37123050",
          "text": "Acupotomy, as one kind acupuncture that has flat knife-shaped tip, has been widely used for treating shoulder pain. However, despite the widespread use of acupotomy in primary medical institutions, large sample size clinical trials have not sufficiently been performed. In this respect, this multi-center retrospective study aimed to investigate the effectiveness and safety of acupotomy in reducing shoulder pain and disability using data from multi-center primary care clinics.",
          "beginSection": "abstract",
          "offsetInBeginSection": 185,
          "endSection": "abstract",
          "offsetInEndSection": 664
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32280270",
          "text": "BACKGROUND\nAcupotomy, which involves the addition of a scalpel function to the conventional acupuncture treatment, has recently been applied as a conservative treatment method for lumbar disc herniation (LDH). This study investigated the effectiveness and safety of acupotomy, compared to manual acupuncture, for the treatment of patients with LDH.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 348
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32280270",
          "text": "BACKGROUND\nAcupotomy, which involves the addition of a scalpel function to the conventional acupuncture treatment, has recently been applied as a conservative treatment method for lumbar disc herniation (LDH).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 209
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32280270",
          "text": "BACKGROUND\nAcupotomy, which involves the addition of a scalpel function to the conventional acupuncture treatment, has recently been applied as a conservative treatment method for lumbar disc herniation (LDH). This study investigated the effectiveness and safety of acupotomy, compared to manual acupuncture, for the treatment of patients with LDH. METHODS\nA total of 146 patients diagnosed with LDH were randomly assigned to either the acupotomy group or the manual acupuncture group at a 1:1 ratio.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 502
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37123050",
          "text": "Objective\nShoulder pain is a common complaint in outpatient clinics and can result in an inability to work or perform household activities, leading to significant socioeconomic burden. Acupotomy, as one kind acupuncture that has flat knife-shaped tip, has been widely used for treating shoulder pain. However, despite the widespread use of acupotomy in primary medical institutions, large sample size clinical trials have not sufficiently been performed.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37123050",
          "text": "Objective\nShoulder pain is a common complaint in outpatient clinics and can result in an inability to work or perform household activities, leading to significant socioeconomic burden. Acupotomy, as one kind acupuncture that has flat knife-shaped tip, has been widely used for treating shoulder pain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 300
        }
      ],
      "ideal_answer": "Acupotomy is a modern acupuncture method that combines the principles of acupuncture with modern surgical techniques, resulting in a flat knife-shaped tip. It has been used to treat shoulder pain and, more recently, as a conservative treatment method for lumbar disc herniation.",
      "exact_answer": "n/a"
    },
    {
      "id": "660d7324fdcbea915f000040",
      "type": "factoid",
      "body": "How many people affected by Parkinson's Disease develop dementia?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34896923",
        "http://www.ncbi.nlm.nih.gov/pubmed/17572053",
        "http://www.ncbi.nlm.nih.gov/pubmed/8660156",
        "http://www.ncbi.nlm.nih.gov/pubmed/31696728",
        "http://www.ncbi.nlm.nih.gov/pubmed/19812474",
        "http://www.ncbi.nlm.nih.gov/pubmed/25745616",
        "http://www.ncbi.nlm.nih.gov/pubmed/573401",
        "http://www.ncbi.nlm.nih.gov/pubmed/27502301",
        "http://www.ncbi.nlm.nih.gov/pubmed/22219231",
        "http://www.ncbi.nlm.nih.gov/pubmed/26228888"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19812474",
          "text": "Subjects with Parkinson disease (PD) frequently develop dementia with greater than one-third meeting neuropathologic diagnostic criteria for Alzheimer disease (AD).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 164
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8660156",
          "text": "CONCLUSION\nApproximately one quarter of the patients with PD had dementia with the motor manifestations of PD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1500,
          "endSection": "abstract",
          "offsetInEndSection": 1610
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8660156",
          "text": "Frequency of dementia in Parkinson disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 43
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17572053",
          "text": "Lewy body dementia and Parkinson disease dementia are frequent causes of degenerative dementia: 20% of the dementias in patients older than 65 years are caused by the former and nearly 80% of patients with advanced Parkinson disease develop the latter.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 252
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17572053",
          "text": "Lewy body dementia and Parkinson disease dementia are frequent causes of degenerative dementia: 20% of the dementias in patients older than 65 years are caused by the former and nearly 80% of patients with advanced Parkinson disease develop the latter. Symptoms of Lewy body dementia include fluctuations of cognitive performance, frontal and visuospatial impairment, visual hallucinations, and parkinsonism.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 408
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8660156",
          "text": "RESULTS\nDementia was found in 67 patients (27.7%). Patients with dementia were older at the time of the study and at onset of PD and had had PD longer than the patients without dementia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 751,
          "endSection": "abstract",
          "offsetInEndSection": 937
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8660156",
          "text": "OBJECTIVE\nTo investigate the frequency of dementia in patients with Parkinson disease (PD). DESIGN\nCommunity-based prevalence study. SETTING\nThe study population comprised 220,858 inhabitants from the Rogaland County, Norway.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 229
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8660156",
          "text": "RESULTS\nDementia was found in 67 patients (27.7%). Patients with dementia were older at the time of the study and at onset of PD and had had PD longer than the patients without dementia. Major depression was more common among patients with dementia (23%) than among patients without dementia (2.3%) (chi 2 , P < .001), and patients with dementia were more often institutionalized than those without dementia (62% vs 6%, respectively, chi 2 , P < .001).",
          "beginSection": "abstract",
          "offsetInBeginSection": 751,
          "endSection": "abstract",
          "offsetInEndSection": 1203
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31696728",
          "text": "BACKGROUND\nWe investigated the structural changes associated with Alzheimer's disease, dementia with Lewy bodies and Parkinson disease dementia by means of cortical thickness analysis. METHODS\nTwo hundred and forty-five participants: 76 Alzheimer's disease, 65 dementia with Lewy bodies, 29 Parkinson disease dementia and 76 cognitively normal controls underwent 3-T T1-weighted magnetic resonance imaging and clinical and cognitive assessments.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17572053",
          "text": "Lewy body dementia and Parkinson disease dementia are frequent causes of degenerative dementia: 20% of the dementias in patients older than 65 years are caused by the former and nearly 80% of patients with advanced Parkinson disease develop the latter. Symptoms of Lewy body dementia include fluctuations of cognitive performance, frontal and visuospatial impairment, visual hallucinations, and parkinsonism. Parkinson disease dementia could be differentiated in two subtypes: a \"subcortical\" subtype, characterized by frontal impairment with apathy and dullness and a \"cortical\" subtype with symptoms similar to those of Lewy body dementia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 641
        }
      ],
      "ideal_answer": "Approximately one-quarter of people affected by Parkinson's Disease develop dementia.",
      "exact_answer": [
        "approximately one-quarter"
      ]
    },
    {
      "id": "661c3d1448a2c27714000005",
      "type": "list",
      "body": "What chromatin signatures are characteristic of active enhancers?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36602897",
        "http://www.ncbi.nlm.nih.gov/pubmed/22593555",
        "http://www.ncbi.nlm.nih.gov/pubmed/34309923",
        "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
        "http://www.ncbi.nlm.nih.gov/pubmed/21106759",
        "http://www.ncbi.nlm.nih.gov/pubmed/22555596",
        "http://www.ncbi.nlm.nih.gov/pubmed/22537144",
        "http://www.ncbi.nlm.nih.gov/pubmed/22421546",
        "http://www.ncbi.nlm.nih.gov/pubmed/29255264",
        "http://www.ncbi.nlm.nih.gov/pubmed/34195788"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36602897",
          "text": "Functional enhancers display specific features including an open chromatin conformation, Histone H3 lysine 27 acetylation, Histone H3 lysine 4 mono-methylation enrichment, and enhancer RNAs production. These features are modified upon developmental cues which impacts their activity. In this review, we describe the current state of knowledge about enhancer functions and the diverse chromatin signatures found on enhancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 590
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "Although certain chromatin features, such as the histone acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active. Individual chromatin marks, such as H3K27ac and H3K27me3, have been identified to distinguish active from inactive enhancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 79,
          "endSection": "abstract",
          "offsetInEndSection": 412
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "Although certain chromatin features, such as the histone acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active. Individual chromatin marks, such as H3K27ac and H3K27me3, have been identified to distinguish active from inactive enhancers. However, the systematic identification of the most informative single modification, or combination thereof, is still lacking.",
          "beginSection": "abstract",
          "offsetInBeginSection": 79,
          "endSection": "abstract",
          "offsetInEndSection": 538
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "Enhancers play a pivotal role in regulating the transcription of distal genes. Although certain chromatin features, such as the histone acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active. Individual chromatin marks, such as H3K27ac and H3K27me3, have been identified to distinguish active from inactive enhancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 412
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "Although certain chromatin features, such as the histone acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active.",
          "beginSection": "abstract",
          "offsetInBeginSection": 79,
          "endSection": "abstract",
          "offsetInEndSection": 286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36602897",
          "text": "Functional enhancers display specific features including an open chromatin conformation, Histone H3 lysine 27 acetylation, Histone H3 lysine 4 mono-methylation enrichment, and enhancer RNAs production. These features are modified upon developmental cues which impacts their activity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36602897",
          "text": "Functional enhancers display specific features including an open chromatin conformation, Histone H3 lysine 27 acetylation, Histone H3 lysine 4 mono-methylation enrichment, and enhancer RNAs production.",
          "beginSection": "abstract",
          "offsetInBeginSection": 166,
          "endSection": "abstract",
          "offsetInEndSection": 367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "Individual chromatin marks, such as H3K27ac and H3K27me3, have been identified to distinguish active from inactive enhancers. However, the systematic identification of the most informative single modification, or combination thereof, is still lacking.",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 538
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "Individual chromatin marks, such as H3K27ac and H3K27me3, have been identified to distinguish active from inactive enhancers. However, the systematic identification of the most informative single modification, or combination thereof, is still lacking. Furthermore, the discovery of enhancer RNAs (eRNAs) provides an alternative approach to directly predicting enhancer activity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 665
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24038352",
          "text": "Individual chromatin marks, such as H3K27ac and H3K27me3, have been identified to distinguish active from inactive enhancers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 287,
          "endSection": "abstract",
          "offsetInEndSection": 412
        }
      ],
      "ideal_answer": "Active enhancers are characterized by the chromatin signatures H3K4me1 and H3K27ac.",
      "exact_answer": [
        [
          "H3K4me1"
        ],
        [
          "H3K27ac"
        ]
      ]
    },
    {
      "id": "661d4fabeac11fad3300001c",
      "type": "list",
      "body": "What are the types of Ehlers-Danlos Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
        "http://www.ncbi.nlm.nih.gov/pubmed/28981071",
        "http://www.ncbi.nlm.nih.gov/pubmed/32518415",
        "http://www.ncbi.nlm.nih.gov/pubmed/16638060",
        "http://www.ncbi.nlm.nih.gov/pubmed/30214474",
        "http://www.ncbi.nlm.nih.gov/pubmed/28739362",
        "http://www.ncbi.nlm.nih.gov/pubmed/34807422",
        "http://www.ncbi.nlm.nih.gov/pubmed/32162201",
        "http://www.ncbi.nlm.nih.gov/pubmed/16353246",
        "http://www.ncbi.nlm.nih.gov/pubmed/32529513"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "Ehlers-Danlos Syndrome (EDS) is a family of multisystemic hereditary connective tissue disorders now comprised of 13 recognized subtypes, classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 344
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "Ehlers-Danlos Syndrome (EDS) is a family of multisystemic hereditary connective tissue disorders now comprised of 13 recognized subtypes, classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal, as designated by the most recent 2017 International classification system.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 420
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "Ehlers-Danlos Syndrome (EDS) is a family of multisystemic hereditary connective tissue disorders now comprised of 13 recognized subtypes, classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal, as designated by the most recent 2017 International classification system. Clinical presentation of this disease can range from mild manifestations including skin hyperextensibility and joint hypermobility, to more severe complications such as vascular and organ rupture.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 617
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "Ehlers-Danlos Syndrome (EDS) is a family of multisystemic hereditary connective tissue disorders now comprised of 13 recognized subtypes, classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal, as designated by the most recent 2017 International classification system. Clinical presentation of this disease can range from mild manifestations including skin hyperextensibility and joint hypermobility, to more severe complications such as vascular and organ rupture. While there may be accompanying inflammation in some of the subtypes of EDS, the pathogenic mechanisms have not been clearly defined.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 751
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638060",
          "text": "The main forms are classical, hypermobile, vascular, kyphoscoliotic A/B, arthrochalasis A/B and dermatosparaxis types. PATIENTS AND METHODS\nWe report our experience in diagnosis and classification of Ehlers-Danlos-syndrome, especially with the combination of clinical and morphological criteria, at the Department of Dermatology of the University of Heidelberg with more than 600 patients between 1984 and 2004. RESULTS\nWe classified those types of EDS which are characterized by regular and characteristic ultrastructural changes in the dermal components, primarily collagen, including the classical, hypermobile and vascular types as well as the less-common arthrochalasis and dermatosparaxis types.",
          "beginSection": "abstract",
          "offsetInBeginSection": 220,
          "endSection": "abstract",
          "offsetInEndSection": 925
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638060",
          "text": "The main forms are classical, hypermobile, vascular, kyphoscoliotic A/B, arthrochalasis A/B and dermatosparaxis types. PATIENTS AND METHODS\nWe report our experience in diagnosis and classification of Ehlers-Danlos-syndrome, especially with the combination of clinical and morphological criteria, at the Department of Dermatology of the University of Heidelberg with more than 600 patients between 1984 and 2004.",
          "beginSection": "abstract",
          "offsetInBeginSection": 220,
          "endSection": "abstract",
          "offsetInEndSection": 633
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638060",
          "text": "BACKGROUND\nThe Ehlers-Danlos syndrome encompasses a group of hereditary disorders of the connective tissue, characterized by hyperextensible skin, joint hypermobility; and varying degrees of vessel and tissue fragility. The main forms are classical, hypermobile, vascular, kyphoscoliotic A/B, arthrochalasis A/B and dermatosparaxis types.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 338
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638060",
          "text": "BACKGROUND\nThe Ehlers-Danlos syndrome encompasses a group of hereditary disorders of the connective tissue, characterized by hyperextensible skin, joint hypermobility; and varying degrees of vessel and tissue fragility. The main forms are classical, hypermobile, vascular, kyphoscoliotic A/B, arthrochalasis A/B and dermatosparaxis types. PATIENTS AND METHODS\nWe report our experience in diagnosis and classification of Ehlers-Danlos-syndrome, especially with the combination of clinical and morphological criteria, at the Department of Dermatology of the University of Heidelberg with more than 600 patients between 1984 and 2004.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 633
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638060",
          "text": "RESULTS\nWe classified those types of EDS which are characterized by regular and characteristic ultrastructural changes in the dermal components, primarily collagen, including the classical, hypermobile and vascular types as well as the less-common arthrochalasis and dermatosparaxis types. The combination of clinical and morphologic features facilitates the selection of candidate genes for molecular genetic investigation. CONCLUSIONS\nBesides the skin, skeleton and vessels, many other organ systems such as eyes and intestine, can be affected in Ehlers-Danlos syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 636,
          "endSection": "abstract",
          "offsetInEndSection": 1210
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638060",
          "text": "PATIENTS AND METHODS\nWe report our experience in diagnosis and classification of Ehlers-Danlos-syndrome, especially with the combination of clinical and morphological criteria, at the Department of Dermatology of the University of Heidelberg with more than 600 patients between 1984 and 2004. RESULTS\nWe classified those types of EDS which are characterized by regular and characteristic ultrastructural changes in the dermal components, primarily collagen, including the classical, hypermobile and vascular types as well as the less-common arthrochalasis and dermatosparaxis types.",
          "beginSection": "abstract",
          "offsetInBeginSection": 341,
          "endSection": "abstract",
          "offsetInEndSection": 925
        }
      ],
      "ideal_answer": "There are 13 types of Ehlers-Danlos Syndrome, including classical, classical-like, cardiac-valvular, vascular, hypermobile, arthrochlasia, dermosparaxis, kyphoscoliotic, brittle cornea syndrome, spondylodysplastic, musculocontractural, myopathic, and periodontal.",
      "exact_answer": [
        [
          "classical"
        ],
        [
          "classical-like"
        ],
        [
          "cardiac-valvular"
        ],
        [
          "vascular"
        ],
        [
          "hypermobile"
        ],
        [
          "arthrochlasia"
        ],
        [
          "dermosparaxis"
        ],
        [
          "kyphoscoliotic"
        ],
        [
          "brittle cornea syndrome"
        ],
        [
          "spondylodysplastic"
        ],
        [
          "musculocontractural"
        ],
        [
          "myopathic"
        ],
        [
          "periodontal"
        ]
      ]
    },
    {
      "id": "65cfe0381930410b13000029",
      "type": "yesno",
      "body": "Can tacrolimus increase risk of Posterior Reversible Encephalopathy Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35469414",
        "http://www.ncbi.nlm.nih.gov/pubmed/35990782",
        "http://www.ncbi.nlm.nih.gov/pubmed/36398875",
        "http://www.ncbi.nlm.nih.gov/pubmed/37120321",
        "http://www.ncbi.nlm.nih.gov/pubmed/36728342",
        "http://www.ncbi.nlm.nih.gov/pubmed/36329183",
        "http://www.ncbi.nlm.nih.gov/pubmed/19096887",
        "http://www.ncbi.nlm.nih.gov/pubmed/24678391",
        "http://www.ncbi.nlm.nih.gov/pubmed/15037879",
        "http://www.ncbi.nlm.nih.gov/pubmed/23290027"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096887",
          "text": "PRES (posterior reversible encephalopathy syndrome), a rare complication of tacrolimus therapy.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 95
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678391",
          "text": "Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 94
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23290027",
          "text": "We report on tacrolimus-associated posterior reversible encephalopathy syndrome with the previously unreported finding of leptomeningeal enhancement occurring separate from the site of parenchymal magnetic resonance signal abnormality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23290027",
          "text": "We report on tacrolimus-associated posterior reversible encephalopathy syndrome with the previously unreported finding of leptomeningeal enhancement occurring separate from the site of parenchymal magnetic resonance signal abnormality. Recognition of this atypical finding as a noninfectious cause of leptomeningeal enhancement may assist those caring for patients affected by posterior reversible encephalopathy syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096887",
          "text": "With increasing numbers of solid organ and hematopoietic stem cell transplantations being performed, there have been significant increases in the use of immunosuppressive agents such as cyclosporine and tacrolimus. Posterior reversible encephalopathy syndrome (PRES) is a serious complication of immunosuppressive therapy use following solid organ or stem cell transplants.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 373
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678391",
          "text": "It has been associated with Posterior Reversible Encephalopathy Syndrome (PRES), a disease of sudden onset that can present as a host of different symptoms, depending on the affected area of the brain. While infectious causes of encephalopathy must always be entertained, the differential diagnosis should also include PRES in the appropriate context. We report three cases of PRES in patients with acute myeloid leukemia (AML) placed on tacrolimus after receiving a bone marrow transplant (BMT).",
          "beginSection": "abstract",
          "offsetInBeginSection": 350,
          "endSection": "abstract",
          "offsetInEndSection": 846
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096887",
          "text": "With increasing numbers of solid organ and hematopoietic stem cell transplantations being performed, there have been significant increases in the use of immunosuppressive agents such as cyclosporine and tacrolimus. Posterior reversible encephalopathy syndrome (PRES) is a serious complication of immunosuppressive therapy use following solid organ or stem cell transplants. Clinical findings including headache, mental status changes, focal neurological deficits, and/or visual disturbances.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096887",
          "text": "These imaging findings predominate in the territory of the posterior cerebral artery. Many studies have shown that the neurotoxicity associated with tacrolimus may occur at therapeutic levels. In most cases of PRES, the symptom complex is reversible by reducing the dosage or withholding the drug for a few days.",
          "beginSection": "abstract",
          "offsetInBeginSection": 824,
          "endSection": "abstract",
          "offsetInEndSection": 1136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096887",
          "text": "Many studies have shown that the neurotoxicity associated with tacrolimus may occur at therapeutic levels. In most cases of PRES, the symptom complex is reversible by reducing the dosage or withholding the drug for a few days. While PRES is an uncommon complication, it is associated with significant morbidity and mortality if it is not expeditiously recognized.",
          "beginSection": "abstract",
          "offsetInBeginSection": 910,
          "endSection": "abstract",
          "offsetInEndSection": 1273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35469414",
          "text": "PRES (posterior reversible encephalopathy syndrome) is a neurological condition characterised by epileptic seizures, altered consciousness, visual disturbances and/or headache with typical neuroimaging showing reversible subcortical vasogenic oedema mainly in parieto-occipital regions. The pathophysiological mechanism is not fully understood. We present a clinical case in the field of liver transplantation where tacrolimus neurotoxicity may play a relevant role in the development of this syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 502
        }
      ],
      "ideal_answer": "Yes, tacrolimus can increase the risk of Posterior Reversible Encephalopathy Syndrome (PRES), a neurological condition characterized by epileptic seizures, altered consciousness, visual disturbances, and/or headache with typical neuroimaging showing reversible subcortical vasogenic edema mainly in parieto-occipital regions. The pathophysiological mechanism is not fully understood, but neurotoxicity associated with tacrolimus may play a relevant role in its development.",
      "exact_answer": "yes"
    },
    {
      "id": "660999e7fdcbea915f00001c",
      "type": "factoid",
      "body": "What is the most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
        "http://www.ncbi.nlm.nih.gov/pubmed/30110194",
        "http://www.ncbi.nlm.nih.gov/pubmed/37653078",
        "http://www.ncbi.nlm.nih.gov/pubmed/31147488",
        "http://www.ncbi.nlm.nih.gov/pubmed/34818112",
        "http://www.ncbi.nlm.nih.gov/pubmed/35764271",
        "http://www.ncbi.nlm.nih.gov/pubmed/34431576",
        "http://www.ncbi.nlm.nih.gov/pubmed/36414192",
        "http://www.ncbi.nlm.nih.gov/pubmed/28889792",
        "http://www.ncbi.nlm.nih.gov/pubmed/35371084"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
          "text": "Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1607,
          "endSection": "abstract",
          "offsetInEndSection": 2075
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
          "text": "Conclusion Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1596,
          "endSection": "abstract",
          "offsetInEndSection": 2075
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
          "text": "Conclusion Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1596,
          "endSection": "abstract",
          "offsetInEndSection": 1972
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
          "text": "Patients (13%) who discontinued treatment because of study drug-related AEs had an ORR (63%) consistent with that of the overall population. Conclusion Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1455,
          "endSection": "abstract",
          "offsetInEndSection": 1972
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37653078",
          "text": "No studies have evaluated the re-immunotherapy regimen including anti-cytotoxic T-lymphocyte antigen-4 antibody for lung cancer treatment. This study aimed to investigate the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab in patients with advanced NSCLC previously treated with anti-programmed death-1 (PD-1) and/or anti-programmed death ligand-1 (PD-L1) antibodies. METHODS\nWe retrospectively reviewed patients with advanced or recurrent NSCLC who received immunotherapy with nivolumab plus ipilimumab (without concomitant cytotoxic chemotherapy) between November 2020 and November 2022 at the National Hospital Organization Kyoto Medical Center, Kyoto, Japan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 104,
          "endSection": "abstract",
          "offsetInEndSection": 791
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
          "text": "Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the nivolumab plus ipilimumab cohort of CheckMate-142, the largest single-study report of an immunotherapy combination in dMMR/MSI-H mCRC, are reported. Patients and Methods Patients received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 718
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
          "text": "Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the nivolumab plus ipilimumab cohort of CheckMate-142, the largest single-study report of an immunotherapy combination in dMMR/MSI-H mCRC, are reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 555
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37653078",
          "text": "No studies have evaluated the re-immunotherapy regimen including anti-cytotoxic T-lymphocyte antigen-4 antibody for lung cancer treatment. This study aimed to investigate the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab in patients with advanced NSCLC previously treated with anti-programmed death-1 (PD-1) and/or anti-programmed death ligand-1 (PD-L1) antibodies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 104,
          "endSection": "abstract",
          "offsetInEndSection": 494
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355075",
          "text": "Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1807,
          "endSection": "abstract",
          "offsetInEndSection": 2075
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37653078",
          "text": "This study aimed to investigate the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab in patients with advanced NSCLC previously treated with anti-programmed death-1 (PD-1) and/or anti-programmed death ligand-1 (PD-L1) antibodies. METHODS\nWe retrospectively reviewed patients with advanced or recurrent NSCLC who received immunotherapy with nivolumab plus ipilimumab (without concomitant cytotoxic chemotherapy) between November 2020 and November 2022 at the National Hospital Organization Kyoto Medical Center, Kyoto, Japan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 243,
          "endSection": "abstract",
          "offsetInEndSection": 791
        }
      ],
      "ideal_answer": "The most effective immunotherapy regimen in patients with MSI-H advanced colorectal cancer is nivolumab plus ipilimumab, which has demonstrated high response rates, encouraging progression-free survival and overall survival at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. This combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.",
      "exact_answer": [
        "nivolumab plus ipilimumab"
      ]
    },
    {
      "id": "661c03c848a2c27714000004",
      "type": "summary",
      "body": "What is the function of the paraoxonase (PON) multigene family?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
        "http://www.ncbi.nlm.nih.gov/pubmed/8661009",
        "http://www.ncbi.nlm.nih.gov/pubmed/15607899",
        "http://www.ncbi.nlm.nih.gov/pubmed/14551701",
        "http://www.ncbi.nlm.nih.gov/pubmed/32487820",
        "http://www.ncbi.nlm.nih.gov/pubmed/11918623",
        "http://www.ncbi.nlm.nih.gov/pubmed/29308836",
        "http://www.ncbi.nlm.nih.gov/pubmed/10931838",
        "http://www.ncbi.nlm.nih.gov/pubmed/20535264",
        "http://www.ncbi.nlm.nih.gov/pubmed/11304470"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3. PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 216
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3. PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 215
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "The paraoxonase (PON) gene family includes three proteins, PON1, PON2 and PON3. PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties. PON2 and PON3 are intracellular enzymes which modulate mitochondrial superoxide anion production and endoplasmic reticulum (ER) stress-induced apoptosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29308836",
          "text": "The paraoxonase (PON) gene family includes three members: PON1, PON2, and PON3 aligned in tandem on chromosome 7 in humans. All PON proteins share considerable structural homology and have the capacity to protect cells from oxidative stress; therefore, they have been implicated in the pathogenesis of several inflammatory diseases, particularly atherosclerosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 362
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29308836",
          "text": "The paraoxonase (PON) gene family includes three members: PON1, PON2, and PON3 aligned in tandem on chromosome 7 in humans. All PON proteins share considerable structural homology and have the capacity to protect cells from oxidative stress; therefore, they have been implicated in the pathogenesis of several inflammatory diseases, particularly atherosclerosis. Increased production of reactive oxygen species as a result of decreased activities of mitochondrial electron transport chain complexes plays a role in the development of many inflammatory diseases, including atherosclerosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 588
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29308836",
          "text": "PON1 and PON3 proteins can be detected in plasma and reside in the high-density lipoprotein fraction and protect against oxidative stress by hydrolyzing certain oxidized lipids in lipoproteins, macrophages, and atherosclerotic lesions. Paraoxonase 2 (PON2) possesses antiatherogenic properties and is associated with lower ROS levels. PON2 is involved in the antioxidative and anti-inflammatory response in intestinal epithelial cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 589,
          "endSection": "abstract",
          "offsetInEndSection": 1024
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29308836",
          "text": "PON1 and PON3 proteins can be detected in plasma and reside in the high-density lipoprotein fraction and protect against oxidative stress by hydrolyzing certain oxidized lipids in lipoproteins, macrophages, and atherosclerotic lesions. Paraoxonase 2 (PON2) possesses antiatherogenic properties and is associated with lower ROS levels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 589,
          "endSection": "abstract",
          "offsetInEndSection": 923
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29308836",
          "text": "Increased production of reactive oxygen species as a result of decreased activities of mitochondrial electron transport chain complexes plays a role in the development of many inflammatory diseases, including atherosclerosis. PON1 and PON3 proteins can be detected in plasma and reside in the high-density lipoprotein fraction and protect against oxidative stress by hydrolyzing certain oxidized lipids in lipoproteins, macrophages, and atherosclerotic lesions. Paraoxonase 2 (PON2) possesses antiatherogenic properties and is associated with lower ROS levels.",
          "beginSection": "abstract",
          "offsetInBeginSection": 363,
          "endSection": "abstract",
          "offsetInEndSection": 923
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties. PON2 and PON3 are intracellular enzymes which modulate mitochondrial superoxide anion production and endoplasmic reticulum (ER) stress-induced apoptosis. The pleiotropic roles exerted by PONs have been mainly investigated in cardiovascular and neurodegenerative diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 80,
          "endSection": "abstract",
          "offsetInEndSection": 488
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29170064",
          "text": "PON1 and PON3 are both associated with high-density lipoprotein (HDL) particles and exert anti-oxidant and anti-inflammatory properties. PON2 and PON3 are intracellular enzymes which modulate mitochondrial superoxide anion production and endoplasmic reticulum (ER) stress-induced apoptosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 80,
          "endSection": "abstract",
          "offsetInEndSection": 370
        }
      ],
      "ideal_answer": "",
      "exact_answer": "n/a"
    },
    {
      "id": "660d1285fdcbea915f000036",
      "type": "yesno",
      "body": "Inflammatory breast cancer is the most aggressive form of breast cancer.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33845027",
        "http://www.ncbi.nlm.nih.gov/pubmed/34973083",
        "http://www.ncbi.nlm.nih.gov/pubmed/16027755",
        "http://www.ncbi.nlm.nih.gov/pubmed/18308144",
        "http://www.ncbi.nlm.nih.gov/pubmed/16154355",
        "http://www.ncbi.nlm.nih.gov/pubmed/24188125",
        "http://www.ncbi.nlm.nih.gov/pubmed/30005774",
        "http://www.ncbi.nlm.nih.gov/pubmed/16735787",
        "http://www.ncbi.nlm.nih.gov/pubmed/22351245",
        "http://www.ncbi.nlm.nih.gov/pubmed/16642401"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16735787",
          "text": "Inflammatory breast cancer is rare but represents the most aggressive and lethal form of locally advanced breast cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 120
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16735787",
          "text": "Inflammatory breast cancer is rare but represents the most aggressive and lethal form of locally advanced breast cancer. The management of inflammatory breast cancer has evolved substantially over the last 40 years; current multimodality therapy regimens combine chemotherapy, surgery, and radiation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 300
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33845027",
          "text": "Inflammatory breast cancer is a rare and aggressive malignancy",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 62
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22351245",
          "text": "Inflammatory breast carcinoma (IBC) is rare; however, it is the most aggressive variant of breast cancer with a very poor outcome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22351245",
          "text": "Inflammatory breast carcinoma (IBC) is rare; however, it is the most aggressive variant of breast cancer with a very poor outcome. Locally advanced breast cancer and acute mastitis have a presentation similar to that of IBC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 224
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24188125",
          "text": "Inflammatory breast cancer (IBC) is the most aggressive and deadly form of breast cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 89
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16642401",
          "text": "Inflammatory breast cancer is a highly aggressive and metastatic form of locally advanced breast cancer that carries a significantly worse prognosis than non-inflammatory breast cancers. Unfortunately, the molecular basis of this deadly form of breast cancer has been understudied.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 281
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22351245",
          "text": "Inflammatory breast carcinoma (IBC) is rare; however, it is the most aggressive variant of breast cancer with a very poor outcome. Locally advanced breast cancer and acute mastitis have a presentation similar to that of IBC. Therefore, the diagnosis of IBC remains a challenge in breast imaging.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 295
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16735787",
          "text": "Inflammatory breast cancer is rare but represents the most aggressive and lethal form of locally advanced breast cancer. The management of inflammatory breast cancer has evolved substantially over the last 40 years; current multimodality therapy regimens combine chemotherapy, surgery, and radiation. While identification of the optimal combination of these traditional therapies remains a goal, novel targeted therapies that have recently become available promise improved responses and survival.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 497
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33845027",
          "text": "Inflammatory breast cancer is a rare and aggressive malignancy that is often initially misdiagnosed because of its similar presentation to more benign breast pathologies such as mastitis, resulting in treatment delays.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 218
        }
      ],
      "ideal_answer": "Yes, inflammatory breast cancer is the most aggressive form of breast cancer.",
      "exact_answer": "yes"
    },
    {
      "id": "661dc376fe9d0b3967000002",
      "type": "yesno",
      "body": "Is the majority of genetic variation present in the coding regions of the genome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
        "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
        "http://www.ncbi.nlm.nih.gov/pubmed/24667321",
        "http://www.ncbi.nlm.nih.gov/pubmed/28797091",
        "http://www.ncbi.nlm.nih.gov/pubmed/30099302",
        "http://www.ncbi.nlm.nih.gov/pubmed/35850704",
        "http://www.ncbi.nlm.nih.gov/pubmed/28076858",
        "http://www.ncbi.nlm.nih.gov/pubmed/26438568",
        "http://www.ncbi.nlm.nih.gov/pubmed/25820936",
        "http://www.ncbi.nlm.nih.gov/pubmed/32940334"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
          "text": "These studies have surprisingly revealed that the majority of genetic variation is not present within the coding region but rather in the non-coding region of the genome, which is also termed as \"Medical Genome\".",
          "beginSection": "abstract",
          "offsetInBeginSection": 223,
          "endSection": "abstract",
          "offsetInEndSection": 435
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
          "text": "These studies have surprisingly revealed that the majority of genetic variation is not present within the coding region but rather in the non-coding region of the genome, which is also termed as \"Medical Genome\". This short review describes how mutations/variations within; regulatory sequences, architectural proteins and transcriptional regulators give rise to the aberrant gene expression profiles that drives cellular transformations and malignancies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 223,
          "endSection": "abstract",
          "offsetInEndSection": 678
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
          "text": "Latest advancements in genomics involving individuals from different races and geographical locations has led to the identification of thousands of common as well as rare genetic variants and copy number variations (CNVs). These studies have surprisingly revealed that the majority of genetic variation is not present within the coding region but rather in the non-coding region of the genome, which is also termed as \"Medical Genome\".",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 435
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32472759",
          "text": "Latest advancements in genomics involving individuals from different races and geographical locations has led to the identification of thousands of common as well as rare genetic variants and copy number variations (CNVs). These studies have surprisingly revealed that the majority of genetic variation is not present within the coding region but rather in the non-coding region of the genome, which is also termed as \"Medical Genome\". This short review describes how mutations/variations within; regulatory sequences, architectural proteins and transcriptional regulators give rise to the aberrant gene expression profiles that drives cellular transformations and malignancies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 678
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
          "text": "Non-coding genetic variation in cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 39
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667321",
          "text": "Genetic variation in the non-coding genome: Involvement of micro-RNAs and long non-coding RNAs in disease.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 106
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35850704",
          "text": "RESULTS\nWe discuss considerations specifically for variants in non-coding regions of the genome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 913,
          "endSection": "abstract",
          "offsetInEndSection": 1009
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370373",
          "text": "The vast majority of somatic variants in cancer genomes occur in non-coding regions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 84
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667321",
          "text": "It has been found that the majority of disease-associated genetic variants identified by genome-wide association studies are located outside of protein-coding regions, where they seem to affect regions that control transcription (promoters, enhancers) and non-coding RNAs that also can influence gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 312
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667321",
          "text": "It has been found that the majority of disease-associated genetic variants identified by genome-wide association studies are located outside of protein-coding regions, where they seem to affect regions that control transcription (promoters, enhancers) and non-coding RNAs that also can influence gene expression. In this review, we focus on two classes of non-coding RNAs that are currently a major focus of interest: micro-RNAs and long non-coding RNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 454
        }
      ],
      "ideal_answer": "No, the majority of genetic variation is not present within the coding region but rather in the non-coding region of the genome.",
      "exact_answer": "no"
    },
    {
      "id": "661d6252eac11fad33000025",
      "type": "factoid",
      "body": "What is the cause of autosomal dominant Polycystic Kidney Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37468838",
        "http://www.ncbi.nlm.nih.gov/pubmed/21115670",
        "http://www.ncbi.nlm.nih.gov/pubmed/29860066",
        "http://www.ncbi.nlm.nih.gov/pubmed/10413889",
        "http://www.ncbi.nlm.nih.gov/pubmed/21332816",
        "http://www.ncbi.nlm.nih.gov/pubmed/31079206",
        "http://www.ncbi.nlm.nih.gov/pubmed/11195048",
        "http://www.ncbi.nlm.nih.gov/pubmed/19686598",
        "http://www.ncbi.nlm.nih.gov/pubmed/25491204",
        "http://www.ncbi.nlm.nih.gov/pubmed/16430766"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860066",
          "text": "Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most frequent genetic disorder of the kidneys, is characterized by a typical presenting symptoms include cysts development in different organs and a non-cysts manifestations. ADPKD is caused by mutations in PKD1 or PKD2 genes. In this study, we aimed to search for molecular causative defects among PKD1 and PKD2 genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 377
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115670",
          "text": "BACKGROUND\nAutosomal dominant polycystic kidney disease (ADPKD) is a common genetic renal disorder with an incidence of 1:1000. Mutations in two genes (PKD1 and PKD2) have been identified as causative. Eighty-five percent of patients with ADPKD carry their mutation in the PKD1 gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 283
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332816",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) is a common and severe renal disease. Mutations of PKD1 and PKD2 genes are responsible for approximately 85% and 15% of ADPKD cases, respectively.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 199
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332816",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) is a common and severe renal disease. Mutations of PKD1 and PKD2 genes are responsible for approximately 85% and 15% of ADPKD cases, respectively. In the present study, PKD1 and PKD2 genes were analyzed in a large Chinese family with ADPKD using denaturing high-performance liquid chromatography and DNA sequencing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 368
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31079206",
          "text": "BACKGROUND\nPolycystic kidney disease (PKD) is one of the most common genetic renal diseases and may be inherited in an autosomal dominant or autosomal recessive pattern. Pathogenic variants in two major genes, PKD1 and PKD2, and two rarer genes, GANAB and DNAJB11, cause autosomal dominant PKD (ADPKD).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 302
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31079206",
          "text": "BACKGROUND\nPolycystic kidney disease (PKD) is one of the most common genetic renal diseases and may be inherited in an autosomal dominant or autosomal recessive pattern. Pathogenic variants in two major genes, PKD1 and PKD2, and two rarer genes, GANAB and DNAJB11, cause autosomal dominant PKD (ADPKD). Early onset and severe PKD can occur with PKD1 and PKD2 pathogenic variants and such phenotypes may be modified by second alleles inherited in trans.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 452
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860066",
          "text": "Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most frequent genetic disorder of the kidneys, is characterized by a typical presenting symptoms include cysts development in different organs and a non-cysts manifestations. ADPKD is caused by mutations in PKD1 or PKD2 genes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 284
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115670",
          "text": "BACKGROUND\nAutosomal dominant polycystic kidney disease (ADPKD) is a common genetic renal disorder with an incidence of 1:1000. Mutations in two genes (PKD1 and PKD2) have been identified as causative.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 201
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10413889",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by genetic heterogeneity. Up to three loci are involved in this disease, PKD1 on chromosome 16p13.3, PKD2 on 4q21, and a third locus of unknown location. Since the identification of the PKD1 gene, the interest was centered in the characterization of the mutations responsible for the disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 384
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10413889",
          "text": "Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by genetic heterogeneity. Up to three loci are involved in this disease, PKD1 on chromosome 16p13.3, PKD2 on 4q21, and a third locus of unknown location.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 245
        }
      ],
      "ideal_answer": "Autosomal dominant Polycystic Kidney Disease is primarily caused by mutations in the PKD1 gene or PKD2 gene.",
      "exact_answer": [
        "PKD1 gene"
      ]
    },
    {
      "id": "65d1300e1930410b13000033",
      "type": "yesno",
      "body": "Is zilucoplan effective for myasthenia gravis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
        "http://www.ncbi.nlm.nih.gov/pubmed/38093160",
        "http://www.ncbi.nlm.nih.gov/pubmed/37204031",
        "http://www.ncbi.nlm.nih.gov/pubmed/33792453",
        "http://www.ncbi.nlm.nih.gov/pubmed/32065623",
        "http://www.ncbi.nlm.nih.gov/pubmed/32833750",
        "http://www.ncbi.nlm.nih.gov/pubmed/34909332",
        "http://www.ncbi.nlm.nih.gov/pubmed/15034472",
        "http://www.ncbi.nlm.nih.gov/pubmed/22941261",
        "http://www.ncbi.nlm.nih.gov/pubmed/20581680"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "INTERPRETATION: Zilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 2570,
          "endSection": "abstract",
          "offsetInEndSection": 2928
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "INTERPRETATION\nZilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2576,
          "endSection": "abstract",
          "offsetInEndSection": 2932
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "INTERPRETATION\nZilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being assessed in an ongoing open-label extension study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2576,
          "endSection": "abstract",
          "offsetInEndSection": 3040
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being assessed in an ongoing open-label extension study.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2801,
          "endSection": "abstract",
          "offsetInEndSection": 3040
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being assessed in an ongoing open-label extension study. FUNDING\nUCB Pharma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2801,
          "endSection": "abstract",
          "offsetInEndSection": 3062
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2801,
          "endSection": "abstract",
          "offsetInEndSection": 2932
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "We aimed to assess safety, efficacy, and tolerability of zilucoplan in patients with acetylcholine receptor autoantibody (AChR)-positive generalised myasthenia gravis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 312,
          "endSection": "abstract",
          "offsetInEndSection": 479
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "INTERPRETATION\nZilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2576,
          "endSection": "abstract",
          "offsetInEndSection": 2800
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "One patient died in each group; neither death (COVID-19 [zilucoplan] and cerebral haemorrhage [placebo]) was considered related to the study drug. INTERPRETATION\nZilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2427,
          "endSection": "abstract",
          "offsetInEndSection": 2932
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37059508",
          "text": "We aimed to assess safety, efficacy, and tolerability of zilucoplan in patients with acetylcholine receptor autoantibody (AChR)-positive generalised myasthenia gravis. METHODS\nRAISE was a randomised, double-blind, placebo-controlled, phase 3 trial that was done at 75 sites in Europe, Japan, and North America.",
          "beginSection": "abstract",
          "offsetInBeginSection": 312,
          "endSection": "abstract",
          "offsetInEndSection": 624
        }
      ],
      "ideal_answer": "Yes, zilucoplan is effective for myasthenia gravis. It has shown rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, and has a favorable safety profile. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis.",
      "exact_answer": "yes"
    },
    {
      "id": "65f77618c4010b4d7800002e",
      "type": "list",
      "body": "Which are the clinical indications for the use of Raltitrexed in patients with colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12056700",
        "http://www.ncbi.nlm.nih.gov/pubmed/9849444",
        "http://www.ncbi.nlm.nih.gov/pubmed/24388340",
        "http://www.ncbi.nlm.nih.gov/pubmed/15083176",
        "http://www.ncbi.nlm.nih.gov/pubmed/8936802",
        "http://www.ncbi.nlm.nih.gov/pubmed/24869761",
        "http://www.ncbi.nlm.nih.gov/pubmed/11872339",
        "http://www.ncbi.nlm.nih.gov/pubmed/9528843",
        "http://www.ncbi.nlm.nih.gov/pubmed/11773166",
        "http://www.ncbi.nlm.nih.gov/pubmed/9376632"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9849444",
          "text": "Raltitrexed (Tomudex) is currently licensed for first-line treatment of advanced colorectal cancer. We evaluated 101 patients treated with raltitrexed whose data were collected prospectively, in order to study the outcome of second-line treatments used after this drug.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 269
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9849444",
          "text": "Raltitrexed (Tomudex) is currently licensed for first-line treatment of advanced colorectal cancer. We evaluated 101 patients treated with raltitrexed whose data were collected prospectively, in order to study the outcome of second-line treatments used after this drug. Of 98 evaluable patients, 50 received second-line treatments, the commonest being 5-fluorouracil (5-FU)-based therapy (22 patients with 20 evaluable) and mitomycin-c (MMC) (22 patients with 18 evaluable).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 474
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24388340",
          "text": "AIMS\nTo evaluate the efficiency and safety profile of raltitrexed-based chemotherapy in the treatment of advanced colorectal cancer. METHODS\nAn electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 332
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8936802",
          "text": "[symbol: see text] Raltitrexed (Tomudex-Zeneca), a new class of cytotoxic drug introduced last year, is claimed to simplify treatment and be as effective as one established fluorouracil regimen while causing less toxicity. We review raltitrexed and assess its place in the treatment of patients in whom colorectal cancer is advanced.",
          "beginSection": "abstract",
          "offsetInBeginSection": 324,
          "endSection": "abstract",
          "offsetInEndSection": 657
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9849444",
          "text": "Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 134
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24388340",
          "text": "AIMS\nTo evaluate the efficiency and safety profile of raltitrexed-based chemotherapy in the treatment of advanced colorectal cancer. METHODS\nAn electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer. The outcomes included overall survival, overall response rate and toxicities.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 410
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9849444",
          "text": "Raltitrexed (Tomudex) is currently licensed for first-line treatment of advanced colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8936802",
          "text": "Systemic chemotherapy, usually with regimens including fluorouracil, can prolong survival in patients with advanced or recurrent disease and may improve their quality of life. [symbol: see text] Raltitrexed (Tomudex-Zeneca), a new class of cytotoxic drug introduced last year, is claimed to simplify treatment and be as effective as one established fluorouracil regimen while causing less toxicity. We review raltitrexed and assess its place in the treatment of patients in whom colorectal cancer is advanced.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 657
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24388340",
          "text": "CONCLUSIONS\nRaltitrexed-based chemotherapy regimen leads to an equivalent overall survival and response rates with acceptable toxicities compared to traditional 5-fluorouracil-based regimen in patients with advanced colorectal cancer. Raltitrexed can be a treatment option for these patients when 5-fluorouracil-based regimens are not tolerated or inappropriate.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1556,
          "endSection": "abstract",
          "offsetInEndSection": 1918
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24388340",
          "text": "METHODS\nAn electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer. The outcomes included overall survival, overall response rate and toxicities. RESULTS\nThis meta-analysis included 11 studies with 4622 patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 135,
          "endSection": "abstract",
          "offsetInEndSection": 479
        }
      ],
      "ideal_answer": "Raltitrexed is used as a first-line treatment for advanced colorectal cancer. It is licensed for this use and has been shown to be effective in treating this condition. It is often used as an alternative to 5-fluorouracil monotherapy.",
      "exact_answer": [
        [
          "first-line treatment"
        ],
        [
          "advanced colorectal cancer"
        ]
      ]
    },
    {
      "id": "661bdc9148a2c27714000001",
      "type": "list",
      "body": "Please list the findings in lateral medullary (Wallenberg) syndrome",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32539005",
        "http://www.ncbi.nlm.nih.gov/pubmed/37275090",
        "http://www.ncbi.nlm.nih.gov/pubmed/32655466",
        "http://www.ncbi.nlm.nih.gov/pubmed/30697437",
        "http://www.ncbi.nlm.nih.gov/pubmed/26350694",
        "http://www.ncbi.nlm.nih.gov/pubmed/27680226",
        "http://www.ncbi.nlm.nih.gov/pubmed/36268328",
        "http://www.ncbi.nlm.nih.gov/pubmed/11310627",
        "http://www.ncbi.nlm.nih.gov/pubmed/10967664",
        "http://www.ncbi.nlm.nih.gov/pubmed/15637417"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32539005",
          "text": "Wallenberg syndrome, or lateral medullar syndrome, is the clinical presentation of the infarct in the territory of posterior inferior cerebellar artery. Its signs and symptoms include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 594
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32539005",
          "text": "Wallenberg syndrome, or lateral medullar syndrome, is the clinical presentation of the infarct in the territory of posterior inferior cerebellar artery. Its signs and symptoms include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia. Neuroanatomical knowledge is essential to its comprehension, study and diagnosis, because the classic neurological manifestations are easy to explain and understand if function and localization of affected anatomical structures are known as if the posterior cerebral circulation is.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 877
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32539005",
          "text": "Its signs and symptoms include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 594
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32539005",
          "text": "Its signs and symptoms include vertigo, nystagmus, diplopia, ipsilateral Horner syndrome, facial ruddiness and dry skin, dysphonia, dysphagia, dysarthria, ipsilateral loss of gag reflex, ipsilateral ataxia, ipsilateral impaired taste, ipsilateral facial pain and paresthesia, decreased ipsilateral blink reflex, contralateral hypoalgesia and thermoanaesthesia in the trunk and limbs; and ipsilateral facial hypoalgesia and thermoanaesthesia. Neuroanatomical knowledge is essential to its comprehension, study and diagnosis, because the classic neurological manifestations are easy to explain and understand if function and localization of affected anatomical structures are known as if the posterior cerebral circulation is.",
          "beginSection": "abstract",
          "offsetInBeginSection": 153,
          "endSection": "abstract",
          "offsetInEndSection": 877
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26350694",
          "text": "BACKGROUND\nVarious sensory impairments have been reported in patients with lateral medullary syndrome, also known as Wallenberg syndrome. The typical sensory impairments experienced by patients with this condition are ipsilateral facial and contralateral trunk and limb thermal hypesthesia and hypoalgesia. Tactile (light touch) sensation is not generally diminished.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 367
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26350694",
          "text": "BACKGROUND\nVarious sensory impairments have been reported in patients with lateral medullary syndrome, also known as Wallenberg syndrome. The typical sensory impairments experienced by patients with this condition are ipsilateral facial and contralateral trunk and limb thermal hypesthesia and hypoalgesia.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 306
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30697437",
          "text": "Medial pontomedullary junctional infarction presenting vertigo, ipsilateral facial paresis, contralateral thermal hypoalgesia and dysphagia without lateral gaze palsy, curtain sign and hoarseness: a case presentation of a novel brain stem stroke syndrome with sensory disturbance-based dysphagia and review of the literature.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 325
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30697437",
          "text": "A 68-year-old woman suddenly developed vertigo, ipsilateral facial paresis, contralateral thermal hypoalgesia (TH) and dysphagia without lateral gaze palsy, curtain sign and hoarseness. Magnetic resonance (MR) imaging showed a small infarction at the right MPMJ.",
          "beginSection": "abstract",
          "offsetInBeginSection": 125,
          "endSection": "abstract",
          "offsetInEndSection": 387
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30697437",
          "text": "A 68-year-old woman suddenly developed vertigo, ipsilateral facial paresis, contralateral thermal hypoalgesia (TH) and dysphagia without lateral gaze palsy, curtain sign and hoarseness.",
          "beginSection": "abstract",
          "offsetInBeginSection": 125,
          "endSection": "abstract",
          "offsetInEndSection": 310
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30697437",
          "text": "A 68-year-old woman suddenly developed vertigo, ipsilateral facial paresis, contralateral thermal hypoalgesia (TH) and dysphagia without lateral gaze palsy, curtain sign and hoarseness. Magnetic resonance (MR) imaging showed a small infarction at the right MPMJ. MR angiography did not show vertebrobasilar arterial dissection, thrombosis or vasospasm.",
          "beginSection": "abstract",
          "offsetInBeginSection": 125,
          "endSection": "abstract",
          "offsetInEndSection": 477
        }
      ],
      "ideal_answer": "The findings in lateral medullary (Wallenberg) syndrome include vertigo, nystagmus, diplopia, Horner syndrome, facial ruddiness, dysphonia, dysphagia, dysarthria, gag reflex loss, ataxia, impaired taste, facial pain, facial paresthesia, decreased blink reflex, contralateral hypoalgesia, and ipsilateral facial hypoalgesia.",
      "exact_answer": [
        [
          "vertigo"
        ],
        [
          "nystagmus"
        ],
        [
          "diplopia"
        ],
        [
          "Horner syndrome"
        ],
        [
          "facial ruddiness"
        ],
        [
          "dysphonia"
        ],
        [
          "dysphagia"
        ],
        [
          "dysarthria"
        ],
        [
          "gag reflex loss"
        ],
        [
          "ataxia"
        ],
        [
          "impaired taste"
        ],
        [
          "facial pain"
        ],
        [
          "facial paresthesia"
        ],
        [
          "decreased blink reflex"
        ],
        [
          "contralateral hypoalgesia"
        ],
        [
          "ipsilateral facial hypoalgesia"
        ]
      ]
    },
    {
      "id": "6614fb7bfdcbea915f000044",
      "type": "summary",
      "body": "What are the new treatments for cystic fibrosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
        "http://www.ncbi.nlm.nih.gov/pubmed/35125294",
        "http://www.ncbi.nlm.nih.gov/pubmed/31899933",
        "http://www.ncbi.nlm.nih.gov/pubmed/32265602",
        "http://www.ncbi.nlm.nih.gov/pubmed/37536552",
        "http://www.ncbi.nlm.nih.gov/pubmed/37575762",
        "http://www.ncbi.nlm.nih.gov/pubmed/34356748",
        "http://www.ncbi.nlm.nih.gov/pubmed/37905296",
        "http://www.ncbi.nlm.nih.gov/pubmed/32290721",
        "http://www.ncbi.nlm.nih.gov/pubmed/36294716"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37536552",
          "text": "Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 324
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37536552",
          "text": "Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 440
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37536552",
          "text": "Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results. We conducted a prospective observational study on 24 CF patients with CF-related diabetes requiring insulin therapy, with the aim to evaluate the effectiveness of ETI on glucose metabolism, glucose variability and body composition.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 672
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34356748",
          "text": "The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 313
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34356748",
          "text": "The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele. However, there is a group of patients, in addition to those with rare mutations, in which despite the presence of a F508del in one allele, it was not possible to identify any mutation in the other allele.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 518
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36986509",
          "text": "Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 113
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32265602",
          "text": "Elexacaftor-tezacaftor-ivacaftor is a newly approved triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapy that contains 2 correctors and a potentiator of the CFTR channel. Its labeled indication for use is for persons 12 years of age and older with at least 1 F508del mutation for the CFTR gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 339
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32265602",
          "text": "Elexacaftor-tezacaftor-ivacaftor is a newly approved triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapy that contains 2 correctors and a potentiator of the CFTR channel.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 215
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32265602",
          "text": "Elexacaftor-tezacaftor-ivacaftor is a newly approved triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapy that contains 2 correctors and a potentiator of the CFTR channel. Its labeled indication for use is for persons 12 years of age and older with at least 1 F508del mutation for the CFTR gene. This drug combination provides potential therapy to many patients who had previously been excluded from CFTR modulation therapy due to the nature of their genetic mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 513
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34356748",
          "text": "The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele. However, there is a group of patients, in addition to those with rare mutations, in which despite the presence of a F508del in one allele, it was not possible to identify any mutation in the other allele. To date, these patients are excluded from treatment with Trikafta in Italy, where the CF patients carrying F508del/unknown represent about 1.3% (71 patients) of the overall Italian CF patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 712
        }
      ],
      "ideal_answer": "The new treatments for cystic fibrosis are CFTR modulator drugs, specifically a disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor (ETI). This therapy is life-transforming for the majority of patients with common mutations like F508del.",
      "exact_answer": "n/a"
    },
    {
      "id": "661c424588784bab31000001",
      "type": "factoid",
      "body": "By which method do micro RNAs (miRNAs) primarily aid in transcriptional and post-transcriptional regulation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37505443",
        "http://www.ncbi.nlm.nih.gov/pubmed/32949853",
        "http://www.ncbi.nlm.nih.gov/pubmed/25618601",
        "http://www.ncbi.nlm.nih.gov/pubmed/21832809",
        "http://www.ncbi.nlm.nih.gov/pubmed/26257769",
        "http://www.ncbi.nlm.nih.gov/pubmed/11896390",
        "http://www.ncbi.nlm.nih.gov/pubmed/29187891",
        "http://www.ncbi.nlm.nih.gov/pubmed/34519918",
        "http://www.ncbi.nlm.nih.gov/pubmed/24737341",
        "http://www.ncbi.nlm.nih.gov/pubmed/26673698"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21832809",
          "text": "Micro-RNAs (miRNAs) play a crucial role in post-transcriptional gene regulation by pairing with target mRNAs to repress protein production. It has been shown that over one-third of human genes are targeted by miRNA.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 215
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21832809",
          "text": "Micro-RNAs (miRNAs) play a crucial role in post-transcriptional gene regulation by pairing with target mRNAs to repress protein production.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 139
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21832809",
          "text": "Micro-RNAs (miRNAs) play a crucial role in post-transcriptional gene regulation by pairing with target mRNAs to repress protein production. It has been shown that over one-third of human genes are targeted by miRNA. Although hundreds of miRNAs have been identified in mammalian genomes, the function of miRNA-based repression in the context of gene regulation networks still remains unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 391
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257769",
          "text": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by degrading their RNA targets or by repressing the translation of messenger RNAs (mRNAs).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 183
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257769",
          "text": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by degrading their RNA targets or by repressing the translation of messenger RNAs (mRNAs). Initially thought to primarily target the 3' untranslated region (3'UTR) of mRNAs, miRNAs have since been shown to also target the 5'UTR and coding sequence (CDS).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 347
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26257769",
          "text": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by degrading their RNA targets or by repressing the translation of messenger RNAs (mRNAs). Initially thought to primarily target the 3' untranslated region (3'UTR) of mRNAs, miRNAs have since been shown to also target the 5'UTR and coding sequence (CDS). In this work, we focus on the post-transcriptional regulation of the BRCA1 gene, a major tumor suppressor and regulator of double-stranded break DNA repair and show that its mRNA is targeted by many members of the miR-15/107 group at a site located within the CDS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 612
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187891",
          "text": "LncRNAs can also function as endogenous competitive RNAs for miRNAs and indirectly regulate gene expression post-transcriptionally. By binding to the 3'-untranslated regions (3'-UTR) of target genes, miRNAs post-transcriptionally regulate gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 280,
          "endSection": "abstract",
          "offsetInEndSection": 535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25618601",
          "text": "More recently, evidence has begun to accumulate describing the complex post-transcriptional regulation in which lncRNAs are involved. It was reported that lncRNAs can be implicated in degradation, translation, pre-messenger RNA (mRNA) splicing, and protein activities and even as microRNAs (miRNAs) sponges in both a sequence-dependent and sequence-independent manner.",
          "beginSection": "abstract",
          "offsetInBeginSection": 438,
          "endSection": "abstract",
          "offsetInEndSection": 806
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187891",
          "text": "LncRNAs regulate gene expression at transcriptional, post-transcriptional, and epigenetic levels via multiple action modes. LncRNAs can also function as endogenous competitive RNAs for miRNAs and indirectly regulate gene expression post-transcriptionally. By binding to the 3'-untranslated regions (3'-UTR) of target genes, miRNAs post-transcriptionally regulate gene expression.",
          "beginSection": "abstract",
          "offsetInBeginSection": 156,
          "endSection": "abstract",
          "offsetInEndSection": 535
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187891",
          "text": "LncRNAs can also function as endogenous competitive RNAs for miRNAs and indirectly regulate gene expression post-transcriptionally. By binding to the 3'-untranslated regions (3'-UTR) of target genes, miRNAs post-transcriptionally regulate gene expression. Herein, we conducted a review of post-transcriptional regulation by lncRNAs and miRNAs of genes associated with biological behaviors of gastric cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 280,
          "endSection": "abstract",
          "offsetInEndSection": 687
        }
      ],
      "ideal_answer": "Micro RNAs (miRNAs) primarily aid in post-transcriptional regulation by binding to mRNA and mediating its degradation or inhibiting translation.",
      "exact_answer": [
        "mRNA binding"
      ]
    },
    {
      "id": "661d6473eac11fad33000027",
      "type": "factoid",
      "body": "What is the cause of Autosomal Recessive Polycystic Kidney Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37456659",
        "http://www.ncbi.nlm.nih.gov/pubmed/15108277",
        "http://www.ncbi.nlm.nih.gov/pubmed/16133180",
        "http://www.ncbi.nlm.nih.gov/pubmed/16199545",
        "http://www.ncbi.nlm.nih.gov/pubmed/33940108",
        "http://www.ncbi.nlm.nih.gov/pubmed/12116208",
        "http://www.ncbi.nlm.nih.gov/pubmed/15771341",
        "http://www.ncbi.nlm.nih.gov/pubmed/26502924",
        "http://www.ncbi.nlm.nih.gov/pubmed/31638247",
        "http://www.ncbi.nlm.nih.gov/pubmed/14983006"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16199545",
          "text": "BACKGROUND\nAutosomal recessive polycystic kidney disease (ARPKD) is caused by mutations in the PKHD1 (polycystic kidney and hepatic disease 1) gene on chromosome 6p12, a large gene spanning 470 kb of genomic DNA.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16199545",
          "text": "BACKGROUND\nAutosomal recessive polycystic kidney disease (ARPKD) is caused by mutations in the PKHD1 (polycystic kidney and hepatic disease 1) gene on chromosome 6p12, a large gene spanning 470 kb of genomic DNA. So far, only micromutations in the 66 exons encoding the longest open reading frame (ORF) have been described, and account for about 80% of mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16199545",
          "text": "Multi-exon deletions of the PKHD1 gene cause autosomal recessive polycystic kidney disease (ARPKD).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 99
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33940108",
          "text": "Autosomal recessive polycystic kidney disease (ARPKD) is a severe disease of early childhood that is clinically characterized by fibrocystic changes of the kidneys and the liver. The main cause of ARPKD are variants in the PKHD1 gene encoding the large transmembrane protein fibrocystin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 287
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33940108",
          "text": "Autosomal recessive polycystic kidney disease (ARPKD) is a severe disease of early childhood that is clinically characterized by fibrocystic changes of the kidneys and the liver. The main cause of ARPKD are variants in the PKHD1 gene encoding the large transmembrane protein fibrocystin. The mechanisms underlying the observed clinical heterogeneity in ARPKD remain incompletely understood, partly due to the fact that genotype-phenotype correlations have been limited to the association of biallelic null variants in PKHD1 with the most severe phenotypes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 556
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16199545",
          "text": "BACKGROUND\nAutosomal recessive polycystic kidney disease (ARPKD) is caused by mutations in the PKHD1 (polycystic kidney and hepatic disease 1) gene on chromosome 6p12, a large gene spanning 470 kb of genomic DNA. So far, only micromutations in the 66 exons encoding the longest open reading frame (ORF) have been described, and account for about 80% of mutations. OBJECTIVE\nTo test the hypothesis that gross genomic rearrangements and mutations in alternatively spliced exons contribute to a subset of the remaining disease alleles.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 534
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16133180",
          "text": "Autosomal recessive polycystic kidney disease (ARPKD) is a severe form of polycystic kidney disease characterized by enlarged kidneys and congenital hepatic fibrosis. Given the poor prognosis for the majority of children with the severe perinatal ARPKD phenotype, there is a regular request for prenatal testing. ARPKD is caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene, which consists of 86 exons that are variably assembled into a number of alternatively spliced transcripts.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 509
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15108277",
          "text": "Autosomal recessive polycystic kidney disease (ARPKD) is an important cause of childhood renal- and liver-related morbidity and mortality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 138
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15108277",
          "text": "PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 73
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15108277",
          "text": "Autosomal recessive polycystic kidney disease (ARPKD) is an important cause of childhood renal- and liver-related morbidity and mortality. The clinical spectrum is widely variable.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 180
        }
      ],
      "ideal_answer": "Autosomal Recessive Polycystic Kidney Disease is caused by variants of the PKHD1 gene.",
      "exact_answer": [
        "PKHD1 gene"
      ]
    },
    {
      "id": "65cf98431930410b1300000b",
      "type": "list",
      "body": "What are the targets of Tarlatamab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
        "http://www.ncbi.nlm.nih.gov/pubmed/36351060",
        "http://www.ncbi.nlm.nih.gov/pubmed/37877814",
        "http://www.ncbi.nlm.nih.gov/pubmed/37355629",
        "http://www.ncbi.nlm.nih.gov/pubmed/37861218",
        "http://www.ncbi.nlm.nih.gov/pubmed/32554516",
        "http://www.ncbi.nlm.nih.gov/pubmed/35815644",
        "http://www.ncbi.nlm.nih.gov/pubmed/31068386",
        "http://www.ncbi.nlm.nih.gov/pubmed/28487384",
        "http://www.ncbi.nlm.nih.gov/pubmed/35983951"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediated tumor lysis. Herein, we report phase I results of tarlatamab in patients with SCLC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 91,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediated tumor lysis. Herein, we report phase I results of tarlatamab in patients with SCLC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 156,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediated tumor lysis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 156,
          "endSection": "abstract",
          "offsetInEndSection": 280
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediated tumor lysis. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 157,
          "endSection": "abstract",
          "offsetInEndSection": 282
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediated tumor lysis. Herein, we report phase I results of tarlatamab in patients with SCLC. PATIENTS AND METHODS\nThis study evaluated tarlatamab in patients with relapsed/refractory SCLC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 156,
          "endSection": "abstract",
          "offsetInEndSection": 449
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediated tumor lysis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 91,
          "endSection": "abstract",
          "offsetInEndSection": 280
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36689692",
          "text": "Herein, we report phase I results of tarlatamab in patients with SCLC. PATIENTS AND METHODS\nThis study evaluated tarlatamab in patients with relapsed/refractory SCLC. The primary end point was safety.",
          "beginSection": "abstract",
          "offsetInBeginSection": 281,
          "endSection": "abstract",
          "offsetInEndSection": 483
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36351060",
          "text": "In multiple patient-derived xenograft models, AMG 757 (tarlatamab), a half-life-extended bispecific T-cell engager (BiTE) immunotherapy that redirects CD3-positive T cells to kill DLL3-expressing cells, exhibited potent and durable antitumor activity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 427,
          "endSection": "abstract",
          "offsetInEndSection": 678
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36351060",
          "text": "In multiple patient-derived xenograft models, AMG 757 (tarlatamab), a half-life-extended bispecific T-cell engager (BiTE) immunotherapy that redirects CD3-positive T cells to kill DLL3-expressing cells, exhibited potent and durable antitumor activity. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 427,
          "endSection": "abstract",
          "offsetInEndSection": 679
        }
      ],
      "ideal_answer": "Tarlatamab targets Delta-like ligand 3 (DLL3) and CD3.",
      "exact_answer": [
        [
          "DLL3"
        ],
        [
          "CD3"
        ]
      ]
    },
    {
      "id": "65f77465c4010b4d78000028",
      "type": "yesno",
      "body": "Is liquid biopsy a cost-effective technique in general population screening for colorectal cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
        "http://www.ncbi.nlm.nih.gov/pubmed/1599742",
        "http://www.ncbi.nlm.nih.gov/pubmed/28988790",
        "http://www.ncbi.nlm.nih.gov/pubmed/21633092",
        "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
        "http://www.ncbi.nlm.nih.gov/pubmed/18347531",
        "http://www.ncbi.nlm.nih.gov/pubmed/11916165",
        "http://www.ncbi.nlm.nih.gov/pubmed/12943152",
        "http://www.ncbi.nlm.nih.gov/pubmed/11035892",
        "http://www.ncbi.nlm.nih.gov/pubmed/31939431"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Conclusions and Relevance\nIn this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2162,
          "endSection": "abstract",
          "offsetInEndSection": 2517
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Conclusions and Relevance\nIn this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. Liquid biopsy tests for colorectal cancer screening may become cost-effective if their cost is substantially lowered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2162,
          "endSection": "abstract",
          "offsetInEndSection": 2635
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Liquid biopsy tests for colorectal cancer screening may become cost-effective if their cost is substantially lowered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2518,
          "endSection": "abstract",
          "offsetInEndSection": 2635
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening. Objective\nTo estimate the cost-effectiveness of liquid biopsy for colorectal cancer screening in the US.",
          "beginSection": "abstract",
          "offsetInBeginSection": 133,
          "endSection": "abstract",
          "offsetInEndSection": 389
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 133,
          "endSection": "abstract",
          "offsetInEndSection": 282
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Colonoscopy-liquid biopsy hybrid had a greater gain in life-years if liquid biopsy could detect polyps but remained too costly. Conclusions and Relevance\nIn this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance. Liquid biopsy tests for colorectal cancer screening may become cost-effective if their cost is substantially lowered.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2032,
          "endSection": "abstract",
          "offsetInEndSection": 2635
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Colonoscopy-liquid biopsy hybrid had a greater gain in life-years if liquid biopsy could detect polyps but remained too costly. Conclusions and Relevance\nIn this economic evaluation of liquid biopsy for colorectal cancer screening, colonoscopy was a cost-effective strategy for colorectal cancer screening in the general population, and the inclusion of liquid biopsy as a first- or second-line screening strategy was not cost-effective at its current cost and screening performance.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2032,
          "endSection": "abstract",
          "offsetInEndSection": 2517
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Importance\nDespite recommendations for universal screening, adherence to colorectal cancer screening in the US is approximately 60%. Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening. Objective\nTo estimate the cost-effectiveness of liquid biopsy for colorectal cancer screening in the US.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 389
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening. Objective\nTo estimate the cost-effectiveness of liquid biopsy for colorectal cancer screening in the US. Design, Setting, and Participants\nIn this economic evaluation, a Markov model was developed to compare no screening and 5 colorectal cancer screening strategies: colonoscopy, liquid biopsy, liquid biopsy following nonadherence to colonoscopy, stool DNA, and fecal immunochemical test.",
          "beginSection": "abstract",
          "offsetInBeginSection": 133,
          "endSection": "abstract",
          "offsetInEndSection": 676
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
          "text": "Importance\nDespite recommendations for universal screening, adherence to colorectal cancer screening in the US is approximately 60%. Liquid biopsy tests are in development for cancer early detection, but it is unclear whether they are cost-effective for colorectal cancer screening.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 282
        }
      ],
      "ideal_answer": "No, liquid biopsy is not a cost-effective technique in general population screening for colorectal cancer at its current cost and screening performance.",
      "exact_answer": "no"
    },
    {
      "id": "65ef8502dffffb9b6b000003",
      "type": "factoid",
      "body": "What causes Mucormycosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36751448",
        "http://www.ncbi.nlm.nih.gov/pubmed/36571098",
        "http://www.ncbi.nlm.nih.gov/pubmed/36569440",
        "http://www.ncbi.nlm.nih.gov/pubmed/36566630",
        "http://www.ncbi.nlm.nih.gov/pubmed/36777925",
        "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
        "http://www.ncbi.nlm.nih.gov/pubmed/35502084",
        "http://www.ncbi.nlm.nih.gov/pubmed/32309127",
        "http://www.ncbi.nlm.nih.gov/pubmed/21686435",
        "http://www.ncbi.nlm.nih.gov/pubmed/24672569"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35502084",
          "text": "Mucormycosis is a rare but devastating fungal infection caused by filamentous fungi of the family Mucoraceae.",
          "beginSection": "abstract",
          "offsetInBeginSection": 201,
          "endSection": "abstract",
          "offsetInEndSection": 310
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24672569",
          "text": "Mucormycosis is an invasive fungal infection caused by filamentous fungi of the Mucoraceae family. The genera most commonly responsible are Mucor or Rhizopus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 158
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24672569",
          "text": "Mucormycosis is an invasive fungal infection caused by filamentous fungi of the Mucoraceae family.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 98
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24672569",
          "text": "Mucormycosis is an invasive fungal infection caused by filamentous fungi of the Mucoraceae family. The genera most commonly responsible are Mucor or Rhizopus. The disease occurs mostly in association with diabetic ketoacidosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25386533",
          "text": "Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 101
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21686435",
          "text": "However, saprophytic fungi of the class Zygomycetes, family Mucoraceae, can cause highly aggressive infections (mucormycoses) mainly in immunocompromised patients. Severe trauma is one of the major risk factors for mucormycosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 84,
          "endSection": "abstract",
          "offsetInEndSection": 312
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36751448",
          "text": "Background: Mucormycosis is a life-threatening infection of the paranasal sinuses and nasal cavities that can easily spread to the orbit and the brain. It is caused by fungi of the family Mucoraceae",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 198
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21686435",
          "text": "However, saprophytic fungi of the class Zygomycetes, family Mucoraceae, can cause highly aggressive infections (mucormycoses) mainly in immunocompromised patients. Severe trauma is one of the major risk factors for mucormycosis. Fungal traumatic wound infection is an unusual complication associated with crash limb injury.",
          "beginSection": "abstract",
          "offsetInBeginSection": 84,
          "endSection": "abstract",
          "offsetInEndSection": 407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36777925",
          "text": "An invasive fungal infection caused by saprophytic and aerobic fungi Rhizopus, Rhizomucor, and Cunninghamella genera of the family Mucoraceae is known as Mucormycosis. Typically, Mucormycosis manifests in patients with conditions like uncontrolled diabetes, renal failure, patients receiving chemotherapy, long term steroid therapy or patients who are immunocompromised such as Acquired Immuno Deficiency Syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 414
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36751448",
          "text": "Background\nMucormycosis is a life-threatening infection of the paranasal sinuses and nasal cavities that can easily spread to the orbit and the brain. It is caused by fungi of the family Mucoraceae. We present a case series of 61 patients diagnosed and treated for rhinocerebral mucormycosis (RCM) at a single tertiary health care center.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 338
        }
      ],
      "ideal_answer": "Mucormycosis is caused by filamentous fungi of the family Mucoraceae, which are ubiquitous saprophytic fungi. It typically manifests in patients with conditions like uncontrolled diabetes, renal failure, patients receiving chemotherapy, long term steroid therapy or patients who are immunocompromised such as Acquired Immuno Deficiency Syndrome.",
      "exact_answer": [
        "fungi of the family Mucoraceae"
      ]
    },
    {
      "id": "66165f2afdcbea915f000051",
      "type": "factoid",
      "body": "When was the first case of human monkey pox diagnosed?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36403582",
        "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
        "http://www.ncbi.nlm.nih.gov/pubmed/2897768",
        "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
        "http://www.ncbi.nlm.nih.gov/pubmed/15617321",
        "http://www.ncbi.nlm.nih.gov/pubmed/2570511",
        "http://www.ncbi.nlm.nih.gov/pubmed/195980",
        "http://www.ncbi.nlm.nih.gov/pubmed/36405891",
        "http://www.ncbi.nlm.nih.gov/pubmed/35038257",
        "http://www.ncbi.nlm.nih.gov/pubmed/36408438"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "The authors report on the first coming out in Gabon of human monkey-pox. Four children in the same family were simultaneously attacked. In one of the two fatal cases, diagnosis of monkey-pox was confirmed by the isolation of the virus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "The authors report on the first coming out in Gabon of human monkey-pox.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 72
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "The authors report on the first coming out in Gabon of human monkey-pox. Four children in the same family were simultaneously attacked.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 135
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "Epidemiology of human Monkey-pox cases in Rivers State, Nigeria January 2017-June 2022.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "A retrospective analysis of monkey pox cases was conducted based on the data obtained from the Rivers State Disease Surveillance and Notification unit from January 2017-June 2022. A total of 112 suspected cases were reported during this period of which 49 (44%) were confirmed by laboratory diagnosis. Obio-Akpor (29) and Port Harcourt (9) Local Government Areas which make up the urban centers of the state recorded most cases of monkey pox.",
          "beginSection": "abstract",
          "offsetInBeginSection": 546,
          "endSection": "abstract",
          "offsetInEndSection": 988
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1649373",
          "text": "[First appearance of monkey pox in human beings in Gabon].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 58
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "The highest burden of cases of monkey pox is recorded in River state, Nigeria. Consequently, there is the need to examine the epidemiology of monkey pox according to time, place, person and geography in Rivers state. A retrospective analysis of monkey pox cases was conducted based on the data obtained from the Rivers State Disease Surveillance and Notification unit from January 2017-June 2022.",
          "beginSection": "abstract",
          "offsetInBeginSection": 329,
          "endSection": "abstract",
          "offsetInEndSection": 725
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "A retrospective analysis of monkey pox cases was conducted based on the data obtained from the Rivers State Disease Surveillance and Notification unit from January 2017-June 2022. A total of 112 suspected cases were reported during this period of which 49 (44%) were confirmed by laboratory diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 546,
          "endSection": "abstract",
          "offsetInEndSection": 847
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "Nigeria recorded increased number of reported monkey pox cases in 2017, with cases occurring in subsequent years. Notably, cases of monkey pox had been reported in western countries from an epidemiologically linked traveler with a travel history to Nigeria. The highest burden of cases of monkey pox is recorded in River state, Nigeria.",
          "beginSection": "abstract",
          "offsetInBeginSection": 71,
          "endSection": "abstract",
          "offsetInEndSection": 407
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36684949",
          "text": "Consequently, there is the need to examine the epidemiology of monkey pox according to time, place, person and geography in Rivers state. A retrospective analysis of monkey pox cases was conducted based on the data obtained from the Rivers State Disease Surveillance and Notification unit from January 2017-June 2022. A total of 112 suspected cases were reported during this period of which 49 (44%) were confirmed by laboratory diagnosis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 408,
          "endSection": "abstract",
          "offsetInEndSection": 847
        }
      ],
      "ideal_answer": "The first case of human monkey pox was diagnosed in the Democratic Republic of the Congo in 1970.",
      "exact_answer": [
        "1970"
      ]
    },
    {
      "id": "661c413f48a2c27714000006",
      "type": "yesno",
      "body": "Does chromatin accessibility affect CRISPR-Cas9 efficiency?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
        "http://www.ncbi.nlm.nih.gov/pubmed/28580607",
        "http://www.ncbi.nlm.nih.gov/pubmed/31349852",
        "http://www.ncbi.nlm.nih.gov/pubmed/35689624",
        "http://www.ncbi.nlm.nih.gov/pubmed/28303677",
        "http://www.ncbi.nlm.nih.gov/pubmed/28800611",
        "http://www.ncbi.nlm.nih.gov/pubmed/31672284",
        "http://www.ncbi.nlm.nih.gov/pubmed/31021236",
        "http://www.ncbi.nlm.nih.gov/pubmed/36459645",
        "http://www.ncbi.nlm.nih.gov/pubmed/32532133"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis. These results indicate that CRISPR-Cas9 mutagenesis is influenced by chromatin accessibility in zebrafish embryos.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1183,
          "endSection": "abstract",
          "offsetInEndSection": 1394
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "In order to further inspect the effect of chromatin on CRISPR-Cas9 mutagenesis, we analysed the relationship of selected chromatin features on CRISPR-Cas9 mutagenesis efficiency using publicly available data from zebrafish embryos. We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis. These results indicate that CRISPR-Cas9 mutagenesis is influenced by chromatin accessibility in zebrafish embryos.",
          "beginSection": "abstract",
          "offsetInBeginSection": 951,
          "endSection": "abstract",
          "offsetInEndSection": 1394
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "In order to further inspect the effect of chromatin on CRISPR-Cas9 mutagenesis, we analysed the relationship of selected chromatin features on CRISPR-Cas9 mutagenesis efficiency using publicly available data from zebrafish embryos. We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 951,
          "endSection": "abstract",
          "offsetInEndSection": 1279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "In order to further inspect the effect of chromatin on CRISPR-Cas9 mutagenesis, we analysed the relationship of selected chromatin features on CRISPR-Cas9 mutagenesis efficiency using publicly available data from zebrafish embryos.",
          "beginSection": "abstract",
          "offsetInBeginSection": 951,
          "endSection": "abstract",
          "offsetInEndSection": 1182
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31349852",
          "text": "The CRISPR/Cas9 system is unable to edit all targetable genomic sites with full efficiency in vivo. We show that Cas9-mediated editing is more efficient in open chromatin regions than in closed chromatin regions in rice.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "These results indicate that CRISPR-Cas9 mutagenesis is influenced by chromatin accessibility in zebrafish embryos.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1280,
          "endSection": "abstract",
          "offsetInEndSection": 1394
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1183,
          "endSection": "abstract",
          "offsetInEndSection": 1279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 1183,
          "endSection": "abstract",
          "offsetInEndSection": 1280
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "CRISPR-Cas9 technology is routinely applied for targeted mutagenesis in model organisms and cell lines. Recent studies indicate that the prokaryotic CRISPR-Cas9 system is affected by eukaryotic chromatin structures. Here, we show that the likelihood of successful mutagenesis correlates with transcript levels during early development in zebrafish (Danio rerio) embryos.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 370
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684067",
          "text": "Using open access datasets generated from early developmental stages of the zebrafish, and guide RNAs selected from the CRISPRz database, we provide further evidence for an association between gene expression during early development and the success of CRISPR-Cas9 mutagenesis in zebrafish embryos. In order to further inspect the effect of chromatin on CRISPR-Cas9 mutagenesis, we analysed the relationship of selected chromatin features on CRISPR-Cas9 mutagenesis efficiency using publicly available data from zebrafish embryos. We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 652,
          "endSection": "abstract",
          "offsetInEndSection": 1279
        }
      ],
      "ideal_answer": "Yes, chromatin accessibility affects CRISPR-Cas9 efficiency. The openness of chromatin regions can significantly impact the efficiency of CRISPR-Cas9 mutagenesis, as demonstrated in various studies involving human cells, rice, and other organisms.",
      "exact_answer": "yes"
    },
    {
      "id": "661d51fdeac11fad3300001d",
      "type": "list",
      "body": "What diseases are included in the differential diagnosis of Ehlers-Danlos Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
        "http://www.ncbi.nlm.nih.gov/pubmed/33856167",
        "http://www.ncbi.nlm.nih.gov/pubmed/26316810",
        "http://www.ncbi.nlm.nih.gov/pubmed/25821090",
        "http://www.ncbi.nlm.nih.gov/pubmed/17640391",
        "http://www.ncbi.nlm.nih.gov/pubmed/30512708",
        "http://www.ncbi.nlm.nih.gov/pubmed/9649943",
        "http://www.ncbi.nlm.nih.gov/pubmed/34807421",
        "http://www.ncbi.nlm.nih.gov/pubmed/29552444",
        "http://www.ncbi.nlm.nih.gov/pubmed/28482708"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "The differential diagnosis of EDS includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1096,
          "endSection": "abstract",
          "offsetInEndSection": 1366
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "The differential diagnosis of EDS includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome. Surgical treatment is reserved for complications, or emergencies involving vascular or orthopedic injury because of the risk of poor wound healing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1096,
          "endSection": "abstract",
          "offsetInEndSection": 1514
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "In recent years, studies have identified multiple gene variants involved in the pathogenesis of specific EDS subtypes as well as elaborate clinical diagnostic criteria and classification models used to differentiate overlapping conditions. The differential diagnosis of EDS includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 856,
          "endSection": "abstract",
          "offsetInEndSection": 1366
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "The differential diagnosis of EDS includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome. Surgical treatment is reserved for complications, or emergencies involving vascular or orthopedic injury because of the risk of poor wound healing. Management techniques each have their own consequences and benefits, which will also be discussed in this review article.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1096,
          "endSection": "abstract",
          "offsetInEndSection": 1636
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "In recent years, studies have identified multiple gene variants involved in the pathogenesis of specific EDS subtypes as well as elaborate clinical diagnostic criteria and classification models used to differentiate overlapping conditions. The differential diagnosis of EDS includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome. Surgical treatment is reserved for complications, or emergencies involving vascular or orthopedic injury because of the risk of poor wound healing.",
          "beginSection": "abstract",
          "offsetInBeginSection": 856,
          "endSection": "abstract",
          "offsetInEndSection": 1514
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33437956",
          "text": "Thorough evaluation incorporates clinical examination, family history, laboratory testing, and imaging. In recent years, studies have identified multiple gene variants involved in the pathogenesis of specific EDS subtypes as well as elaborate clinical diagnostic criteria and classification models used to differentiate overlapping conditions. The differential diagnosis of EDS includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 752,
          "endSection": "abstract",
          "offsetInEndSection": 1366
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25821090",
          "text": "In this review, we revise the differential diagnosis of JHS/EDS-HT with those heritable connective tissue disorders which show a significant overlap with the former and mostly include EDS classic, vascular and kyphoscoliotic types, osteogenesis imperfecta, Marfan syndrome, Loeys-Dietz syndrome, arterial tortuosity syndrome, and lateral meningocele syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1091,
          "endSection": "abstract",
          "offsetInEndSection": 1450
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25821090",
          "text": "In this review, we revise the differential diagnosis of JHS/EDS-HT with those heritable connective tissue disorders which show a significant overlap with the former and mostly include EDS classic, vascular and kyphoscoliotic types, osteogenesis imperfecta, Marfan syndrome, Loeys-Dietz syndrome, arterial tortuosity syndrome, and lateral meningocele syndrome. A diagnostic flow chart is also offered with the attempt to support the less experienced clinician in stringently recognizing JHS/EDS-HT and stimulate the debate in the scientific community for both management and research purposes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1091,
          "endSection": "abstract",
          "offsetInEndSection": 1683
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316810",
          "text": "When GJH is accompanied by pain in ≥4 joints over a period ≥3 months in the absence of other conditions that cause chronic pain, the hypermobility syndrome (HMS) may be diagnosed. In addition, GJH is also a clinical sign that is frequently present in hereditary diseases of the connective tissue, such as the Marfan syndrome, osteogenesis imperfecta, and the Ehlers-Danlos syndrome. However, within the Ehlers-Danlos spectrum, a similar subcategory of patients having similar clinical features as HMS but lacking a specific genetic profile was identified: Ehlers-Danlos syndrome hypermobility type (EDS-HT).",
          "beginSection": "abstract",
          "offsetInBeginSection": 102,
          "endSection": "abstract",
          "offsetInEndSection": 709
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316810",
          "text": "In addition, GJH is also a clinical sign that is frequently present in hereditary diseases of the connective tissue, such as the Marfan syndrome, osteogenesis imperfecta, and the Ehlers-Danlos syndrome. However, within the Ehlers-Danlos spectrum, a similar subcategory of patients having similar clinical features as HMS but lacking a specific genetic profile was identified: Ehlers-Danlos syndrome hypermobility type (EDS-HT). Researchers and clinicians have struggled for decades with the highly diverse clinical presentation within the HMS and EDS-HT phenotypes (Challenge 1) and the lack of understanding of the pathological mechanisms that underlie the development of pain and its persistence (Challenge 2).",
          "beginSection": "abstract",
          "offsetInBeginSection": 282,
          "endSection": "abstract",
          "offsetInEndSection": 994
        }
      ],
      "ideal_answer": "The differential diagnosis of Ehlers-Danlos Syndrome includes hypermobility spectrum disorders, Marfan syndrome, Loey-Dietz syndrome, Cutis laxa syndromes, autosomal dominant polycystic kidney disease, osteogenesis Imperfecta Type 1, fibromyalgia, depression, and chronic fatigue syndrome. These conditions present with similar symptoms and should be considered in the diagnosis of Ehlers-Danlos Syndrome.",
      "exact_answer": [
        [
          "hypermobility spectrum disorders"
        ],
        [
          "Marfan syndrome"
        ],
        [
          "Loey-Dietz syndrome"
        ],
        [
          "Cutis laxa syndromes"
        ],
        [
          "autosomal dominant polycystic kidney disease"
        ],
        [
          "osteogenesis Imperfecta Type 1"
        ],
        [
          "fibromyalgia"
        ],
        [
          "depression"
        ],
        [
          "chronic fatigue syndrome"
        ]
      ]
    },
    {
      "id": "65cfa70f1930410b1300000f",
      "type": "summary",
      "body": "What is the mechanism of action of Nemolizumab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37888917",
        "http://www.ncbi.nlm.nih.gov/pubmed/37801534",
        "http://www.ncbi.nlm.nih.gov/pubmed/37556125",
        "http://www.ncbi.nlm.nih.gov/pubmed/37650357",
        "http://www.ncbi.nlm.nih.gov/pubmed/35842249",
        "http://www.ncbi.nlm.nih.gov/pubmed/32074418",
        "http://www.ncbi.nlm.nih.gov/pubmed/35834124",
        "http://www.ncbi.nlm.nih.gov/pubmed/35412530",
        "http://www.ncbi.nlm.nih.gov/pubmed/37121713",
        "http://www.ncbi.nlm.nih.gov/pubmed/32640132"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35842249",
          "text": "Nemolizumab is a humanized monoclonal antibody that blocks the α subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling. It reduces inflammation and lesion severity in atopic dermatitis and prurigo nodularis by restoring epithelial function and promoting skin barrier integrity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 304,
          "endSection": "abstract",
          "offsetInEndSection": 656
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35842249",
          "text": "Nemolizumab is a humanized monoclonal antibody that blocks the α subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling. It reduces inflammation and lesion severity in atopic dermatitis and prurigo nodularis by restoring epithelial function and promoting skin barrier integrity. This review synthesizes the latest information on the functions of IL-31 and presents the current evidence, including clinical trial results, on the use of nemolizumab in the treatment of atopic dermatitis and prurigo nodularis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 304,
          "endSection": "abstract",
          "offsetInEndSection": 885
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35842249",
          "text": "As the immune and nervous systems are interrelated, IL-31 has a key role in the treatment of atopic dermatitis and prurigo nodularis. Nemolizumab is a humanized monoclonal antibody that blocks the α subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling. It reduces inflammation and lesion severity in atopic dermatitis and prurigo nodularis by restoring epithelial function and promoting skin barrier integrity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 170,
          "endSection": "abstract",
          "offsetInEndSection": 656
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35842249",
          "text": "As the immune and nervous systems are interrelated, IL-31 has a key role in the treatment of atopic dermatitis and prurigo nodularis. Nemolizumab is a humanized monoclonal antibody that blocks the α subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling.",
          "beginSection": "abstract",
          "offsetInBeginSection": 170,
          "endSection": "abstract",
          "offsetInEndSection": 498
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35842249",
          "text": "It contributes to skin barrier inflammation, dysfunction, and remodeling. As the immune and nervous systems are interrelated, IL-31 has a key role in the treatment of atopic dermatitis and prurigo nodularis. Nemolizumab is a humanized monoclonal antibody that blocks the α subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling.",
          "beginSection": "abstract",
          "offsetInBeginSection": 96,
          "endSection": "abstract",
          "offsetInEndSection": 498
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32074418",
          "text": "Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 235
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32074418",
          "text": "Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. METHODS\nWe conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and week 8, as compared with placebo, in patients with moderate-to-severe prurigo nodularis and severe pruritus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35834124",
          "text": "Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic kidney disease associated pruritus (CKDaP) and systemic sclerosis (SSc). IL-31 is a neuroimmune cytokine that induces itch, inflammation, keratinocyte differentiation and fibroblast activation in chronic pruritic skin diseases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 582
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412530",
          "text": "Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to symptoms such as dermatitis and pruritus. Nemolizumab is an anti-IL-31 receptor α-chain (IL-31RA) monoclonal antibody agent that is efficacious in improving symptoms of AD in several phase II and phase III studies in recent years. Nemolizumab demonstrates great efficacy in reducing pruritus and to a lesser degree, dermatitis associated with AD.",
          "beginSection": "abstract",
          "offsetInBeginSection": 140,
          "endSection": "abstract",
          "offsetInEndSection": 581
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35834124",
          "text": "Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic kidney disease associated pruritus (CKDaP) and systemic sclerosis (SSc). IL-31 is a neuroimmune cytokine that induces itch, inflammation, keratinocyte differentiation and fibroblast activation in chronic pruritic skin diseases. Nemolizumab (Mitchga® Syringes) was approved in Japan on 28 March 2022 for use in adults and children over the age of 13 years for the treatment of itch associated with AD (only when existing treatment is insufficiently effective).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 814
        }
      ],
      "ideal_answer": "Nemolizumab is a humanized monoclonal antibody that blocks the α subunit of the IL-31 receptor, modulating the neuroimmune response and rapidly alleviating itching by directly blocking signaling. It reduces inflammation and lesion severity in atopic dermatitis and prurigo nodularis by restoring epithelial function and promoting skin barrier integrity.",
      "exact_answer": "n/a"
    },
    {
      "id": "65f774a4c4010b4d78000029",
      "type": "factoid",
      "body": "What type of colorectal cancer screening is the most cost-effective for general population?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26338314",
        "http://www.ncbi.nlm.nih.gov/pubmed/37971743",
        "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
        "http://www.ncbi.nlm.nih.gov/pubmed/28973514",
        "http://www.ncbi.nlm.nih.gov/pubmed/30980665",
        "http://www.ncbi.nlm.nih.gov/pubmed/31790657",
        "http://www.ncbi.nlm.nih.gov/pubmed/26685321",
        "http://www.ncbi.nlm.nih.gov/pubmed/22901118",
        "http://www.ncbi.nlm.nih.gov/pubmed/25704067",
        "http://www.ncbi.nlm.nih.gov/pubmed/11035892"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
          "text": "CONCLUSIONS\nColonoscopy represents a cost-effective means of screening for colorectal cancer because it reduces mortality at relatively low incremental costs. Low compliance rates render colonoscopy every 10 years the most cost-effective primary screening strategy for colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2091,
          "endSection": "abstract",
          "offsetInEndSection": 2378
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
          "text": "CONCLUSIONS\nColonoscopy represents a cost-effective means of screening for colorectal cancer because it reduces mortality at relatively low incremental costs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2091,
          "endSection": "abstract",
          "offsetInEndSection": 2249
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338314",
          "text": "Faecal immunochemical tests (FITs) and colonoscopy are two common screening tools for colorectal cancer(CRC). Most cost-effectiveness studies focused on survival as the outcome, and were based on modeling techniques instead of real world observational data.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 257
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338314",
          "text": "Faecal immunochemical tests (FITs) and colonoscopy are two common screening tools for colorectal cancer(CRC). Most cost-effectiveness studies focused on survival as the outcome, and were based on modeling techniques instead of real world observational data. This study evaluated the cost-effectiveness of these two tests to detect colorectal neoplastic lesions based on data from a 5-year community screening service.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 417
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973514",
          "text": "BACKGROUND\nPopulation-based screening to prevent colorectal cancer (CRC) death is effective, but the effectiveness of postpolypectomy surveillance is unclear. OBJECTIVE\nTo evaluate the additional benefit in terms of cost-effectiveness of colonoscopy surveillance in a screening setting. DESIGN\nMicrosimulation using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 388
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973514",
          "text": "BACKGROUND\nPopulation-based screening to prevent colorectal cancer (CRC) death is effective, but the effectiveness of postpolypectomy surveillance is unclear. OBJECTIVE\nTo evaluate the additional benefit in terms of cost-effectiveness of colonoscopy surveillance in a screening setting.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 288
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973514",
          "text": "OBJECTIVE\nTo evaluate the additional benefit in terms of cost-effectiveness of colonoscopy surveillance in a screening setting. DESIGN\nMicrosimulation using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model. DATA SOURCES\nDutch CRC screening program and published literature.",
          "beginSection": "abstract",
          "offsetInBeginSection": 161,
          "endSection": "abstract",
          "offsetInEndSection": 457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338314",
          "text": "When compared to FIT, colonoscopy is considered cost-effective for screening adenoma, advanced neoplasia, and a composite endpoint of advanced neoplasia or stage I CRC.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1289,
          "endSection": "abstract",
          "offsetInEndSection": 1457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11033584",
          "text": "Low compliance rates render colonoscopy every 10 years the most cost-effective primary screening strategy for colorectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2250,
          "endSection": "abstract",
          "offsetInEndSection": 2378
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973514",
          "text": "RESULTS OF SENSITIVITY ANALYSIS\nWhen using a parameter set representing low colorectal lesion prevalence or when colonoscopy costs were halved or colorectal lesion incidence was doubled, screening plus surveillance became cost-effective compared with screening without surveillance. LIMITATION\nLimited data on FIT performance and background CRC risk in the surveillance population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1749,
          "endSection": "abstract",
          "offsetInEndSection": 2132
        }
      ],
      "ideal_answer": "Colonoscopy is the most cost-effective colorectal cancer screening strategy for the general population.",
      "exact_answer": [
        "colonoscopy"
      ]
    },
    {
      "id": "65f37aeac4010b4d7800000c",
      "type": "yesno",
      "body": "Is Cri du Chat syndrome (CdCS) a genetic syndrome caused by deletions in the long arm of chromosome 5",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37908952",
        "http://www.ncbi.nlm.nih.gov/pubmed/36660031",
        "http://www.ncbi.nlm.nih.gov/pubmed/1978567",
        "http://www.ncbi.nlm.nih.gov/pubmed/26059676",
        "http://www.ncbi.nlm.nih.gov/pubmed/7896290",
        "http://www.ncbi.nlm.nih.gov/pubmed/18437967",
        "http://www.ncbi.nlm.nih.gov/pubmed/25236835",
        "http://www.ncbi.nlm.nih.gov/pubmed/1606717",
        "http://www.ncbi.nlm.nih.gov/pubmed/25514263",
        "http://www.ncbi.nlm.nih.gov/pubmed/995018"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514263",
          "text": "Cri du chat syndrome (CdcS), also known as 5p deletion syndrome is a genetic disorder caused by the partial deletion of chromatin from the short arm of chromosome 5.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 165
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25236835",
          "text": "Cri du Chat Syndrome (CdCS) is rare and occurs as a result of a partial deletion in the short arm of chromosome 5.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 114
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25236835",
          "text": "Cri du Chat Syndrome (CdCS) is rare and occurs as a result of a partial deletion in the short arm of chromosome 5. There are no reports in the literature from the West African sub-region and indeed very few from Africa.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514263",
          "text": "Cri du chat syndrome (CdcS), also known as 5p deletion syndrome is a genetic disorder caused by the partial deletion of chromatin from the short arm of chromosome 5. There is a paucity of literature on the dental manifestations in CdcS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 236
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514263",
          "text": "Cri du chat syndrome (CdcS), also known as 5p deletion syndrome is a genetic disorder caused by the partial deletion of chromatin from the short arm of chromosome 5. There is a paucity of literature on the dental manifestations in CdcS. The purposes of this report are to present the case of a nine-year-old girl with the syndrome, CdcS and to review its dental and clinical manifestations and their management in children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 423
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059676",
          "text": "The cri-du-chat syndrome is a rare genetic disorder caused by deletions in the short arm of chromosome 5.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 105
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25236835",
          "text": "Cri du Chat Syndrome (CdCS) is rare and occurs as a result of a partial deletion in the short arm of chromosome 5. There are no reports in the literature from the West African sub-region and indeed very few from Africa. A case of Cri du Chat Syndrome is described in Ghana.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059676",
          "text": "The cri-du-chat syndrome is a rare genetic disorder caused by deletions in the short arm of chromosome 5. It presents with a distinctive catlike high-pitched cry, psychomotor delays, microcephaly, craniofacial abnormalities, and, in many cases, ocular findings.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 261
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1978567",
          "text": "Since the cri-du-chat syndrome is correlated with deletions involving the short arm of chromosome 5 (5p), DNA fragments known to detect restriction fragment length polymorphisms (RFLPs) along 5p were used to establish whether the paternal or the maternal chromosome had suffered the deletion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 100,
          "endSection": "abstract",
          "offsetInEndSection": 392
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18437967",
          "text": "BACKGROUND\nCri-du-chat syndrome is a genetic disorder associated with various sized deletions of the short arm of chromosome 5. There are typical physical features, but individual phenotypes vary considerably.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 209
        }
      ],
      "ideal_answer": "Yes, Cri du Chat syndrome (CdCS) is a genetic syndrome caused by deletions in the short arm of chromosome 5.",
      "exact_answer": "no"
    },
    {
      "id": "66168d7bfdcbea915f000056",
      "type": "summary",
      "body": "Mortality in schizophrenia.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
        "http://www.ncbi.nlm.nih.gov/pubmed/29723811",
        "http://www.ncbi.nlm.nih.gov/pubmed/22249081",
        "http://www.ncbi.nlm.nih.gov/pubmed/25822814",
        "http://www.ncbi.nlm.nih.gov/pubmed/33009566",
        "http://www.ncbi.nlm.nih.gov/pubmed/21741216",
        "http://www.ncbi.nlm.nih.gov/pubmed/29900527",
        "http://www.ncbi.nlm.nih.gov/pubmed/35152418",
        "http://www.ncbi.nlm.nih.gov/pubmed/28923795",
        "http://www.ncbi.nlm.nih.gov/pubmed/11040880"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
          "text": "Persons with schizophrenia have an exceptionally short life expectancy. High mortality is found in all age groups, resulting in a life expectancy of approximately 20 years below that of the general population. Evidence suggests that persons with schizophrenia may not have seen the same improvement in life expectancy as the general population during the past decades.",
          "beginSection": "abstract",
          "offsetInBeginSection": 333,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
          "text": "Persons with schizophrenia have an exceptionally short life expectancy. High mortality is found in all age groups, resulting in a life expectancy of approximately 20 years below that of the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 333,
          "endSection": "abstract",
          "offsetInEndSection": 542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249081",
          "text": "RECENT FINDINGS\nPatients with schizophrenia have two-fold to three-fold higher mortality rates compared with the general population, corresponding to a 10-25-year reduction in life expectancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 340
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
          "text": "High mortality is found in all age groups, resulting in a life expectancy of approximately 20 years below that of the general population. Evidence suggests that persons with schizophrenia may not have seen the same improvement in life expectancy as the general population during the past decades. Thus, the mortality gap not only persists but may actually have increased.",
          "beginSection": "abstract",
          "offsetInBeginSection": 405,
          "endSection": "abstract",
          "offsetInEndSection": 776
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
          "text": "High mortality is found in all age groups, resulting in a life expectancy of approximately 20 years below that of the general population. Evidence suggests that persons with schizophrenia may not have seen the same improvement in life expectancy as the general population during the past decades.",
          "beginSection": "abstract",
          "offsetInBeginSection": 405,
          "endSection": "abstract",
          "offsetInEndSection": 701
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25822814",
          "text": "Patients with schizophrenia have a diminished life expectancy of 15-20 years compared to the general population. Over the last decades excess mortality of suicide has decreased, whereas excess mortality of physical illness, especially cardiovascular disease has increased.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 272
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313570",
          "text": "This article reviews the literature on excess early mortality in persons with schizophrenia and suggests reasons for the high mortality as well as possible ways to reduce it. Persons with schizophrenia have an exceptionally short life expectancy. High mortality is found in all age groups, resulting in a life expectancy of approximately 20 years below that of the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 158,
          "endSection": "abstract",
          "offsetInEndSection": 542
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25822814",
          "text": "Patients with schizophrenia have a diminished life expectancy of 15-20 years compared to the general population.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 112
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25822814",
          "text": "Patients with schizophrenia have a diminished life expectancy of 15-20 years compared to the general population. Over the last decades excess mortality of suicide has decreased, whereas excess mortality of physical illness, especially cardiovascular disease has increased. Focus attends current somatic co-morbidity, side effects to medication and poor lifestyle.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 363
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249081",
          "text": "RECENT FINDINGS\nPatients with schizophrenia have two-fold to three-fold higher mortality rates compared with the general population, corresponding to a 10-25-year reduction in life expectancy. Although the mortality rate from suicide is high, natural causes of death account for a greater part of the reduction in life expectancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 148,
          "endSection": "abstract",
          "offsetInEndSection": 478
        }
      ],
      "ideal_answer": "The mortality rate in schizophrenia is two-fold to three-fold higher than in the general population, corresponding to a 10-25 year reduction in life expectancy. This gap has persisted or even widened over time, and is mainly due to natural causes of death, particularly cardiovascular disease.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d2428eac11fad33000017",
      "type": "yesno",
      "body": "Is ICD-10 encoding sensitive for capturing paediatric sepsis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
        "http://www.ncbi.nlm.nih.gov/pubmed/30059504",
        "http://www.ncbi.nlm.nih.gov/pubmed/31438253",
        "http://www.ncbi.nlm.nih.gov/pubmed/26700284",
        "http://www.ncbi.nlm.nih.gov/pubmed/37936832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34840874",
        "http://www.ncbi.nlm.nih.gov/pubmed/23385099",
        "http://www.ncbi.nlm.nih.gov/pubmed/16224307",
        "http://www.ncbi.nlm.nih.gov/pubmed/18066356",
        "http://www.ncbi.nlm.nih.gov/pubmed/10179251"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Results\nWe analyzed 998 hospital admissions of children with blood culture-proven sepsis. The sensitivity of ICD-10 coding abstraction was 60% (95%-CI 57-63) for sepsis; 35% (95%-CI 31-39) for sepsis with organ dysfunction, using an explicit abstraction strategy; and 65% (95%-CI 61-69) using an implicit abstraction strategy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 650,
          "endSection": "abstract",
          "offsetInEndSection": 976
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "The sensitivity of ICD-10 coding abstraction was 60% (95%-CI 57-63) for sepsis; 35% (95%-CI 31-39) for sepsis with organ dysfunction, using an explicit abstraction strategy; and 65% (95%-CI 61-69) using an implicit abstraction strategy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 735,
          "endSection": "abstract",
          "offsetInEndSection": 971
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "The sensitivity of ICD-10 coding abstraction was 60% (95%-CI 57-63) for sepsis; 35% (95%-CI 31-39) for sepsis with organ dysfunction, using an explicit abstraction strategy; and 65% (95%-CI 61-69) using an implicit abstraction strategy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 740,
          "endSection": "abstract",
          "offsetInEndSection": 976
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "The sensitivity of ICD-10 coding abstraction was 60% (95%-CI 57-63) for sepsis; 35% (95%-CI 31-39) for sepsis with organ dysfunction, using an explicit abstraction strategy; and 65% (95%-CI 61-69) using an implicit abstraction strategy. For septic shock, the sensitivity of ICD-10 coding abstraction was 43% (95%-CI 37-50).",
          "beginSection": "abstract",
          "offsetInBeginSection": 740,
          "endSection": "abstract",
          "offsetInEndSection": 1063
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Results\nWe analyzed 998 hospital admissions of children with blood culture-proven sepsis. The sensitivity of ICD-10 coding abstraction was 60% (95%-CI 57-63) for sepsis; 35% (95%-CI 31-39) for sepsis with organ dysfunction, using an explicit abstraction strategy; and 65% (95%-CI 61-69) using an implicit abstraction strategy. For septic shock, the sensitivity of ICD-10 coding abstraction was 43% (95%-CI 37-50).",
          "beginSection": "abstract",
          "offsetInBeginSection": 650,
          "endSection": "abstract",
          "offsetInEndSection": 1063
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "The sensitivity of ICD-10 coding abstraction was 60% (95%-CI 57-63) for sepsis; 35% (95%-CI 31-39) for sepsis with organ dysfunction, using an explicit abstraction strategy; and 65% (95%-CI 61-69) using an implicit abstraction strategy. For septic shock, the sensitivity of ICD-10 coding abstraction was 43% (95%-CI 37-50). Agreement of ICD-10 coding abstraction with validated study data varied by the underlying infection type and disease severity (p < 0.05).",
          "beginSection": "abstract",
          "offsetInBeginSection": 740,
          "endSection": "abstract",
          "offsetInEndSection": 1201
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Conclusions\nIn this population-based study, we found a poor representation of sepsis and sepsis with organ dysfunction by ICD-10 coding abstraction in children with blood culture-proven sepsis when compared against a prospective validated research dataset. Sepsis estimates in children based on ICD-10 coding may thus severely underestimate the true prevalence of the disease. Supplementary Information\nThe online version contains supplementary material available at 10.1007/s44253-023-00006-1.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1415,
          "endSection": "abstract",
          "offsetInEndSection": 1911
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "For septic shock, the sensitivity of ICD-10 coding abstraction was 43% (95%-CI 37-50). Agreement of ICD-10 coding abstraction with validated study data varied by the underlying infection type and disease severity (p < 0.05). The estimated national incidence of sepsis, inferred from ICD-10 coding abstraction, was 12.5 per 100,000 children (95%-CI 11.7-13.5) and 21.0 per 100,000 children (95%-CI 19.8-22.2) using validated study data.",
          "beginSection": "abstract",
          "offsetInBeginSection": 977,
          "endSection": "abstract",
          "offsetInEndSection": 1412
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "Conclusions\nIn this population-based study, we found a poor representation of sepsis and sepsis with organ dysfunction by ICD-10 coding abstraction in children with blood culture-proven sepsis when compared against a prospective validated research dataset. Sepsis estimates in children based on ICD-10 coding may thus severely underestimate the true prevalence of the disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1415,
          "endSection": "abstract",
          "offsetInEndSection": 1791
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37342815",
          "text": "We compared the agreement of validated study data on sepsis criteria with ICD-10 coding abstraction obtained at the participating hospitals. Results\nWe analyzed 998 hospital admissions of children with blood culture-proven sepsis. The sensitivity of ICD-10 coding abstraction was 60% (95%-CI 57-63) for sepsis; 35% (95%-CI 31-39) for sepsis with organ dysfunction, using an explicit abstraction strategy; and 65% (95%-CI 61-69) using an implicit abstraction strategy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 507,
          "endSection": "abstract",
          "offsetInEndSection": 976
        }
      ],
      "ideal_answer": "No, ICD-10 encoding is not sensitive for capturing paediatric sepsis. The sensitivity of ICD-10 coding abstraction for sepsis in children is only 60% and for sepsis with organ dysfunction is 35%.",
      "exact_answer": "no"
    },
    {
      "id": "65cf96ce1930410b1300000a",
      "type": "yesno",
      "body": "Is Amivantamab used for non–small-cell lung cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35652704",
        "http://www.ncbi.nlm.nih.gov/pubmed/37022784",
        "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
        "http://www.ncbi.nlm.nih.gov/pubmed/36756143",
        "http://www.ncbi.nlm.nih.gov/pubmed/36652175",
        "http://www.ncbi.nlm.nih.gov/pubmed/36979929",
        "http://www.ncbi.nlm.nih.gov/pubmed/37284196",
        "http://www.ncbi.nlm.nih.gov/pubmed/36868177",
        "http://www.ncbi.nlm.nih.gov/pubmed/34913823",
        "http://www.ncbi.nlm.nih.gov/pubmed/37882460"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37022784",
          "text": "FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 134
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34913823",
          "text": "Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 90
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34913823",
          "text": "INTRODUCTION\nAmivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations following progression on chemotherapy, marking a watershed moment for a class of mutations which is generally associated with poor outcomes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 356
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652704",
          "text": "OBJECTIVE: To evaluate clinical data regarding the use of amivantamab and mobocertinib for epidermal growth factor receptor (EGFR) exon 20 insertion mutation non-small cell lung cancer (NSCLC) and assess their potential impact on the care of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 251
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652704",
          "text": "OBJECTIVE\nTo evaluate clinical data regarding the use of amivantamab and mobocertinib for epidermal growth factor receptor (EGFR) exon 20 insertion mutation non-small cell lung cancer (NSCLC) and assess their potential impact on the care of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 250
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652704",
          "text": "Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 102
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652704",
          "text": "OBJECTIVE\nTo evaluate clinical data regarding the use of amivantamab and mobocertinib for epidermal growth factor receptor (EGFR) exon 20 insertion mutation non-small cell lung cancer (NSCLC) and assess their potential impact on the care of patients. DATA SOURCES\nA comprehensive literature search of PubMed and Clinicaltrials.gov was conducted using the terms amivantamab, Rybrevant, JNJ-61186372, mobocertinib, Exkivity, TAK-788.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 433
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37882460",
          "text": "Aim: We assessed relative efficacy and safety of amivantamab versus mobocertinib in patients with non-small-cell lung cancer with EGFR exon 20 insertion (exon20ins) mutations who progressed on prior platinum-based chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35616682",
          "text": "BACKGROUND\nAmivantamab was approved on May 21st, 2021, by United States food and drug administration with the brand name Rybervant, used particularly for adult patients with exon20 insertion of epithelial growth factor receptor with locally advanced metastatic non-small cell lung cancer. OBJECTIVE\nIn this review, we explain the non-small cell lung cancer and molecular distinctions between non-small cell lung cancer and small cell lung cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 448
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652704",
          "text": "OBJECTIVE\nTo evaluate clinical data regarding the use of amivantamab and mobocertinib for epidermal growth factor receptor (EGFR) exon 20 insertion mutation non-small cell lung cancer (NSCLC) and assess their potential impact on the care of patients. DATA SOURCES\nA comprehensive literature search of PubMed and Clinicaltrials.gov was conducted using the terms amivantamab, Rybrevant, JNJ-61186372, mobocertinib, Exkivity, TAK-788. STUDY SELECTION AND DATA EXTRACTION\nRelevant English-language clinical trials were evaluated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 529
        }
      ],
      "ideal_answer": "Yes, Amivantamab is used for non-small-cell lung cancer with EGFR exon 20 insertion mutations.",
      "exact_answer": "yes"
    },
    {
      "id": "65f7754ec4010b4d7800002b",
      "type": "yesno",
      "body": "Do very elderly stage III colorectal cancer patients present clinical benefit from oxaliplatin-based adjuvant chemotherapy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16943526",
        "http://www.ncbi.nlm.nih.gov/pubmed/37498507",
        "http://www.ncbi.nlm.nih.gov/pubmed/24071534",
        "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
        "http://www.ncbi.nlm.nih.gov/pubmed/28699092",
        "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
        "http://www.ncbi.nlm.nih.gov/pubmed/36252550",
        "http://www.ncbi.nlm.nih.gov/pubmed/26021722",
        "http://www.ncbi.nlm.nih.gov/pubmed/33311791",
        "http://www.ncbi.nlm.nih.gov/pubmed/25731317"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
          "text": "OBJECTIVE\nElderly patients derive similar benefits from 5-fluorouracil-based adjuvant chemotherapy in Stage III colon cancer; however, conflicting data exist regarding additional benefit from oxaliplatin, fluorouracil and leucovorin (FOLFOX) chemotherapy. METHODS\nSingle-center, retrospective analysis was performed to compare the safety and efficacy of adjuvant oxaliplatin, fluorouracil and leucovorin-4 chemotherapy in older patients (age ≥65 years) with younger patients with Stage III colon cancer after surgical resection. RESULTS\nAmong 391 patients with Stage III colon cancer, 229 patients received adjuvant oxaliplatin, fluorouracil and leucovorin chemotherapy (87 (43.5%) ≥65 years old versus 142 (74.3%) <65 years old).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 734
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
          "text": "OBJECTIVE\nElderly patients derive similar benefits from 5-fluorouracil-based adjuvant chemotherapy in Stage III colon cancer; however, conflicting data exist regarding additional benefit from oxaliplatin, fluorouracil and leucovorin (FOLFOX) chemotherapy. METHODS\nSingle-center, retrospective analysis was performed to compare the safety and efficacy of adjuvant oxaliplatin, fluorouracil and leucovorin-4 chemotherapy in older patients (age ≥65 years) with younger patients with Stage III colon cancer after surgical resection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
          "text": "OBJECTIVE\nElderly patients derive similar benefits from 5-fluorouracil-based adjuvant chemotherapy in Stage III colon cancer; however, conflicting data exist regarding additional benefit from oxaliplatin, fluorouracil and leucovorin (FOLFOX) chemotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 255
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29861156",
          "text": "CONCLUSIONS\nDespite a modestly increased rate of hospital admission and early chemotherapy cessation, we demonstrate a persistent survival benefit for the addition of oxaliplatin to a fluoropyrimidine as adjuvant treatment for stage III colon cancer in elderly patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1381,
          "endSection": "abstract",
          "offsetInEndSection": 1651
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
          "text": "CONCLUSIONS\nAdjuvant oxaliplatin, fluorouracil and leucovorin chemotherapy resulted in similar efficacy without significant increase in toxicity in older patients aged ≥65 when compared with younger patients with curatively resected Stage III colon cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1315,
          "endSection": "abstract",
          "offsetInEndSection": 1571
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252550",
          "text": "INTRODUCTION\nAdjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin-based chemotherapeutic regimens for elderly patients remains to be elucidated. The aim of the present study was to examine the tolerability and efficacy of adjuvant CAPOX (capecitabine and oxaliplatin) therapy for elderly patients in comparison with young patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 441
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252550",
          "text": "INTRODUCTION\nAdjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin-based chemotherapeutic regimens for elderly patients remains to be elucidated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
          "text": "METHODS\nSingle-center, retrospective analysis was performed to compare the safety and efficacy of adjuvant oxaliplatin, fluorouracil and leucovorin-4 chemotherapy in older patients (age ≥65 years) with younger patients with Stage III colon cancer after surgical resection. RESULTS\nAmong 391 patients with Stage III colon cancer, 229 patients received adjuvant oxaliplatin, fluorouracil and leucovorin chemotherapy (87 (43.5%) ≥65 years old versus 142 (74.3%) <65 years old).",
          "beginSection": "abstract",
          "offsetInBeginSection": 258,
          "endSection": "abstract",
          "offsetInEndSection": 734
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
          "text": "METHODS\nSingle-center, retrospective analysis was performed to compare the safety and efficacy of adjuvant oxaliplatin, fluorouracil and leucovorin-4 chemotherapy in older patients (age ≥65 years) with younger patients with Stage III colon cancer after surgical resection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 258,
          "endSection": "abstract",
          "offsetInEndSection": 530
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204187",
          "text": "METHODS\nSingle-center, retrospective analysis was performed to compare the safety and efficacy of adjuvant oxaliplatin, fluorouracil and leucovorin-4 chemotherapy in older patients (age ≥65 years) with younger patients with Stage III colon cancer after surgical resection. RESULTS\nAmong 391 patients with Stage III colon cancer, 229 patients received adjuvant oxaliplatin, fluorouracil and leucovorin chemotherapy (87 (43.5%) ≥65 years old versus 142 (74.3%) <65 years old). Older patients had similar clinico-pathological characteristics as younger patients except for higher Charlson-Age comorbidity score (median 3.44 versus 2.85, P < 0.01).",
          "beginSection": "abstract",
          "offsetInBeginSection": 258,
          "endSection": "abstract",
          "offsetInEndSection": 904
        }
      ],
      "ideal_answer": "Yes, very elderly stage III colorectal cancer patients can present clinical benefit from oxaliplatin-based adjuvant chemotherapy, such as FOLFOX4, as it maintains its efficacy and safety ratio in selected elderly patients.",
      "exact_answer": "yes"
    },
    {
      "id": "660982eefdcbea915f000012",
      "type": "factoid",
      "body": "Where would Odocoileus virginianus be found?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37429851",
        "http://www.ncbi.nlm.nih.gov/pubmed/36710856",
        "http://www.ncbi.nlm.nih.gov/pubmed/37494882",
        "http://www.ncbi.nlm.nih.gov/pubmed/12678047",
        "http://www.ncbi.nlm.nih.gov/pubmed/30016213",
        "http://www.ncbi.nlm.nih.gov/pubmed/35436343",
        "http://www.ncbi.nlm.nih.gov/pubmed/27379074",
        "http://www.ncbi.nlm.nih.gov/pubmed/23568932",
        "http://www.ncbi.nlm.nih.gov/pubmed/24686388",
        "http://www.ncbi.nlm.nih.gov/pubmed/19922743"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35436343",
          "text": "The white-tailed deer (Odocoileus virginianus) is a popular game species in North America and often lives in close proximity to humans and domestic animals.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 156
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27379074",
          "text": "Over 50 years ago, serologic surveys first suggested the susceptibility of white-tailed deer (Odocoileus virginianus), the most abundant free-ranging ruminant in North America, to BVDV.",
          "beginSection": "abstract",
          "offsetInBeginSection": 803,
          "endSection": "abstract",
          "offsetInEndSection": 988
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24686388",
          "text": "A 2-year-old male free-ranging white-tailed deer (Odocoileus virginianus) was diagnosed with bilateral expansile tumors of antler origin. The deer was found dead by a landowner in High Springs, Florida. Two roughly spherical, multilobular, broad-based, bony, velvet-covered masses originated from each antler pedicle.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 317
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24686388",
          "text": "A 2-year-old male free-ranging white-tailed deer (Odocoileus virginianus) was diagnosed with bilateral expansile tumors of antler origin. The deer was found dead by a landowner in High Springs, Florida.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 202
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24686388",
          "text": "A 2-year-old male free-ranging white-tailed deer (Odocoileus virginianus) was diagnosed with bilateral expansile tumors of antler origin.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 137
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35436343",
          "text": "The white-tailed deer (Odocoileus virginianus) is a popular game species in North America and often lives in close proximity to humans and domestic animals. Deer with neurologic signs are of high interest to the general public and wildlife managers because of disease and safety concerns.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 288
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27379074",
          "text": "Over 50 years ago, serologic surveys first suggested the susceptibility of white-tailed deer (Odocoileus virginianus), the most abundant free-ranging ruminant in North America, to BVDV. However, susceptibility of white-tailed deer to BVDV infection does not alone imply a role in the epidemiology of the virus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 803,
          "endSection": "abstract",
          "offsetInEndSection": 1113
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35436343",
          "text": "Distinctive Gross Presentation in Free-Ranging White-Tailed Deer (Odocoileus virginianus) with Rabies.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 102
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30016213",
          "text": "Pituitary Abscesses in Four Free-ranging White-tailed Deer ( Odocoileus virginianus).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 85
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24686388",
          "text": "Antleroma in a free-ranging white-tailed deer (Odocoileus virginianus).",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 71
        }
      ],
      "ideal_answer": "Free-ranging white-tailed deer (Odocoileus virginianus) are found in North America.",
      "exact_answer": [
        "North America"
      ]
    },
    {
      "id": "65f868eac4010b4d78000056",
      "type": "summary",
      "body": "What is the rationale behind treating melanoma with immunotherapy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
        "http://www.ncbi.nlm.nih.gov/pubmed/35247927",
        "http://www.ncbi.nlm.nih.gov/pubmed/33256089",
        "http://www.ncbi.nlm.nih.gov/pubmed/15001157",
        "http://www.ncbi.nlm.nih.gov/pubmed/26263706",
        "http://www.ncbi.nlm.nih.gov/pubmed/22042018",
        "http://www.ncbi.nlm.nih.gov/pubmed/16762733",
        "http://www.ncbi.nlm.nih.gov/pubmed/30040090",
        "http://www.ncbi.nlm.nih.gov/pubmed/8977556",
        "http://www.ncbi.nlm.nih.gov/pubmed/37251404"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 472
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 631
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762733",
          "text": "Melanoma has been widely studied as a target for immunotherapy because it has been considered more susceptible to immune attack than other tumors and because of the relative ease with which melanoma cells can be adapted to in vitro culture. The availability of hundreds of melanoma cell lines for study has led to the identification of tumor antigens and the development of monoclonal antibodies and T cells against these antigens, revolutionizing the understanding of how the immune system sees and reacts to cancer. This article reviews the recent clinical results of trials exploring different immunotherapy strategies against melanoma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 639
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30040090",
          "text": "Immunotherapy for the treatment of advanced melanoma has become a primary treatment in the clinic. Current therapies include systemic cytokines, immune checkpoint inhibitors, and localized intratumoral therapies. Checkpoint inhibitors block natural pathways that dampen or inhibit an immune response to stimulus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 312
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26263706",
          "text": "Melanoma is a malignancy in which the immune system plays a central role, thus explaining the effectiveness of therapeutic vaccination and cellular immunotherapy with tumor-infiltrating lymphocytes. The identification of specific melanoma antigens was an important step in the development of these new approaches. These treatments are capable of yielding tumor responses that last several years, but the response rate is currently inadequate.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 442
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762733",
          "text": "Melanoma has been widely studied as a target for immunotherapy because it has been considered more susceptible to immune attack than other tumors and because of the relative ease with which melanoma cells can be adapted to in vitro culture. The availability of hundreds of melanoma cell lines for study has led to the identification of tumor antigens and the development of monoclonal antibodies and T cells against these antigens, revolutionizing the understanding of how the immune system sees and reacts to cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 517
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30040090",
          "text": "Immunotherapy for the treatment of advanced melanoma has become a primary treatment in the clinic. Current therapies include systemic cytokines, immune checkpoint inhibitors, and localized intratumoral therapies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 212
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use.",
          "beginSection": "abstract",
          "offsetInBeginSection": 356,
          "endSection": "abstract",
          "offsetInEndSection": 789
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32671117",
          "text": "Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762733",
          "text": "Melanoma has been widely studied as a target for immunotherapy because it has been considered more susceptible to immune attack than other tumors and because of the relative ease with which melanoma cells can be adapted to in vitro culture.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 240
        }
      ],
      "ideal_answer": "Melanoma is treated with immunotherapy because it is an immunologic malignancy, meaning it responds to immunotherapy. This is evident in the higher prevalence of melanoma in immune-compromised patients, the recognition of melanoma antigens by tumor-infiltrating T lymphocytes, and the documented response of melanoma to immunotherapy.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d56c0eac11fad3300001f",
      "type": "yesno",
      "body": "Is there a specific cure for Ehlers-Danlos Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34560710",
        "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
        "http://www.ncbi.nlm.nih.gov/pubmed/34845584",
        "http://www.ncbi.nlm.nih.gov/pubmed/7455751",
        "http://www.ncbi.nlm.nih.gov/pubmed/10906878",
        "http://www.ncbi.nlm.nih.gov/pubmed/30512708",
        "http://www.ncbi.nlm.nih.gov/pubmed/18324963",
        "http://www.ncbi.nlm.nih.gov/pubmed/30214474",
        "http://www.ncbi.nlm.nih.gov/pubmed/9762220",
        "http://www.ncbi.nlm.nih.gov/pubmed/31328377"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30512708",
          "text": "Ehlers-Danlos syndrome do not have any specific etiological treatment. The management is poorly systematized due to the absence of controlled clinical trials or good clinical practice recommendations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1203,
          "endSection": "abstract",
          "offsetInEndSection": 1403
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30512708",
          "text": "Ehlers-Danlos syndrome do not have any specific etiological treatment. The management is poorly systematized due to the absence of controlled clinical trials or good clinical practice recommendations. Patients should be seen in a department of genetics, physical medicine and rehabilitation or rheumatology to avoid the diagnostic odyssey and help preventing disease complications.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1203,
          "endSection": "abstract",
          "offsetInEndSection": 1584
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30512708",
          "text": "Ehlers-Danlos syndrome do not have any specific etiological treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1203,
          "endSection": "abstract",
          "offsetInEndSection": 1273
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7455751",
          "text": "Ehlers-Danlos syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 23
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis. A review of the pathophysiology of the disease reveals possible mechanisms for this spinal abnormality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 297,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 297,
          "endSection": "abstract",
          "offsetInEndSection": 404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "Clinical case analysis of a case of Ehlers-Danlos with non-adjacent spondylolisthesis. Review of this case reveals progressive lytic non-adjacent spondylolisthesis in a child with Ehlers-Danlos syndrome. There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "Review of this case reveals progressive lytic non-adjacent spondylolisthesis in a child with Ehlers-Danlos syndrome. There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis. A review of the pathophysiology of the disease reveals possible mechanisms for this spinal abnormality.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15552563",
          "text": "Review of this case reveals progressive lytic non-adjacent spondylolisthesis in a child with Ehlers-Danlos syndrome. There are no other reported cases of Ehlers-Danlos syndrome associated with non-adjacent spondylolisthesis.",
          "beginSection": "abstract",
          "offsetInBeginSection": 180,
          "endSection": "abstract",
          "offsetInEndSection": 404
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34845584",
          "text": "Successful multidisciplinary management of vascular Ehlers-Danlos syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 75
        }
      ],
      "ideal_answer": "No, there is no specific cure for Ehlers-Danlos Syndrome.",
      "exact_answer": "no"
    },
    {
      "id": "65cfa8f81930410b13000010",
      "type": "factoid",
      "body": "What mutation is associated with the VEXAS syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36537591",
        "http://www.ncbi.nlm.nih.gov/pubmed/37062784",
        "http://www.ncbi.nlm.nih.gov/pubmed/37062498",
        "http://www.ncbi.nlm.nih.gov/pubmed/37418279",
        "http://www.ncbi.nlm.nih.gov/pubmed/36948992",
        "http://www.ncbi.nlm.nih.gov/pubmed/35793467",
        "http://www.ncbi.nlm.nih.gov/pubmed/34480172",
        "http://www.ncbi.nlm.nih.gov/pubmed/38091008",
        "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
        "http://www.ncbi.nlm.nih.gov/pubmed/36692560"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38091008",
          "text": "The majority of UBA1 mutations in VEXAS syndrome comprise hemizygous mutations affecting methionine-41 (M41), leading to the expression of UBA1M41T, UBA1M41V, or UBA1M41L and globally reduced protein polyubiquitination.",
          "beginSection": "abstract",
          "offsetInBeginSection": 238,
          "endSection": "abstract",
          "offsetInEndSection": 457
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Vacuoles, E1 enzyme, x-linked, autoinflammatory, and somatic mutation (VEXAS) syndrome is a recently described disease associated with high morbidity and mortality. VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 286
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Following blood analysis, both patients were diagnosed with VEXAS syndrome resulting from a mutation in the UBA1 gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 726,
          "endSection": "abstract",
          "offsetInEndSection": 844
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793467",
          "text": "Finally, we report a patient, clinically diagnosed with VEXAS syndrome, with 2 novel mutations in UBA1 occurring in cis on the same allele. One mutation (c.121 A>T; p.Met41Leu) caused severely reduced translation of UBA1b in a reporter assay, but coexpression with the second mutation (c.119 G>C; p.Gly40Ala) rescued UBA1b levels to those of canonical mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1281,
          "endSection": "abstract",
          "offsetInEndSection": 1643
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein. Loss of UBA1 leads to a broad range of inflammatory conditions and a clinical course often refractive to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 165,
          "endSection": "abstract",
          "offsetInEndSection": 400
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Vacuoles, E1 enzyme, x-linked, autoinflammatory, and somatic mutation (VEXAS) syndrome is a recently described disease associated with high morbidity and mortality. VEXAS syndrome results from a somatic mutation affecting UBA1, a gene that codes for the E1 ubiquitin activating protein. Loss of UBA1 leads to a broad range of inflammatory conditions and a clinical course often refractive to therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 400
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793467",
          "text": "Finally, we report a patient, clinically diagnosed with VEXAS syndrome, with 2 novel mutations in UBA1 occurring in cis on the same allele.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1281,
          "endSection": "abstract",
          "offsetInEndSection": 1420
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34480172",
          "text": "UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 81
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201420",
          "text": "Following blood analysis, both patients were diagnosed with VEXAS syndrome resulting from a mutation in the UBA1 gene. Our report highlights the pivotal role dermatologists have in early diagnosis of patients with VEXAS syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 726,
          "endSection": "abstract",
          "offsetInEndSection": 955
        }
      ],
      "ideal_answer": "The UBA1 mutation is associated with the VEXAS syndrome.",
      "exact_answer": [
        "UBA1"
      ]
    },
    {
      "id": "65f774dec4010b4d7800002a",
      "type": "yesno",
      "body": "Should routine PET-CT scan be indicated in the initial evaluation of locally advanced rectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30899056",
        "http://www.ncbi.nlm.nih.gov/pubmed/33962569",
        "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
        "http://www.ncbi.nlm.nih.gov/pubmed/23420438",
        "http://www.ncbi.nlm.nih.gov/pubmed/30556862",
        "http://www.ncbi.nlm.nih.gov/pubmed/23196674",
        "http://www.ncbi.nlm.nih.gov/pubmed/22875644",
        "http://www.ncbi.nlm.nih.gov/pubmed/19370430",
        "http://www.ncbi.nlm.nih.gov/pubmed/21422901",
        "http://www.ncbi.nlm.nih.gov/pubmed/31229791"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "Our study aims to look at the utility of PET in routine preoperative staging of rectal cancer within 2 two colorectal units, and to determine if PET did result in a change in management. METHODS\nPatients in Nepean Hospital (NSW) and Peter MacCallum Cancer Centre (VIC) who were diagnosed with rectal cancer between 1 January 2017 and 31 December 2021 were included in this retrospective study. All patients who did not have a PET scan were excluded.",
          "beginSection": "abstract",
          "offsetInBeginSection": 448,
          "endSection": "abstract",
          "offsetInEndSection": 899
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "Positron emission tomography(PET) is used in detection of recurrence or metastasis, but its value in routine preoperative rectal cancer staging remains unclear. Studies report that preoperative PET altered the stage in 39% and changed the management in 17-27% of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 175,
          "endSection": "abstract",
          "offsetInEndSection": 447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "BACKGROUND\nAccurate staging for rectal cancer is pertinent with recent introduction of rectum-sparing approaches for patients showing complete clinical response on restaging. Positron emission tomography(PET) is used in detection of recurrence or metastasis, but its value in routine preoperative rectal cancer staging remains unclear. Studies report that preoperative PET altered the stage in 39% and changed the management in 17-27% of patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 447
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "Positron emission tomography(PET) is used in detection of recurrence or metastasis, but its value in routine preoperative rectal cancer staging remains unclear. Studies report that preoperative PET altered the stage in 39% and changed the management in 17-27% of patients. Our study aims to look at the utility of PET in routine preoperative staging of rectal cancer within 2 two colorectal units, and to determine if PET did result in a change in management.",
          "beginSection": "abstract",
          "offsetInBeginSection": 175,
          "endSection": "abstract",
          "offsetInEndSection": 634
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "PET scan results were then compared with MRI and CT results. RESULTS\nThree hundred and fifty-seven patients were included in the study. 30.3% of the patients had Stage 3 rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 900,
          "endSection": "abstract",
          "offsetInEndSection": 1086
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "30.3% of the patients had Stage 3 rectal cancer. 71.7% received neoadjuvant therapy. PET scan provided additional information in 55.5% of patients when compared with CT and MRI alone; 18.2% of the PET findings resulted in an altered management for the patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1038,
          "endSection": "abstract",
          "offsetInEndSection": 1298
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "BACKGROUND\nAccurate staging for rectal cancer is pertinent with recent introduction of rectum-sparing approaches for patients showing complete clinical response on restaging. Positron emission tomography(PET) is used in detection of recurrence or metastasis, but its value in routine preoperative rectal cancer staging remains unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 335
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "Retrospective audit: Utility of PET scan in routine preoperative rectal cancer staging.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 87
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36117452",
          "text": "METHODS\nPatients in Nepean Hospital (NSW) and Peter MacCallum Cancer Centre (VIC) who were diagnosed with rectal cancer between 1 January 2017 and 31 December 2021 were included in this retrospective study. All patients who did not have a PET scan were excluded. PET scan results were then compared with MRI and CT results.",
          "beginSection": "abstract",
          "offsetInBeginSection": 637,
          "endSection": "abstract",
          "offsetInEndSection": 960
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420438",
          "text": "CONCLUSIONS\nThe TLG of the primary tumor in the initial FDG-PET/CT can be considered as a prognostic factor for patients with locally advanced rectal cancer treated with neoadjuvant CCRT.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1217,
          "endSection": "abstract",
          "offsetInEndSection": 1404
        }
      ],
      "ideal_answer": "No, routine PET-CT scan is not indicated in the initial evaluation of locally advanced rectal cancer patients. However, it might have a role in rectal cancer staging and treatment planning based on the combination model's improved performance for risk prediction.",
      "exact_answer": "no"
    },
    {
      "id": "65f03163dffffb9b6b000005",
      "type": "list",
      "body": "Please list the selective endothelin A receptor antagonists",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32726116",
        "http://www.ncbi.nlm.nih.gov/pubmed/32985601",
        "http://www.ncbi.nlm.nih.gov/pubmed/32197449",
        "http://www.ncbi.nlm.nih.gov/pubmed/32942043",
        "http://www.ncbi.nlm.nih.gov/pubmed/31593221",
        "http://www.ncbi.nlm.nih.gov/pubmed/32249614",
        "http://www.ncbi.nlm.nih.gov/pubmed/31875652",
        "http://www.ncbi.nlm.nih.gov/pubmed/31884859",
        "http://www.ncbi.nlm.nih.gov/pubmed/21451953",
        "http://www.ncbi.nlm.nih.gov/pubmed/25598351"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31875652",
          "text": "Endothelin receptor antagonists (ERAs) such as, ambrisentan, macitentan and sitaxentan are primarily used for the treatment of pulmonary arterial hypertension.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 159
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21451953",
          "text": "More recently, case series revealed beneficial effects of both the dual endothelin receptor antagonist bosentan and the phosphodiesterase-5 inhibitor sildenafil. The efficacy of sitaxentan, a selective endothelin receptor A (ERA) antagonist in the reversal of POPH, is still unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 208,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31875652",
          "text": "Endothelin receptor antagonists (ERAs) such as, ambrisentan, macitentan and sitaxentan are primarily used for the treatment of pulmonary arterial hypertension. Considering the rise in endothelin in pre-eclampsia, ERAs may also be useful in its treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21451953",
          "text": "More recently, case series revealed beneficial effects of both the dual endothelin receptor antagonist bosentan and the phosphodiesterase-5 inhibitor sildenafil. The efficacy of sitaxentan, a selective endothelin receptor A (ERA) antagonist in the reversal of POPH, is still unclear. We report a case of POPH that was successfully treated with oral sitaxentan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 208,
          "endSection": "abstract",
          "offsetInEndSection": 568
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31875652",
          "text": "Endothelin receptor antagonists (ERAs) such as, ambrisentan, macitentan and sitaxentan are primarily used for the treatment of pulmonary arterial hypertension. Considering the rise in endothelin in pre-eclampsia, ERAs may also be useful in its treatment. To evaluate the pharmacokinetics of ERAs, a rapid ultra-performance liquid chromatography tandem mass spectrometry method was developed and validated to determine the concentration of ambrisentan, macitentan and sitaxentan in human plasma.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 494
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21451953",
          "text": "The efficacy of sitaxentan, a selective endothelin receptor A (ERA) antagonist in the reversal of POPH, is still unclear. We report a case of POPH that was successfully treated with oral sitaxentan.",
          "beginSection": "abstract",
          "offsetInBeginSection": 370,
          "endSection": "abstract",
          "offsetInEndSection": 568
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21451953",
          "text": "The efficacy of sitaxentan, a selective endothelin receptor A (ERA) antagonist in the reversal of POPH, is still unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 370,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21451953",
          "text": "The efficacy of sitaxentan, a selective endothelin receptor A (ERA) antagonist in the reversal of POPH, is still unclear. We report a case of POPH that was successfully treated with oral sitaxentan. Haemodynamic and symptomatic improvements were maintained after a 12-week long-term treatment period.",
          "beginSection": "abstract",
          "offsetInBeginSection": 370,
          "endSection": "abstract",
          "offsetInEndSection": 670
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21451953",
          "text": "Prostanoids have been shown to be effective in the treatment of POPH and have been used as a bridge to liver transplantation. More recently, case series revealed beneficial effects of both the dual endothelin receptor antagonist bosentan and the phosphodiesterase-5 inhibitor sildenafil. The efficacy of sitaxentan, a selective endothelin receptor A (ERA) antagonist in the reversal of POPH, is still unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 82,
          "endSection": "abstract",
          "offsetInEndSection": 491
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31884859",
          "text": "Term placentas were dually perfused with the selective ETAR (ET type A receptor) antagonists sitaxentan and ambrisentan or the nonselective ETAR/ETBR antagonist macitentan and subsequently exposed to ET-1 in the fetal circulation.",
          "beginSection": "abstract",
          "offsetInBeginSection": 382,
          "endSection": "abstract",
          "offsetInEndSection": 612
        }
      ],
      "ideal_answer": "Sitaxentan, ambrisentan, and zibotentan are selective endothelin A receptor antagonists.",
      "exact_answer": [
        [
          "sitaxentan"
        ],
        [
          "ambrisentan"
        ],
        [
          "zibotentan"
        ]
      ]
    },
    {
      "id": "65f846bfc4010b4d78000045",
      "type": "summary",
      "body": "What is the transmission mechanism of the Hendra virus in humans?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33363250",
        "http://www.ncbi.nlm.nih.gov/pubmed/28054443",
        "http://www.ncbi.nlm.nih.gov/pubmed/28407738",
        "http://www.ncbi.nlm.nih.gov/pubmed/26978066",
        "http://www.ncbi.nlm.nih.gov/pubmed/22172152",
        "http://www.ncbi.nlm.nih.gov/pubmed/12615503",
        "http://www.ncbi.nlm.nih.gov/pubmed/28636633",
        "http://www.ncbi.nlm.nih.gov/pubmed/23534359",
        "http://www.ncbi.nlm.nih.gov/pubmed/26060997",
        "http://www.ncbi.nlm.nih.gov/pubmed/24260503"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407738",
          "text": "BACKGROUND\nHendra virus is a paramyxovirus that causes periodic serious disease and fatalities in horses and humans in Australia first identified in 1994. Pteropid bats (commonly known as flying-foxes) are the natural host of the virus, and the putative route of infection in horses is by ingestion or inhalation of material contaminated by flying-fox urine or other bodily fluids. Humans become infected after close contact with infected horses.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 446
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407738",
          "text": "BACKGROUND\nHendra virus is a paramyxovirus that causes periodic serious disease and fatalities in horses and humans in Australia first identified in 1994. Pteropid bats (commonly known as flying-foxes) are the natural host of the virus, and the putative route of infection in horses is by ingestion or inhalation of material contaminated by flying-fox urine or other bodily fluids.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 381
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28054443",
          "text": "Hendra virus was identified in horses and humans in 1994, in Queensland, Australia. Flying foxes are the natural host. Horses are thought to acquire infection by direct or indirect contact with infected flying fox urine.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 220
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407738",
          "text": "Pteropid bats (commonly known as flying-foxes) are the natural host of the virus, and the putative route of infection in horses is by ingestion or inhalation of material contaminated by flying-fox urine or other bodily fluids. Humans become infected after close contact with infected horses. Horse owners in Australia are encouraged to vaccinate their horses against Hendra virus to reduce the risk of Hendra virus infection, and to prevent potential transmission to humans.",
          "beginSection": "abstract",
          "offsetInBeginSection": 155,
          "endSection": "abstract",
          "offsetInEndSection": 629
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26978066",
          "text": "Hendra virus causes acute and highly fatal infection in horses and humans. Pteropid bats (flying-foxes) are the natural host of the virus, with age and species being risk factors for infection. Urine is the primary route of excretion in flying-foxes, with viral RNA more frequently detected in Pteropus alecto and P. conspicillatus than other species.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 351
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28054443",
          "text": "Hendra virus was identified in horses and humans in 1994, in Queensland, Australia. Flying foxes are the natural host.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 118
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26978066",
          "text": "Hendra virus causes acute and highly fatal infection in horses and humans. Pteropid bats (flying-foxes) are the natural host of the virus, with age and species being risk factors for infection.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 193
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28054443",
          "text": "Humans are infected from close contact with infected horses. To reduce risk of infection in horses and humans, Australian horse owners are encouraged to vaccinate horses against the virus and adopt property risk mitigation practices that focus on reducing flying fox horse contact and contamination of horses' environment with flying fox bodily fluids. This study investigates uptake of four Hendra virus risk mitigation practices in a sample of non- and partially vaccinating horse owners living close to previous Hendra virus cases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 221,
          "endSection": "abstract",
          "offsetInEndSection": 755
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407738",
          "text": "Humans become infected after close contact with infected horses. Horse owners in Australia are encouraged to vaccinate their horses against Hendra virus to reduce the risk of Hendra virus infection, and to prevent potential transmission to humans.",
          "beginSection": "abstract",
          "offsetInBeginSection": 382,
          "endSection": "abstract",
          "offsetInEndSection": 629
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28054443",
          "text": "To reduce risk of infection in horses and humans, Australian horse owners are encouraged to vaccinate horses against the virus and adopt property risk mitigation practices that focus on reducing flying fox horse contact and contamination of horses' environment with flying fox bodily fluids. This study investigates uptake of four Hendra virus risk mitigation practices in a sample of non- and partially vaccinating horse owners living close to previous Hendra virus cases.",
          "beginSection": "abstract",
          "offsetInBeginSection": 282,
          "endSection": "abstract",
          "offsetInEndSection": 755
        }
      ],
      "ideal_answer": "The Hendra virus is primarily transmitted to humans from infected horses, which in turn are infected by flying foxes through close contact with bodily fluids of infected horses, posing a significant risk to veterinarians and horse owners.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d5c97eac11fad33000021",
      "type": "factoid",
      "body": "What is the cause of Prader-Willi Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37491450",
        "http://www.ncbi.nlm.nih.gov/pubmed/19561787",
        "http://www.ncbi.nlm.nih.gov/pubmed/31353046",
        "http://www.ncbi.nlm.nih.gov/pubmed/26022164",
        "http://www.ncbi.nlm.nih.gov/pubmed/10626556",
        "http://www.ncbi.nlm.nih.gov/pubmed/26738920",
        "http://www.ncbi.nlm.nih.gov/pubmed/22903639",
        "http://www.ncbi.nlm.nih.gov/pubmed/37511333",
        "http://www.ncbi.nlm.nih.gov/pubmed/16038620",
        "http://www.ncbi.nlm.nih.gov/pubmed/9401540"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903639",
          "text": "Prader-Willi syndrome is caused by the lack of paternal contribution for the imprinted 15q11-q13 region that originates through a number of mechanisms such as paternal deletion of 15q11-q13, maternal uniparental disomy, or by an imprinting defect due to epimutations in the paternal imprinting center.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 301
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31353046",
          "text": "Prader-Willi syndrome (PWS) is a neurobehavioral and epigenetic disorder caused by the deficiency of paternally expressed genes in the chromosome 15q11-q13.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 156
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31353046",
          "text": "Prader-Willi syndrome (PWS) is a neurobehavioral and epigenetic disorder caused by the deficiency of paternally expressed genes in the chromosome 15q11-q13. This unique molecular defect renders PWS an exciting opportunity to explore epigenetic therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 252
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10626556",
          "text": "Prader-Willi syndrome is a multigenic disorder with developmental and neurobehavioural abnormalities. There are multiple genetic causes, although all ultimately involve the loss of paternally derived gene expression of chromosome region 15q11-q13.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 247
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10626556",
          "text": "Prader-Willi syndrome is a multigenic disorder with developmental and neurobehavioural abnormalities. There are multiple genetic causes, although all ultimately involve the loss of paternally derived gene expression of chromosome region 15q11-q13. Multiple imprinted genes expressed only from the paternal allele have been identified in the specific region of human chromosome 15q associated with Prader-Willi syndrome and in the syntenic mouse chromosome 7C region, including a novel polycistronic gene (SNURF-SNRPN) that encodes two independent proteins.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 556
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26738920",
          "text": "Prader-Willi syndrome is a congenital neurodevelopmental disorder resulting from deletion of the paternal copies of genes within the chromosome region 15q11-q13.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 161
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26738920",
          "text": "Prader-Willi syndrome is a congenital neurodevelopmental disorder resulting from deletion of the paternal copies of genes within the chromosome region 15q11-q13. Patients with Prader-Willi syndrome often exhibit excessive daytime sleepiness, excessive appetite, and obesity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 274
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903639",
          "text": "Prader-Willi syndrome is caused by the lack of paternal contribution for the imprinted 15q11-q13 region that originates through a number of mechanisms such as paternal deletion of 15q11-q13, maternal uniparental disomy, or by an imprinting defect due to epimutations in the paternal imprinting center. In the present report, we describe a female patient with complex maternal uniparental trisomy for the 15q11-q13 Prader-Willi syndrome critical region due to a de novo interstitial duplication of 15q11-q13 region that is present in one of the maternal homologs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 562
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561787",
          "text": "We report the case of an infant with Prader-Willi syndrome due to loss of the paternal copy of chromosome 15q11.2-13, who presented with severe proteinuria and microscopic hematuria.",
          "beginSection": "abstract",
          "offsetInBeginSection": 239,
          "endSection": "abstract",
          "offsetInEndSection": 421
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903639",
          "text": "Prader-Willi syndrome is caused by the lack of paternal contribution for the imprinted 15q11-q13 region that originates through a number of mechanisms such as paternal deletion of 15q11-q13, maternal uniparental disomy, or by an imprinting defect due to epimutations in the paternal imprinting center. In the present report, we describe a female patient with complex maternal uniparental trisomy for the 15q11-q13 Prader-Willi syndrome critical region due to a de novo interstitial duplication of 15q11-q13 region that is present in one of the maternal homologs. As a result, the patient has three maternally derived copies of the Prader-Willi syndrome critical region and absence of paternal 15 contribution and thus, presents with a Prader-Willi syndrome phenotype with risk for developing additional phenotypes (e.g., autism and psychiatric phenotypes) characteristic of maternally derived duplications of this region.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 921
        }
      ],
      "ideal_answer": "Prader-Willi Syndrome is caused by the deficiency of paternally expressed genes in chromosome 15q11-q13, which can result from paternal deletion of 15q11-q13, maternal uniparental disomy, or an imprinting defect due to epimutations in the paternal imprinting center.",
      "exact_answer": [
        "paternal deletion of 15q11-q13"
      ]
    },
    {
      "id": "65cfe1d21930410b1300002a",
      "type": "yesno",
      "body": "Can capivasertib be used for breast cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
        "http://www.ncbi.nlm.nih.gov/pubmed/36508589",
        "http://www.ncbi.nlm.nih.gov/pubmed/37046675",
        "http://www.ncbi.nlm.nih.gov/pubmed/35398754",
        "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
        "http://www.ncbi.nlm.nih.gov/pubmed/30619511",
        "http://www.ncbi.nlm.nih.gov/pubmed/32035020",
        "http://www.ncbi.nlm.nih.gov/pubmed/31101994",
        "http://www.ncbi.nlm.nih.gov/pubmed/30288930",
        "http://www.ncbi.nlm.nih.gov/pubmed/37543694"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36508589",
          "text": "In the phase III CAPItello-291 study, the combination of fulvestrant and capivasertib more than doubled progression-free survival compared with fulvestrant alone in patients with hormone receptor-positive, HER2-negative breast cancer who have developed resistance to aromatase inhibitors and CDK4/6 inhibitors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 310
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36508589",
          "text": "In the phase III CAPItello-291 study, the combination of fulvestrant and capivasertib more than doubled progression-free survival compared with fulvestrant alone in patients with hormone receptor-positive, HER2-negative breast cancer who have developed resistance to aromatase inhibitors and CDK4/6 inhibitors. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 311
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36508589",
          "text": "In the phase III CAPItello-291 study, the combination of fulvestrant and capivasertib more than doubled progression-free survival compared with fulvestrant alone in patients with hormone receptor-positive, HER2-negative breast cancer who have developed resistance to aromatase inhibitors and CDK4/6 inhibitors. The AKT inhibitor could become a treatment option for these patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 380
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
          "text": "CONCLUSIONS: Capivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor. ",
          "beginSection": "abstract",
          "offsetInBeginSection": 2088,
          "endSection": "abstract",
          "offsetInEndSection": 2418
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
          "text": "CONCLUSIONS\nCapivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2094,
          "endSection": "abstract",
          "offsetInEndSection": 2422
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
          "text": "BACKGROUND\nCapivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 241
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
          "text": "CONCLUSIONS\nCapivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor. (Funded by AstraZeneca and the National Cancer Institute; CAPItello-291 ClinicalTrials.gov number, NCT04305496. ).",
          "beginSection": "abstract",
          "offsetInBeginSection": 2094,
          "endSection": "abstract",
          "offsetInEndSection": 2536
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
          "text": "CONCLUSIONS\nCapivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor. (Funded by AstraZeneca and the National Cancer Institute; CAPItello-291 ClinicalTrials.gov number, NCT04305496.",
          "beginSection": "abstract",
          "offsetInBeginSection": 2094,
          "endSection": "abstract",
          "offsetInEndSection": 2534
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37256976",
          "text": "Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor-positive advanced breast cancer are limited. METHODS\nIn a phase 3, randomized, double-blind trial, we enrolled eligible pre-, peri-, and postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who had had a relapse or disease progression during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy. Patients were randomly assigned in a 1:1 ratio to receive capivasertib plus fulvestrant or placebo plus fulvestrant.",
          "beginSection": "abstract",
          "offsetInBeginSection": 81,
          "endSection": "abstract",
          "offsetInEndSection": 795
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35671774",
          "text": "BACKGROUND\nCapivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit appeared to be independent of the phosphoinositide 3-kinase (PI3K)/AKT/phosphatase and tensin homologue (PTEN) pathway alteration status of tumours, as ascertained using assays available at the time.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 453
        }
      ],
      "ideal_answer": "Yes, capivasertib can be used for breast cancer in combination with fulvestrant for patients with hormone receptor-positive, HER2-negative breast cancer who have developed resistance to aromatase inhibitors and CDK4/6 inhibitors. This combination has been shown to more than double progression-free survival in these patients.",
      "exact_answer": "yes"
    },
    {
      "id": "65f777d7c4010b4d78000032",
      "type": "factoid",
      "body": "What is the optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34586340",
        "http://www.ncbi.nlm.nih.gov/pubmed/26897480",
        "http://www.ncbi.nlm.nih.gov/pubmed/32966845",
        "http://www.ncbi.nlm.nih.gov/pubmed/38012438",
        "http://www.ncbi.nlm.nih.gov/pubmed/23741691",
        "http://www.ncbi.nlm.nih.gov/pubmed/37184445",
        "http://www.ncbi.nlm.nih.gov/pubmed/31566843",
        "http://www.ncbi.nlm.nih.gov/pubmed/24263329",
        "http://www.ncbi.nlm.nih.gov/pubmed/23536485",
        "http://www.ncbi.nlm.nih.gov/pubmed/27106552"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741691",
          "text": "PURPOSE\nThe optimal time between neoadjuvant chemoradiotherapy (CRT) and surgery for rectal cancer has been debated. This study evaluated the influence of this interval on oncological outcomes. METHODS\nWe compared postoperative complications, pathological downstaging, disease recurrence, and survival in patients with locally advanced rectal cancer who underwent surgical resection <8 weeks (group A, n = 105) to those who had surgery ≥8 weeks (group B, n = 48) after neoadjuvant CRT.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 487
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37184445",
          "text": "BACKGROUND\nThe optimal interval from completion of neoadjuvant chemoradiotherapy (CRT) to surgery in locally advanced rectal cancer remains controversial. It seems that delayed surgery is associated with an increase in pathological complete response rates.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 256
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31566843",
          "text": "AIM\nThe aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks' interval between completion of neoadjuvant chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 227
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31566843",
          "text": "AIM\nThe aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks' interval between completion of neoadjuvant chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer. METHOD\nThis was a randomized trial which included a total of 330 patients from two institutions.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 326
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31566843",
          "text": "AIM\nThe aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks' interval between completion of neoadjuvant chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer. METHOD\nThis was a randomized trial which included a total of 330 patients from two institutions. Patients with locally advanced (T3-4N0M0, TxN+M0) rectal cancer were randomized into 8- and 12-week interval groups.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 443
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37184445",
          "text": "BACKGROUND\nThe optimal interval from completion of neoadjuvant chemoradiotherapy (CRT) to surgery in locally advanced rectal cancer remains controversial. It seems that delayed surgery is associated with an increase in pathological complete response rates. However, the prognostic effect of delayed surgery in poor responders is unclear.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 337
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741691",
          "text": "This study evaluated the influence of this interval on oncological outcomes. METHODS\nWe compared postoperative complications, pathological downstaging, disease recurrence, and survival in patients with locally advanced rectal cancer who underwent surgical resection <8 weeks (group A, n = 105) to those who had surgery ≥8 weeks (group B, n = 48) after neoadjuvant CRT.",
          "beginSection": "abstract",
          "offsetInBeginSection": 117,
          "endSection": "abstract",
          "offsetInEndSection": 487
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741691",
          "text": "METHODS\nWe compared postoperative complications, pathological downstaging, disease recurrence, and survival in patients with locally advanced rectal cancer who underwent surgical resection <8 weeks (group A, n = 105) to those who had surgery ≥8 weeks (group B, n = 48) after neoadjuvant CRT.",
          "beginSection": "abstract",
          "offsetInBeginSection": 196,
          "endSection": "abstract",
          "offsetInEndSection": 487
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741691",
          "text": "This study evaluated the influence of this interval on oncological outcomes. METHODS\nWe compared postoperative complications, pathological downstaging, disease recurrence, and survival in patients with locally advanced rectal cancer who underwent surgical resection <8 weeks (group A, n = 105) to those who had surgery ≥8 weeks (group B, n = 48) after neoadjuvant CRT. RESULTS\nOf 153 patients, 117 (76.5%) were male and 36 (23.5%) were female.",
          "beginSection": "abstract",
          "offsetInBeginSection": 117,
          "endSection": "abstract",
          "offsetInEndSection": 564
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741691",
          "text": "PURPOSE\nThe optimal time between neoadjuvant chemoradiotherapy (CRT) and surgery for rectal cancer has been debated. This study evaluated the influence of this interval on oncological outcomes.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 193
        }
      ],
      "ideal_answer": "The optimal timing of surgical resection after a neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients is 8 weeks. This is based on the study that found that 8 weeks is the critical threshold for optimal tumor response and achieving pathological complete response (pCR). Additionally, a longer interval before surgery after completing neoadjuvant CRT was associated with worse overall and disease-free survival in tumors with a poor pathological response to preoperative CRT.",
      "exact_answer": [
        "8 weeks"
      ]
    },
    {
      "id": "660812b4fdcbea915f000006",
      "type": "yesno",
      "body": "Is Kagami-Ogata associated with a deletion in chromosome 14",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35864517",
        "http://www.ncbi.nlm.nih.gov/pubmed/33179779",
        "http://www.ncbi.nlm.nih.gov/pubmed/34746047",
        "http://www.ncbi.nlm.nih.gov/pubmed/34055463",
        "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
        "http://www.ncbi.nlm.nih.gov/pubmed/30232357",
        "http://www.ncbi.nlm.nih.gov/pubmed/31853915",
        "http://www.ncbi.nlm.nih.gov/pubmed/35361407",
        "http://www.ncbi.nlm.nih.gov/pubmed/29375845",
        "http://www.ncbi.nlm.nih.gov/pubmed/31753000"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1157,
          "endSection": "abstract",
          "offsetInEndSection": 1254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30232357",
          "text": "Maternally inherited 133kb deletion of 14q32 causing Kagami-Ogata syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 75
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient. It was not sufficient, however, to produce Temple syndrome or any other pathogenic phenotype in the patient's mother.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1157,
          "endSection": "abstract",
          "offsetInEndSection": 1372
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "The mother's chromosomal microarray also confirmed the identical 14q32.2 deletion, although she presented a normal phenotype. The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1031,
          "endSection": "abstract",
          "offsetInEndSection": 1254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "The mother's chromosomal microarray also confirmed the identical 14q32.2 deletion, although she presented a normal phenotype. The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient. It was not sufficient, however, to produce Temple syndrome or any other pathogenic phenotype in the patient's mother.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1031,
          "endSection": "abstract",
          "offsetInEndSection": 1372
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "Deletions of the 14q32 region without involving DMRs, and encompassing only the RTL1as and MEG8 genes, are poorly described in the literature. The mother's chromosomal microarray also confirmed the identical 14q32.2 deletion, although she presented a normal phenotype. The maternally inherited 14q32 deletion was responsible for Kagami-Ogata syndrome in our patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 888,
          "endSection": "abstract",
          "offsetInEndSection": 1254
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37222159",
          "text": "Kagami-Ogata syndrome and Temple syndrome are imprinting disorders caused by the abnormal expression of genes in an imprinted cluster on chromosome 14q32. Here, we report a female with mild features of the Kagami-Ogata syndrome phenotype with polyhydramnios, neonatal hypotonia, feeding difficulties, abnormal foot morphology, patent foramen ovale, distal arthrogryposis, normal facial profile, and a bell-shaped thorax without coat hanger ribs. The single nucleotide polymorphism array revealed the interstitial deletion of chromosome 14q32.2-q32.31 (117 kb in size), involving the RTL1as and MEG8 genes, and other small nucleolar RNAs and microRNAs.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 651
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30232357",
          "text": "The maternally transmitted deletion was responsible for Kagami-Ogata syndrome in the patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1011,
          "endSection": "abstract",
          "offsetInEndSection": 1104
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30232357",
          "text": "Microarray analysis also confirmed the identical deletion in the patient's mother, who was reported to be normal. Additional molecular analyses determined the exact size and breakpoints of the deletion as well as methylation states in both the patient and her mother. The maternally transmitted deletion was responsible for Kagami-Ogata syndrome in the patient.",
          "beginSection": "abstract",
          "offsetInBeginSection": 743,
          "endSection": "abstract",
          "offsetInEndSection": 1104
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35864517",
          "text": "Kagami-Ogata syndrome is a rare genetic imprinting disorder involving the 14q32.2 genomic location of chromosome 14.",
          "beginSection": "abstract",
          "offsetInBeginSection": 12,
          "endSection": "abstract",
          "offsetInEndSection": 128
        }
      ],
      "ideal_answer": "Yes, Kagami-Ogata syndrome is associated with a deletion in chromosome 14.",
      "exact_answer": "yes"
    },
    {
      "id": "6614f672fdcbea915f000042",
      "type": "factoid",
      "body": "Are children affected by multiple sclerosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32940341",
        "http://www.ncbi.nlm.nih.gov/pubmed/34940954",
        "http://www.ncbi.nlm.nih.gov/pubmed/17438237",
        "http://www.ncbi.nlm.nih.gov/pubmed/17438239",
        "http://www.ncbi.nlm.nih.gov/pubmed/27572855",
        "http://www.ncbi.nlm.nih.gov/pubmed/29434433",
        "http://www.ncbi.nlm.nih.gov/pubmed/24647558",
        "http://www.ncbi.nlm.nih.gov/pubmed/15753431",
        "http://www.ncbi.nlm.nih.gov/pubmed/24665290",
        "http://www.ncbi.nlm.nih.gov/pubmed/17122726"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17438237",
          "text": "There is increasing appreciation that multiple sclerosis (MS) can begin in childhood or adolescence, but pediatric MS continues to be a rare entity, with an estimated 2 to 5% of patients with MS experiencing their first clinical symptoms before age 16. A prompt diagnosis of pediatric MS is important to optimize overall management of both the physical and social impact of the disease. The widespread use of disease-modifying therapies (DMT) for MS in adults, as early as following an initial isolated episode, has led to the use of DMT in children and adolescents with MS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 574
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17438237",
          "text": "There is increasing appreciation that multiple sclerosis (MS) can begin in childhood or adolescence, but pediatric MS continues to be a rare entity, with an estimated 2 to 5% of patients with MS experiencing their first clinical symptoms before age 16. A prompt diagnosis of pediatric MS is important to optimize overall management of both the physical and social impact of the disease.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 386
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17438237",
          "text": "There is increasing appreciation that multiple sclerosis (MS) can begin in childhood or adolescence, but pediatric MS continues to be a rare entity, with an estimated 2 to 5% of patients with MS experiencing their first clinical symptoms before age 16.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 252
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29434433",
          "text": "Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease. Although cognitive impairment has been well established in adult patients with MS, its occurrence in patients with pediatric-onset MS has recently been reported.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 249
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29434433",
          "text": "Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease. Although cognitive impairment has been well established in adult patients with MS, its occurrence in patients with pediatric-onset MS has recently been reported. In this review, I discuss the main features of cognitive impairment in pediatric MS as determined by long-term follow-up studies, neuropsychiatric test batteries, and the results of neuroradiological imaging studies that investigated the pathogenesis of pediatric MS.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 517
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24647558",
          "text": "BACKGROUND\nPediatric-onset multiple sclerosis (MS) patients represent a subpopulation who are diagnosed during the course of development. Social cognitive deficits have recently been recognized in adults with MS. It is critical to identify whether these youngest patients with the disorder are also at risk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 307
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29434433",
          "text": "The most commonly affected cognitive domains in adults are attention, processing speed, and visuomotor skills; language and intelligence are also affected in pediatric MS. A young age at disease onset is the strongest risk factor for these impairments, which may be due to the effect of inflammatory demyelination and neurodegeneration on the developing central nervous system and neural networks in children. Cognitive impairment has long-term effects on patients' academic life and the quality of their social life. Therefore, all patients with pediatric MS should be screened and monitored for cognitive impairment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 518,
          "endSection": "abstract",
          "offsetInEndSection": 1136
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29434433",
          "text": "The most commonly affected cognitive domains in adults are attention, processing speed, and visuomotor skills; language and intelligence are also affected in pediatric MS. A young age at disease onset is the strongest risk factor for these impairments, which may be due to the effect of inflammatory demyelination and neurodegeneration on the developing central nervous system and neural networks in children.",
          "beginSection": "abstract",
          "offsetInBeginSection": 518,
          "endSection": "abstract",
          "offsetInEndSection": 927
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27572855",
          "text": "The International Pediatric Multiple Sclerosis Study Group held its inaugural educational program, \"The World of Pediatric MS: A Global Update,\" in September 2014 to discuss advances and challenges in the diagnosis and management of pediatric multiple sclerosis (MS) and other neuroinflammatory CNS disorders. Highlights included a discussion on the revised diagnostic criteria, which enable the differentiation of MS, acute disseminated encephalomyelitis, neuromyelitis optica, and other neuroinflammatory disorders. While these criteria currently identify clinical and MRI features for a particular diagnosis, advances in biomarkers may prove to be useful in the future.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 672
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27572855",
          "text": "The International Pediatric Multiple Sclerosis Study Group held its inaugural educational program, \"The World of Pediatric MS: A Global Update,\" in September 2014 to discuss advances and challenges in the diagnosis and management of pediatric multiple sclerosis (MS) and other neuroinflammatory CNS disorders. Highlights included a discussion on the revised diagnostic criteria, which enable the differentiation of MS, acute disseminated encephalomyelitis, neuromyelitis optica, and other neuroinflammatory disorders.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 517
        }
      ],
      "ideal_answer": "Yes, children can be affected by multiple sclerosis. It is a rare neuroinflammatory and neurodegenerative disease that can have a significant impact on long-term physical and cognitive outcomes. A young age at disease onset is the strongest risk factor for cognitive impairment, which may be due to the effect of inflammatory demyelination and neurodegeneration on the developing central nervous system and neural networks in children. All patients with pediatric MS should be screened and monitored for cognitive impairment.",
      "exact_answer": [
        "Yes"
      ]
    },
    {
      "id": "661d4aa3eac11fad33000019",
      "type": "list",
      "body": "What are the current approaches for gene therapy for Phenylketonuria (PKU)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37401651",
        "http://www.ncbi.nlm.nih.gov/pubmed/32731837",
        "http://www.ncbi.nlm.nih.gov/pubmed/31364419",
        "http://www.ncbi.nlm.nih.gov/pubmed/27858753",
        "http://www.ncbi.nlm.nih.gov/pubmed/36145721",
        "http://www.ncbi.nlm.nih.gov/pubmed/31970201",
        "http://www.ncbi.nlm.nih.gov/pubmed/28392568",
        "http://www.ncbi.nlm.nih.gov/pubmed/36064264",
        "http://www.ncbi.nlm.nih.gov/pubmed/25503695",
        "http://www.ncbi.nlm.nih.gov/pubmed/34503562"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31970201",
          "text": "Gene therapy for PKU is a promising novel approach to promote lifelong neurological protection while allowing unrestricted dietary phenylalanine intake. In this study, liver-tropic recombinant AAV2/8 vectors were used to deliver CRISPR/Cas9 machinery and facilitate correction of the Pah  allele by homologous recombination.",
          "beginSection": "abstract",
          "offsetInBeginSection": 513,
          "endSection": "abstract",
          "offsetInEndSection": 837
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31970201",
          "text": "Gene therapy for PKU is a promising novel approach to promote lifelong neurological protection while allowing unrestricted dietary phenylalanine intake. In this study, liver-tropic recombinant AAV2/8 vectors were used to deliver CRISPR/Cas9 machinery and facilitate correction of the Pah  allele by homologous recombination. Additionally, a non-homologous end joining (NHEJ) inhibitor, vanillin, was co-administered with the viral drug to promote homology-directed repair (HDR) with the AAV-provided repair template.",
          "beginSection": "abstract",
          "offsetInBeginSection": 513,
          "endSection": "abstract",
          "offsetInEndSection": 1029
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31364419",
          "text": "Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 202
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31364419",
          "text": "Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment. However, somewhat unanticipated improvement in neuropsychiatric outcome upon long-term treatment of adults with PKU with enzyme substitution therapy might slowly change this assumption.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 388
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31364419",
          "text": "Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment. However, somewhat unanticipated improvement in neuropsychiatric outcome upon long-term treatment of adults with PKU with enzyme substitution therapy might slowly change this assumption. In parallel, PKU was for a long time considered to be an excellent test system for experimental gene therapy of a Mendelian autosomal recessive defect of the liver due to an outstanding mouse model and the easy to analyze and well-defined therapeutic end point, that is, blood l-phenylalanine concentration.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 696
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31364419",
          "text": "However, somewhat unanticipated improvement in neuropsychiatric outcome upon long-term treatment of adults with PKU with enzyme substitution therapy might slowly change this assumption. In parallel, PKU was for a long time considered to be an excellent test system for experimental gene therapy of a Mendelian autosomal recessive defect of the liver due to an outstanding mouse model and the easy to analyze and well-defined therapeutic end point, that is, blood l-phenylalanine concentration. Lifelong treatment by targeting the mouse liver (or skeletal muscle) was achieved using different approaches, including (1) recombinant adeno-associated viral (rAAV) or nonviral naked DNA vector-based gene addition, (2) genome editing using base editors delivered by rAAV vectors, and (3) by delivering rAAVs for promoter-less insertion of the PAH-cDNA into the Pah locus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 203,
          "endSection": "abstract",
          "offsetInEndSection": 1069
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37401651",
          "text": "Phenylketonuria (PKU) or hyperphenylalaninemia is considered a paradigm for an inherited (metabolic) liver defect and is, based on murine models that replicate all human pathology, an exemplar model for experimental studies on liver gene therapy.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 246
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37401651",
          "text": "Phenylketonuria (PKU) or hyperphenylalaninemia is considered a paradigm for an inherited (metabolic) liver defect and is, based on murine models that replicate all human pathology, an exemplar model for experimental studies on liver gene therapy. Variants in the PAH gene that lead to hyperphenylalaninemia are never fatal (although devastating if untreated), newborn screening has been available for two generations, and dietary treatment has been considered for a long time as therapeutic and satisfactory. However, significant shortcomings of contemporary dietary treatment of PKU remain.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 591
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37401651",
          "text": "Phenylketonuria (PKU) or hyperphenylalaninemia is considered a paradigm for an inherited (metabolic) liver defect and is, based on murine models that replicate all human pathology, an exemplar model for experimental studies on liver gene therapy. Variants in the PAH gene that lead to hyperphenylalaninemia are never fatal (although devastating if untreated), newborn screening has been available for two generations, and dietary treatment has been considered for a long time as therapeutic and satisfactory.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 508
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31364419",
          "text": "In parallel, PKU was for a long time considered to be an excellent test system for experimental gene therapy of a Mendelian autosomal recessive defect of the liver due to an outstanding mouse model and the easy to analyze and well-defined therapeutic end point, that is, blood l-phenylalanine concentration. Lifelong treatment by targeting the mouse liver (or skeletal muscle) was achieved using different approaches, including (1) recombinant adeno-associated viral (rAAV) or nonviral naked DNA vector-based gene addition, (2) genome editing using base editors delivered by rAAV vectors, and (3) by delivering rAAVs for promoter-less insertion of the PAH-cDNA into the Pah locus.",
          "beginSection": "abstract",
          "offsetInBeginSection": 389,
          "endSection": "abstract",
          "offsetInEndSection": 1069
        }
      ],
      "ideal_answer": "Current approaches for gene therapy for Phenylketonuria (PKU) include gene addition, genome editing, base editing, gene insertion, and gene replacement using recombinant viral (adenovirus, adeno-associated virus, and lentivirus) and non-viral (naked DNA or lipid nanoparticle-messenger RNA) vector delivery methods. These methods aim to promote lifelong neurological protection while allowing unrestricted dietary phenylalanine intake.",
      "exact_answer": [
        [
          "gene addition"
        ],
        [
          "genome editing"
        ],
        [
          "gene editing"
        ],
        [
          "base editing"
        ],
        [
          "gene insertion"
        ],
        [
          "gene replacement"
        ],
        [
          "recombinant viral vector delivery"
        ],
        [
          "non-viral vector delivery"
        ]
      ]
    },
    {
      "id": "65d134bd1930410b13000037",
      "type": "factoid",
      "body": "What disease can be treated with Trofinetide?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37291210",
        "http://www.ncbi.nlm.nih.gov/pubmed/37191913",
        "http://www.ncbi.nlm.nih.gov/pubmed/37568516",
        "http://www.ncbi.nlm.nih.gov/pubmed/37635789",
        "http://www.ncbi.nlm.nih.gov/pubmed/38024580",
        "http://www.ncbi.nlm.nih.gov/pubmed/38035006",
        "http://www.ncbi.nlm.nih.gov/pubmed/28964591",
        "http://www.ncbi.nlm.nih.gov/pubmed/35149233",
        "http://www.ncbi.nlm.nih.gov/pubmed/30918097",
        "http://www.ncbi.nlm.nih.gov/pubmed/12942847"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38035006",
          "text": "Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above. The drug significantly improved Rett syndrome behavioral scores Rett syndrome behavioral questionnaire in clinical studies. Although further research is needed to assess potential adverse events, Trofinetide's notable efficacy signifies a significant advancement in Rett syndrome treatment, offering a new therapeutic avenue with the potential to ameliorate the condition.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 480
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38035006",
          "text": "Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above. The drug significantly improved Rett syndrome behavioral scores Rett syndrome behavioral questionnaire in clinical studies.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 231
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38035006",
          "text": "Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 107
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964591",
          "text": "BACKGROUND\nThis study aimed to determine the safety and tolerability of trofinetide and to evaluate efficacy measures in adolescent and adult females with Rett syndrome, a serious and debilitating neurodevelopmental condition for which no therapies are available for its core features.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 285
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38035006",
          "text": "Trofinetide-a new chapter in rett syndrome's treatment.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 55
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37291210",
          "text": "Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 75
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964591",
          "text": "CONCLUSION\nTrofinetide was well tolerated in adolescent and adult females with Rett syndrome. Although this study had a relatively short duration in a small number of subjects with an advanced stage of disease, consistent efficacy trends at the higher dose were observed in several outcome measures that assess important dimensions of Rett syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1237,
          "endSection": "abstract",
          "offsetInEndSection": 1586
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964591",
          "text": "CONCLUSION\nTrofinetide was well tolerated in adolescent and adult females with Rett syndrome. Although this study had a relatively short duration in a small number of subjects with an advanced stage of disease, consistent efficacy trends at the higher dose were observed in several outcome measures that assess important dimensions of Rett syndrome. These results represented clinically meaningful improvement from the perspective of the clinicians as well as the caregivers.",
          "beginSection": "abstract",
          "offsetInBeginSection": 1237,
          "endSection": "abstract",
          "offsetInEndSection": 1712
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964591",
          "text": "BACKGROUND\nThis study aimed to determine the safety and tolerability of trofinetide and to evaluate efficacy measures in adolescent and adult females with Rett syndrome, a serious and debilitating neurodevelopmental condition for which no therapies are available for its core features. METHODS\nThis was an exploratory, phase 2, multicenter, double-blind, placebo-controlled, dose-escalation study of the safety and tolerability of trofinetide in 56 adolescent and adult females with Rett syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 499
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37291210",
          "text": "Rett syndrome is a rare, genetic neurodevelopmental disorder. Trofinetide is a synthetic analog of glycine-proline-glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 271
        }
      ],
      "ideal_answer": "Trofinetide is used to treat Rett syndrome, a neurological disorder that affects brain development in girls and women.",
      "exact_answer": [
        "Rett syndrome"
      ]
    },
    {
      "id": "65f7789dc4010b4d78000034",
      "type": "factoid",
      "body": "Which is the most reliable liquid biopsy technique after complete resection of  colorectal cancer metastases?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32628360",
        "http://www.ncbi.nlm.nih.gov/pubmed/25959553",
        "http://www.ncbi.nlm.nih.gov/pubmed/25182470",
        "http://www.ncbi.nlm.nih.gov/pubmed/38007059",
        "http://www.ncbi.nlm.nih.gov/pubmed/30554222",
        "http://www.ncbi.nlm.nih.gov/pubmed/33738696",
        "http://www.ncbi.nlm.nih.gov/pubmed/35337361",
        "http://www.ncbi.nlm.nih.gov/pubmed/33667566",
        "http://www.ncbi.nlm.nih.gov/pubmed/26484313",
        "http://www.ncbi.nlm.nih.gov/pubmed/32858879"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32628360",
          "text": "Liquid biopsy is a promising method in detecting colorectal cancer (CRC). However, previous meta-analyses only focused on the diagnostic performance of cell-free DNA (cfDNA). Therefore, we firstly evaluated the overall performance of all liquid biopsy methods.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 260
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32628360",
          "text": "Liquid biopsy is a promising method in detecting colorectal cancer (CRC). However, previous meta-analyses only focused on the diagnostic performance of cell-free DNA (cfDNA).",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 174
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182470",
          "text": "Circulating tumor cells (CTCs) have attracted interest as biomarkers of cancer metastases but only recently has a reliable method of CTC detection been developed. CTCs can be thought of as a liquid biopsy from the blood, and they can be used in pathological and molecular assays.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 279
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182470",
          "text": "Circulating tumor cells (CTCs) have attracted interest as biomarkers of cancer metastases but only recently has a reliable method of CTC detection been developed. CTCs can be thought of as a liquid biopsy from the blood, and they can be used in pathological and molecular assays. CTCs may ideally replace metastatic tissue biopsies in the prediction and monitoring of therapeutic responses and tumor recurrence.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 411
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959553",
          "text": "Consequently, a liquid biopsy made of tumor cells and tumor DNA that is able to track cancer evolution, as a fingerprint of the patient's individual tumor, and is easy to perform at every stage of the disease course, sounds attractive. This article mainly focuses on the applications of CTCs to track tumor dynamics in real time using colorectal cancer as a model system. The analysis of viable CTCs at DNA, RNA and protein levels, as well as their expansion in vitro, may allow deep investigation of the features of metastases-initiating cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 390,
          "endSection": "abstract",
          "offsetInEndSection": 935
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30554222",
          "text": "Recently, many authors reported the usefulness of liquid biopsy for the management of malignancy. Summary and Key Messages: The peripheral blood of cancer patients is a pool of cells and/or cell products derived from the primary or metastatic tumor, including circulating tumor cells (CTCs), circulating free (cf) DNA or RNA, and exosomes containing proteins, nucleic acids, and lipids. CTCs are tumor cells that can be isolated from peripheral blood.",
          "beginSection": "abstract",
          "offsetInBeginSection": 143,
          "endSection": "abstract",
          "offsetInEndSection": 594
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959553",
          "text": "While the circulating tumor DNA might be more representative of the bulk of the metastatic tumor, CTCs are thought to reflect more of the metastases-initiating cells. Consequently, a liquid biopsy made of tumor cells and tumor DNA that is able to track cancer evolution, as a fingerprint of the patient's individual tumor, and is easy to perform at every stage of the disease course, sounds attractive. This article mainly focuses on the applications of CTCs to track tumor dynamics in real time using colorectal cancer as a model system.",
          "beginSection": "abstract",
          "offsetInBeginSection": 223,
          "endSection": "abstract",
          "offsetInEndSection": 761
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959553",
          "text": "While the circulating tumor DNA might be more representative of the bulk of the metastatic tumor, CTCs are thought to reflect more of the metastases-initiating cells. Consequently, a liquid biopsy made of tumor cells and tumor DNA that is able to track cancer evolution, as a fingerprint of the patient's individual tumor, and is easy to perform at every stage of the disease course, sounds attractive.",
          "beginSection": "abstract",
          "offsetInBeginSection": 223,
          "endSection": "abstract",
          "offsetInEndSection": 625
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30554222",
          "text": "Recently, many authors reported the usefulness of liquid biopsy for the management of malignancy. Summary and Key Messages: The peripheral blood of cancer patients is a pool of cells and/or cell products derived from the primary or metastatic tumor, including circulating tumor cells (CTCs), circulating free (cf) DNA or RNA, and exosomes containing proteins, nucleic acids, and lipids.",
          "beginSection": "abstract",
          "offsetInBeginSection": 143,
          "endSection": "abstract",
          "offsetInEndSection": 529
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959553",
          "text": "Consequently, a liquid biopsy made of tumor cells and tumor DNA that is able to track cancer evolution, as a fingerprint of the patient's individual tumor, and is easy to perform at every stage of the disease course, sounds attractive. This article mainly focuses on the applications of CTCs to track tumor dynamics in real time using colorectal cancer as a model system.",
          "beginSection": "abstract",
          "offsetInBeginSection": 390,
          "endSection": "abstract",
          "offsetInEndSection": 761
        }
      ],
      "ideal_answer": "Circulating tumor cells (CTCs) are the most reliable liquid biopsy technique after complete resection of colorectal cancer metastases, as they showed the best diagnostic performance among all liquid biopsy methods.",
      "exact_answer": [
        "CTCs"
      ]
    },
    {
      "id": "65f59e46c4010b4d78000015",
      "type": "factoid",
      "body": "Where is the tumor of follicular infundibulum usually found?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28550716",
        "http://www.ncbi.nlm.nih.gov/pubmed/25761672",
        "http://www.ncbi.nlm.nih.gov/pubmed/26143173",
        "http://www.ncbi.nlm.nih.gov/pubmed/26170707",
        "http://www.ncbi.nlm.nih.gov/pubmed/11401679",
        "http://www.ncbi.nlm.nih.gov/pubmed/1769423",
        "http://www.ncbi.nlm.nih.gov/pubmed/30809409",
        "http://www.ncbi.nlm.nih.gov/pubmed/25387502",
        "http://www.ncbi.nlm.nih.gov/pubmed/21747619",
        "http://www.ncbi.nlm.nih.gov/pubmed/9082365"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30809409",
          "text": "Tumor of the follicular infundibulum or infundibuloma is a relatively rare benign adnexal tumor usually solitary and located in the head, neck, and trunk. Here we present a 70-year-old woman with a tender vulvar lesion.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 219
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30809409",
          "text": "Tumor of the follicular infundibulum or infundibuloma is a relatively rare benign adnexal tumor usually solitary and located in the head, neck, and trunk.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 154
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21747619",
          "text": "Tumor of the follicular infundibulum (TFI) is an uncommon benign adnexal tumor that usually presents as a solitary keratotic papule on the face or scalp of elderly patients.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 173
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1769423",
          "text": "Tumor of follicular infundibulum.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 33
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28550716",
          "text": "scalp follicular infundibulum",
          "beginSection": "title",
          "offsetInBeginSection": 23,
          "endSection": "title",
          "offsetInEndSection": 52
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21747619",
          "text": "Tumor of the follicular infundibulum (TFI) is an uncommon benign adnexal tumor that usually presents as a solitary keratotic papule on the face or scalp of elderly patients. Histopathologically, it typically manifests as a plate-like fenestrated proliferation of monomorphic pale-staining cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 295
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25387502",
          "text": "Tumor of follicular infundibulum with unique features.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 54
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30809409",
          "text": "A Case of Tumor of Follicular Infundibulum Involving the Vulva.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 63
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11401679",
          "text": "BACKGROUND\nTumor of the follicular infundibulum (TFI) is a relatively rare tumor which clinically presents as a solitary keratotic papule usually on the head and neck which on microscopic examination typically reveals a plate-like fenestrated epithelial tumor composed of pale staining cells.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 292
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1769423",
          "text": "Tumor of the follicular infundibulum is a rare, benign proliferative follicular disorder.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 89
        }
      ],
      "ideal_answer": "The tumor of follicular infundibulum is usually found in the scalp.",
      "exact_answer": [
        "scalp"
      ]
    },
    {
      "id": "6616576afdcbea915f000050",
      "type": "summary",
      "body": "Mechanisms that explain irritable bowel syndrome.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
        "http://www.ncbi.nlm.nih.gov/pubmed/27159638",
        "http://www.ncbi.nlm.nih.gov/pubmed/21957758",
        "http://www.ncbi.nlm.nih.gov/pubmed/21537540",
        "http://www.ncbi.nlm.nih.gov/pubmed/1483881",
        "http://www.ncbi.nlm.nih.gov/pubmed/11284772",
        "http://www.ncbi.nlm.nih.gov/pubmed/16500602",
        "http://www.ncbi.nlm.nih.gov/pubmed/26155376",
        "http://www.ncbi.nlm.nih.gov/pubmed/23279011",
        "http://www.ncbi.nlm.nih.gov/pubmed/12182741"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors. Identical irritable bowel syndrome symptoms are probably due to different disease processes; grouping patients with this disorder into either diarrhoea-predominant or constipation-predominant subtypes promotes heterogeneity. An approach based on the underlying pathophysiology could help to develop therapies that target causes and ultimately provide a cure for patients with irritable bowel syndrome.",
          "beginSection": "abstract",
          "offsetInBeginSection": 626,
          "endSection": "abstract",
          "offsetInEndSection": 1532
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21957758",
          "text": "Irritable bowel syndrome is a frequent functional disorder of gastrointestinal tract.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 85
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483881",
          "text": "Irritable bowel syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 25
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Pathophysiology of irritable bowel syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 44
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21957758",
          "text": "[Irritable bowel syndrome].",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 27
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors. Identical irritable bowel syndrome symptoms are probably due to different disease processes; grouping patients with this disorder into either diarrhoea-predominant or constipation-predominant subtypes promotes heterogeneity.",
          "beginSection": "abstract",
          "offsetInBeginSection": 626,
          "endSection": "abstract",
          "offsetInEndSection": 1355
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483881",
          "text": "The irritable bowel syndrome is a common disorder of gastrointestinal motility.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 79
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors.",
          "beginSection": "abstract",
          "offsetInBeginSection": 626,
          "endSection": "abstract",
          "offsetInEndSection": 1130
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors",
          "beginSection": "abstract",
          "offsetInBeginSection": 626,
          "endSection": "abstract",
          "offsetInEndSection": 1129
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
          "text": "Traditionally, irritable bowel syndrome has been considered to be a disorder with no known underlying structural or biochemical explanation, but this concept is likely to be outdated.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 183
        }
      ],
      "ideal_answer": "Irritable bowel syndrome is a functional gastrointestinal disorder that can be caused by genetic factors, post-infectious changes, chronic infections, disturbances in the intestinal microbiota, low-grade mucosal inflammation, immune activation, altered intestinal permeability, disordered bile salt metabolism, abnormalities in serotonin metabolism, and alterations in brain function. These mechanisms can lead to identical symptoms, and grouping patients based on symptoms promotes heterogeneity.",
      "exact_answer": "n/a"
    },
    {
      "id": "661d4c2eeac11fad3300001a",
      "type": "factoid",
      "body": "What is the cause of Rett Syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37408271",
        "http://www.ncbi.nlm.nih.gov/pubmed/11738862",
        "http://www.ncbi.nlm.nih.gov/pubmed/10508514",
        "http://www.ncbi.nlm.nih.gov/pubmed/23400946",
        "http://www.ncbi.nlm.nih.gov/pubmed/12180070",
        "http://www.ncbi.nlm.nih.gov/pubmed/12111643",
        "http://www.ncbi.nlm.nih.gov/pubmed/35263890",
        "http://www.ncbi.nlm.nih.gov/pubmed/10826991",
        "http://www.ncbi.nlm.nih.gov/pubmed/24970834",
        "http://www.ncbi.nlm.nih.gov/pubmed/24615633"
      ],
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11738862",
          "text": "About 80% of classic Rett syndrome is caused by mutations in the gene for methyl-CpG-binding protein (MeCP2) in Xq28. MeCP2 links DNA methylation to transcriptional repression, and MECP2 mutations likely cause partial or complete loss of function of the protein, leading to inappropriate transcription of downstream genes at critical times in brain development. More severe and milder variant forms can all be caused by similar mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 531
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11738862",
          "text": "About 80% of classic Rett syndrome is caused by mutations in the gene for methyl-CpG-binding protein (MeCP2) in Xq28. MeCP2 links DNA methylation to transcriptional repression, and MECP2 mutations likely cause partial or complete loss of function of the protein, leading to inappropriate transcription of downstream genes at critical times in brain development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10508514",
          "text": "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 94
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11738862",
          "text": "Rett syndrome is an X-linked dominant neurodevelopmental disorder primarily affecting girls. About 80% of classic Rett syndrome is caused by mutations in the gene for methyl-CpG-binding protein (MeCP2) in Xq28. MeCP2 links DNA methylation to transcriptional repression, and MECP2 mutations likely cause partial or complete loss of function of the protein, leading to inappropriate transcription of downstream genes at critical times in brain development.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 454
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11738862",
          "text": "About 80% of classic Rett syndrome is caused by mutations in the gene for methyl-CpG-binding protein (MeCP2) in Xq28.",
          "beginSection": "abstract",
          "offsetInBeginSection": 93,
          "endSection": "abstract",
          "offsetInEndSection": 210
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11738862",
          "text": "Rett syndrome is an X-linked dominant neurodevelopmental disorder primarily affecting girls. About 80% of classic Rett syndrome is caused by mutations in the gene for methyl-CpG-binding protein (MeCP2) in Xq28.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 210
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400946",
          "text": "Rett syndrome (RTT) is an X-linked postnatal neurological disorder, primarily affecting females and characterized by regression, epilepsy, stereotypical hand movements, and motor abnormalities. Its prevalence is about 1 in 10,000 female births. RTT is caused by mutations within methyl CpG-binding protein 2 (MECP2) gene.",
          "beginSection": "abstract",
          "offsetInBeginSection": 0,
          "endSection": "abstract",
          "offsetInEndSection": 321
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400946",
          "text": "Its prevalence is about 1 in 10,000 female births. RTT is caused by mutations within methyl CpG-binding protein 2 (MECP2) gene. Over 200 individual nucleotide changes in the gene, which cause pathogenic mutations, have been reported; however, eight most commonly occurring missense and nonsense mutations account for almost 70% of all mutations.",
          "beginSection": "abstract",
          "offsetInBeginSection": 194,
          "endSection": "abstract",
          "offsetInEndSection": 539
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10508514",
          "text": "Using a systematic gene screening approach, we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT.",
          "beginSection": "abstract",
          "offsetInBeginSection": 787,
          "endSection": "abstract",
          "offsetInEndSection": 970
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11738862",
          "text": "Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome.",
          "beginSection": "title",
          "offsetInBeginSection": 0,
          "endSection": "title",
          "offsetInEndSection": 80
        }
      ],
      "ideal_answer": "Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome.",
      "exact_answer": [
        "Mutations of MECP2"
      ]
    }
  ]
}